Compositions and methods for enhancing Anti-tumor immunity
Patent Information
- Application Number
- PCT/US2024/024053
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-04-14
- Filing Date
- 2024-04-11
- Publication Date
- 2024-12-05
AI Technical Summary
Current cancer therapies face challenges in selectively targeting and destroying tumor cells while sparing healthy cells, particularly in inducing long-term immunity and preventing cancer relapse.
Administration of a Delta Like Ligand 3 (DLL3) targeting trispecific protein, comprising a domain that binds to human CD3, a half-life extension domain, and a domain that specifically binds to DLL3, to enhance anti-tumor immunity and increase memory T cells.
The DLL3 targeting trispecific protein induces long-term immunity, increases specific immune cell populations, and potentially delays or prevents cancer relapse by selectively targeting tumor cells.
Smart Images

Figure US2024024053_05122024_PF_FP_ABST
Abstract
Description
WSGR Docket No.47517-770.601 COMPOSITIONS AND METHODS FOR ENHANCING ANTI-TUMOR IMMUNITY CROSS REFERENCE
[0001] This application claims the benefit of priority to U.S. Provisional Application Serial No. 63 / 496,186, filed on April 14, 2023, which is herein expressly incorporated by reference in its entirety, including any drawings. BACKGROUND OF THE INVENTION
[0002] The selective destruction of an individual cell or a specific cell type is often desirable in a variety of clinical settings. For example, it is a primary goal of cancer therapy to specifically destroy tumor cells, while leaving healthy cells and tissues intact and undamaged. One such method is by inducing an immune response against the tumor, to make immune effector cells such as natural killer (NK) cells or cytotoxic T lymphocytes (CTLs) attack and destroy tumor cells. SUMMARY OF THE INVENTION
[0003] Disclosed herein are methods for inducing long term immunity in a subject, comprising administering an effective amount of a Delta Like Ligand 3 (DLL3) targeting trispecific protein to the subject, wherein the DLL3 targeting trispecific protein comprises (a) a first domain (A) which specifically binds to human CD3; (b) a second domain (B) which is a half-life extension domain; and (c) a third domain (C) which specifically binds to DLL3.
[0004] Disclosed herein are methods for inducing epitope spreading in a subject, comprising administering an effective amount of a Delta Like Ligand 3 (DLL3) targeting trispecific protein to the subject, wherein the DLL3 targeting trispecific protein comprises (a) a first domain (A) which specifically binds to human CD3; (b) a second domain (B) which is a half-life extension domain; and (c) a third domain (C) which specifically binds to DLL3.
[0005] Disclosed herein are methods for increasing memory T cells in a subject, comprising administering an effective amount of a Delta Like Ligand 3 (DLL3) targeting trispecific protein to the subject, wherein the DLL3 targeting trispecific protein comprises (a) a first domain (A) which specifically binds to human CD3; (b) a second domain (B) which is a half-life extension domain; and (c) a third domain (C) which specifically binds to DLL3; wherein the memory T cells are increased in the subject as compared to a subject without the administration.
[0006] Disclosed herein are methods for treating a subject in need thereof, comprising administering an effective amount of a Delta Like Ligand 3 (DLL3) targeting trispecific protein to the subject, wherein the DLL3 targeting trispecific protein comprises (a) a first domain (A) which specifically binds to human CD3; (b) a second domain (B) which is a half-life extension domain;WSGR Docket No.47517-770.601 and (c) a third domain (C) which specifically binds to DLL3; wherein the subject in need thereof is prone to cancer relapse.
[0007] In some embodiments, the DLL3 targeting trispecific protein is administered at a dosage of about 1 µg to about 100 mg. In some embodiments, the DLL3 targeting trispecific protein is administered at a dosage of about 1 µg to about 14 mg. In some embodiments, the DLL3 targeting trispecific protein is administered at a dosage of about 1 µg to about 5 mg. In some embodiments, the DLL3 targeting trispecific protein is administered at a dosage of about 1 µg to about 2 mg. In some embodiments, the DLL3 targeting trispecific protein is administered at a dosage of about 1 µg to about 1 mg. In some embodiments, the DLL3 targeting trispecific protein is administered at a dosage of about 15 µg to about 3600 µg. In some embodiments, the DLL3 targeting trispecific protein is administered at a dosage of about 15 µg. In some embodiments, the DLL3 targeting trispecific protein is administered at a dosage of about 45 µg. In some embodiments, the DLL3 targeting trispecific protein is administered at a dosage of about 135 µg. In some embodiments, the DLL3 targeting trispecific protein is administered at a dosage of about 405 µg. In some embodiments, the DLL3 targeting trispecific protein is administered at a dosage of about 1215 µg. In some embodiments, the DLL3 targeting trispecific protein is administered at a dosage of about 3600 µg. In some embodiments, the DLL3 targeting trispecific protein is administered at a dosage of about 5 mg. In some embodiments, the DLL3 targeting trispecific protein is administered at a dosage of about 7 mg. In some embodiments, the DLL3 targeting trispecific protein is administered at a dosage of about 10 mg. In some embodiments, the DLL3 targeting trispecific protein is administered at a dosage of about 12 mg. In some embodiments, the DLL3 targeting trispecific protein is administered at a dosage of about 14 mg. In some embodiments, the DLL3 targeting trispecific protein is administered at a dosage of about 20 mg. In some embodiments, the DLL3 targeting trispecific protein is administered at a dosage of about 50 mg.
[0008] In some embodiments, the DLL3 targeting trispecific protein is administered once a week. In some embodiments, the DLL3 targeting trispecific protein is administered twice per week. In some embodiments, the DLL3 targeting trispecific protein is administered every other week. In some embodiments, the DLL3 targeting trispecific protein is administered every three weeks. In some embodiments, the DLL3 targeting trispecific protein is administered intravenously, intraperitoneally, subcutaneously, intramuscularly, topically or intradermally.
[0009] In some embodiments, the domains are linked in the order H2N-(A)-(B)-(C)-COOH, or by linkers L1 and L2.
[0010] In some embodiments, the DLL3 targeting trispecific protein is administered according to a schedule comprising the following steps: (i) administration of a first dose of the DLL3 targetingWSGR Docket No.47517-770.601 trispecific protein, and (ii) administration of a second dose of the DLL3 targeting trispecific protein, wherein the second dose is higher than the first dose. In some embodiments, the first dose is about 1 mg to about 50 mg. In some embodiments, the first dose is about 1 mg to about 20 mg. In some embodiments, the first dose is about 1 mg to about 10 mg. In some embodiments, the first dose is about 1 mg to about 5 mg. In some embodiments, the first dose is about 1 mg to about 3 mg. In some embodiments, the first dose is about 2000 µg. In some embodiments, the first dose is about 3600 µg. In some embodiments, the first dose is administered for about 1 week to about 36 weeks. In some embodiments, the first dose is administered for about 1 week to about 27 weeks. In some embodiments, the first dose is administered for about 1 week to about 18 weeks. In some embodiments, the first dose is administered for about 1 week to about 9 weeks. In some embodiments, the first dose is administered once a day. In some embodiments, the first dose is administered twice a day. In some embodiments, the first dose is administered three times a day. In some embodiments, the first dose is administered five times a day. In some embodiments, the first dose is administered once a week. In some embodiments, the first dose is administered twice per week. In some embodiments, the first dose is administered every other week. In some embodiments, the first dose is administered every three weeks. In some embodiments, the first dose is administered intravenously, intraperitoneally, subcutaneously, intramuscularly, topically or intradermally. In some embodiments, the second dose is about 1 mg to about 100 mg. In some embodiments, the second dose is about 1 mg to about 50 mg. In some embodiments, the second dose is about 50 mg to about 100 mg. In some embodiments, the second dose is about 7.2 mg. In some embodiments, the second dose is about 12 mg. In some embodiments, the second dose is about 24 mg. In some embodiments, the second dose is administered for about 1 week to about 36 weeks. In some embodiments, the second dose is administered for about 1 week to about 27 weeks. In some embodiments, the second dose is administered for about 1 week to about 18 weeks. In some embodiments, the second dose is administered for about 1 week to about 9 weeks. In some embodiments, the second dose is administered once a day. In some embodiments, the second dose is administered twice a day. In some embodiments, the second dose is administered three times a day. In some embodiments, the second dose is administered five times a day. In some embodiments, the second dose is administered once a week. In some embodiments, the second dose is administered twice per week. In some embodiments, the second dose is administered every other week. In some embodiments, the second dose is administered every three weeks. In some embodiments, the second dose is maintained to the end of the schedule after the administration of the first dose. In some embodiments, the second dose is administered intravenously, intraperitoneally, subcutaneously, intramuscularly, topically or intradermally.WSGR Docket No.47517-770.601
[0011] In some embodiments, the DLL3 targeting trispecific protein has an elimination half-time of at least 12 hours, at least 20 hours, at least 25 hours, at least 30 hours, at least 35 hours, at least 40 hours, at least 45 hours, at least 50 hours, or at least 100 hours.
[0012] In some embodiments, the third domain comprises a VHH domain. In some embodiments, the VHH domain is human, humanized, affinity matured, or a combination thereof. In some embodiments, the third domain comprises one or more sequences selected from the group consisting of SEQ ID NO: 1-442. In some embodiments, the first domain comprises a variable light chain and variable heavy chain each of which is capable of specifically binding to human CD3. In some embodiments, the first domain is humanized or human. In some embodiments, the second domain binds human serum albumin. In some embodiments, the second domain comprises a scFv, a variable heavy domain (VH), a variable light domain (VL), a peptide, a ligand, or a small molecule. In some embodiments, linkers L1 and L2 are each independently selected from (GS)n, (GGS)n, (GGGS)n, (GGSG)n, (GGSGG)n, (GGGGS)n, or GGGGSGGGS, wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, linkers L1 and L2 are each independently (GGGGS)4, (GGGGS)3, or GGGGSGGGS. In some embodiments, the domains are linked in the order H2N- (C)-L1-(B)-L2-(A)-COOH. In some embodiments, the DLL3 targeting trispecific protein is less than about 80 kDa. In some embodiments, the DLL3 targeting trispecific protein is about 50 to about 75 kDa. In some embodiments, the DLL3 targeting trispecific protein is less than about 60 kDa. In some embodiments, the DLL3 targeting trispecific protein comprises a sequence selected from the group consisting of SEQ ID NO: 1890-1891. In some embodiments, the DLL3 targeting trispecific protein comprises a sequence as set forth in SEQ ID NO: 1890. In some embodiments, the subject has a cancer or is prone to have a cancer. In some embodiments, the subject is prone to cancer relapse. In some embodiments, the cancer comprises a cancer associated with DLL3. In some embodiments, the cancer is a neuroendocrine cancer, a prostate cancer, a lung cancer, a stomach cancer, a squamous cell carcinoma, a pancreatic cancer, a cholangiocarcinoma, a triple negative breast cancer or an ovarian cancer. In some embodiments, the cancer is a small cell lung cancer. In some embodiments, the cancer is a neuroendocrine prostate cancer.
[0013] In some embodiments, CD8+ / CD69+T cells in the subject are increased after the administration as compared to CD8+ / CD69+T cells in a subject without the administration. In some embodiments, CD8+ / CD25+T cells in the subject are increased after the administration as compared to CD8+ / CD25+T cells in a subject without the administration. In some embodiments, the CD8+ / CD69+T cells are increased by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at leastWSGR Docket No.47517-770.601 20%, at least 25%, at least 30%, or at least 35% as compared to the subject without the administration. In some embodiments, the CD8+ / CD69+T cells are increased by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 25%, about 30%, or about 35% as compared to the subject without the administration. In some embodiments, the CD8+ / CD25+T cells are increased by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 25%, at least 30%, or at least 35% as compared to the subject without the administration. In some embodiments, the CD8+ / CD25+T cells are increased by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 25%, about 30%, or about 35% as compared to the subject without the administration. In some embodiments, the CD8+ / CD69+T cells or the CD8+ / CD25+ T cells are increased about 12 hours, about 24 hours, about 48 hours, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days post the administration. In some embodiments, the CD8+ / CD69+T cells or the CD8+ / CD25+ T cells are increased within about 12 hours, about 24 hours, about 48 hours, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days upon the administration.
[0014] In some embodiments, memory T cells are increased in the subject as compared to a subject without the administration. In some embodiments, the memory T cells comprises central memory T cells, effector memory T cells, tissue-resident memory T cells, or stem cell-like memory T cells. In some embodiments, the memory T cells are increased by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 25%, at least 30%, or at least 35% as compared to the subject without the administration. In some embodiments, the memory T cells are increased by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 25%, about 30%, or about 35% as compared to the subject without the administration.
[0015] In some embodiments, the central memory T cells comprise T cells expressing at least one marker selected from the group consisting of CCR7+, CD45RA-, CD45RO+, CD62L+, and CD27+. In some embodiments, the central memory T cells comprise T cells expressing CCR7+, CD45RA-,WSGR Docket No.47517-770.601 CD45RO+, CD62L+, and CD27+. In some embodiments, the effector memory T cells comprise T cells expressing at least one marker selected from the group consisting of CCR7-, CD45RA-, CD45RO+, CD62L-, and CD27-. In some embodiments, the effector memory T cells comprise T cells expressing CCR7-, CD45RA-, CD45RO+, CD62L-, and CD27-. In some embodiments, the tissue-resident memory T cells comprise T cells expressing at least one marker selected from the group consisting of CD69+and CD103+. In some embodiments, the tissue-resident memory T cells comprise T cells expressing CD69+and CD103+. In some embodiments, the stem cell-like memory T cells comprise T cells expressing at least one marker selected from the group consisting of CCR7+, CD95+, CD45RO-, CD27+, CD45RA+, CD62L+, and CD122+. In some embodiments, the stem cell-like memory T cells comprise T cells expressing CCR7+, CD95+, CD45RO-, CD27+, CD45RA+, CD62L+, and CD122+.
[0016] In some embodiments, the subject has an increased level of a cytokine after the administration as compared to a subject without the administration. In some embodiments, the cytokine comprises interleukin-2 (IL-2), IL-7, or IL-15. In some embodiments, the cytokine comprises a proinflammatory cytokine or a chemokine. In some embodiments, the cytokine of the subject are released from the cancer cells. In some embodiments, endogenous T cell response is activated. In some embodiments, a long-term immunity is induced. In some embodiments,
[0017] In some embodiments, the subject had cancer and the cancer had regressed. In some embodiments, the cancer regression is a result of a treatment. In some embodiments, the treatment comprises administering an effective amount of the DLL3 targeting trispecific protein. In some embodiments, the treatment comprises administering a therapeutic agent. In some embodiments, the tumor had regressed to an undetectable size. In some embodiments, the subject had been clinically diagnosed as cancer free. In some embodiments, the subject has cancer relapse after the administration of the DLL3 targeting trispecific protein; and wherein the relapsed cancer develops slower than a relapsed cancer in a subject without the administration. In some embodiments, the subject is prone to cancer relapse; and wherein the subject is clinically cancer free. In some embodiments, the subject is clinically cancer free for at least 5 days, at least 10 days, at least 15 days, at least 20 days, at least 30 days, at least 40 days, at least 50 days, at least 60 days, at least 70 days, at least 80 days, at least 90 days, or at least 100 days.
[0018] Further disclosed herein are methods for treating a subject in need thereof, comprising determining the subject is prone to cancer relapse; and administering an effective amount of a Delta Like Ligand 3 (DLL3) targeting trispecific protein to the subject, wherein the DLL3 targetingWSGR Docket No.47517-770.601 trispecific protein comprises (a) a first domain (A) which specifically binds to human CD3; (b) a second domain (B) which is a half-life extension domain; and (c) a third domain (C) which specifically binds to DLL3.
[0019] Further disclosed herein are methods for treating a subject in need thereof, comprising administering an effective amount of a Delta Like Ligand 3 (DLL3) targeting trispecific protein to the subject, wherein the DLL3 targeting trispecific protein comprises (a) a first domain (A) which specifically binds to human CD3; (b) a second domain (B) which is a half-life extension domain; and (c) a third domain (C) which specifically binds to DLL3; wherein the subject is determined to be prone to cancer relapse.
[0020] Further disclosed herein are methods for enhancing immunity and immune response in a subject in need thereof, comprising administering an effective amount of a Delta Like Ligand 3 (DLL3) targeting trispecific protein to the subject, wherein the DLL3 targeting trispecific protein comprises (a) a first domain (A) which specifically binds to human CD3; (b) a second domain (B) which is a half-life extension domain; and (c) a third domain (C) which specifically binds to DLL3. INCORPORATION BY REFERENCE
[0021] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference in their entireties to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
[0023] FIG.1 illustrates the various domains of an exemplary DLL3 targeting trispecific protein of this disclosure.
[0024] FIGs.2A-2C to TriTAC molecules. FIG.2A FIG.2B shows the human CD3 (hCD3e, Y axis) and mouse CD3 FIG.2C
[0025] FIGs.3A-3B depict that TriTACs engaged and activated endogenous T cells in vivo and displayed anti-tumor activity and toxicity. FIG.3A shows the anti-tumor activity of an anti-humanWSGR Docket No.47517-770.601 . FIG. 3B shows the body weight loss and toxicity induced by anti-mouse / human EGFR targeting TriTAC molecule.
[0026] FIG.4 Mice implanted with MC38-hDLL3. n=9.
[0027] FIG.5 shows the increased activation in CD8+ TILs by an exemplary TriTAC.
[0028] FIG.6 depicts a model demonstrating potential mechanisms for TriTACs to induce long term immunity and epitope spread.
[0029] FIGs.7A-7D show the long-term immunity induced in mice cured by an exemplary TriTAC. FIG.7A illustrates a schematic of study design. FIG.7B shows the anti-tumor activity of treated with the exemplary TriTAC or vehicle on days 8-17. FIG.7C shows the tumor volume changes from the tumor free mice from (B) were rechallenged on study day 30 with 2 × 106parental MC38 cells on the opposite flank. n=9 for naive mice, n=10 for previously treated with 1000 µg / kg, n=7 for previously treated with 200 µg / kg. FIG.7D shows the increase in CD8+ DETAILED DESCRIPTION OF THE INVENTION
[0030] Described herein, in some embodiments, are proteins that specifically bind delta-like ligand 3 (DLL3) and multispecific (e.g., trispecific) containing the same, pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such proteins thereof. Also provided are methods of using at least one of: the DLL3 targeting trispecific proteins in the prevention, and / or treatment of diseases, conditions and disorders, particularly in enhancing anti-tumor immunity, inducing long-term immunity and inducing tumor antigen spreading. The DLL3 targeting trispecific proteins are capable of specifically binding to DLL3 as well as CD3 and have a half-life extension domain, such as a domain that is capable of specifically binding to human albumin (ALB). Fig.1 depicts one non-limiting example of a trispecific DLL3- binding protein. In some embodiments, the DLL3 targeting trispecific protein comprises an antibody, such as a trispecific antibody. Definitions
[0031] An “antibody” typically refers to a Y-shaped tetrameric protein comprising two heavy (H) and two light (L) polypeptide chains held together by covalent disulfide bonds and non-covalent interactions. Human light chains comprise a variable domain (VL) and a constant domain (CL) wherein the constant domain may be readily classified as kappa or lambda based on amino acid sequence and gene loci. Each heavy chain comprises one variable domain (VH) and a constantWSGR Docket No.47517-770.601 region, which in the case of IgG, IgA, and IgD, comprises three domains termed CH1, CH2, and CH3 (IgM and IgE have a fourth domain, CH4). In IgG, IgA, and IgD classes the CH1 and CH2 domains are separated by a flexible hinge region, which is a proline and cysteine rich segment of variable length (generally from about 10 to about 60 amino acids in IgG). The variable domains in both the light and heavy chains are joined to the constant domains by a “J” region of about 12 or more amino acids and the heavy chain also has a “D” region of about 10 additional amino acids. Each class of antibody further comprises inter-chain and intra-chain disulfide bonds formed by paired cysteine residues. There are two types of native disulfide bridges or bonds in immunoglobulin molecules: interchain and intrachain disulfide bonds. The location and number of interchain disulfide bonds vary according to the immunoglobulin class and species. Interchain disulfide bonds are located on the surface of the immunoglobulin, are accessible to solvent and are usually relatively easily reduced. In the human IgG1 isotype there are four interchain disulfide bonds, one from each heavy chain to the light chain and two between the heavy chains. The interchain disulfide bonds are not required for chain association. As is well known the cysteine rich IgG1 hinge region of the heavy chain has generally been held to consist of three parts: an upper hinge, a core hinge, and a lower hinge. Those skilled in the art will appreciate that that the IgG1 hinge region contain the cysteines in the heavy chain that comprise the interchain disulfide bonds (two heavy / heavy, two heavy / light), which provide structural flexibility that facilitates Fab movements. The interchain disulfide bond between the light and heavy chain of IgG1 are formed between C214 of the kappa or lambda light chain and C220 in the upper hinge region of the heavy chain. The interchain disulfide bonds between the heavy chains are at positions C226 and C229 (all numbered per the EU index according to Kabat, et al., infra.)
[0032] As used herein the term “antibody” includes polyclonal antibodies, multiclonal antibodies, monoclonal antibodies, chimeric antibodies, humanized and primatized antibodies, CDR grafted antibodies, human antibodies, recombinantly produced antibodies, intrabodies, multispecific antibodies, bispecific antibodies, monovalent antibodies, multivalent antibodies, anti-idiotypic antibodies, synthetic antibodies, including muteins and variants thereof, immunospecific antibody fragments such as Fd, Fab, F(ab')2, F(ab') fragments, single-chain fragments (e.g., ScFv and ScFvFc), disulfide-linked Fvs (sdFv), a Fd fragment consisting of the VH and CH1 domains, linear antibodies, single domain antibodies such as sdAb (VH, VL, or VHH domains); and derivatives thereof including Fc fusions and other modifications, and any other immunoreactive molecule so long as it comprises a domain having a binding site for preferential association or binding with a DLL3 protein. Moreover, unless dictated otherwise by contextual constraints the term further comprises all classes of antibodies (i.e., IgA, IgD, IgE, IgG, and IgM) and all subclasses (i.e., IgG1,WSGR Docket No.47517-770.601 IgG2, IgG3, IgG4, IgA1, and IgA2). Heavy-chain constant domains that correspond to the different classes of antibodies are typically denoted by the corresponding lower case Greek letter alpha, delta, epsilon, gamma, and mu, respectively. Light chains of the antibodies from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (kappa) and lambda (lambda ), based on the amino acid sequences of their constant domains.
[0033] In some embodiments, the DLL3 binding domain of the DLL3 targeting trispecific proteins of this disclosure comprises a heavy chain only antibody, such as a VH or a VHH domain. In some cases, the DLL3 binding proteins comprise a heavy chain only antibody that is an engineered human VH domain. In some examples, the engineered human VH domain is produced by panning of phage display libraries. In some embodiments, the DLL3 binding domain of the DLL3 targeting trispecific proteins of this disclosure comprise a VHH. The term “VHH,” as used herein, refers to single chain antibody binding domain devoid of light chain. In some cases, a VHH is derived from an antibody of the type that can be found in Camelidae or cartilaginous fish which are naturally devoid of light chains or to a synthetic and non-immunized VHH which can be constructed accordingly. Each heavy chain comprises a variable region encoded by V-, D- and J exons. A VHH, in some cases, is a natural VHH, such as a Camelid-derived VHH, or a recombinant protein comprising a heavy chain variable domain. In some embodiments, the VHH is derived from a species selected from the group consisting of camels, llamas, vicugnas, guanacos, and cartilaginous fish (such as, but not limited to, sharks). In another embodiment, the VHH is derived from an alpaca (such as, but not limited to, a Huacaya Alpaca or a Suri alpaca).
[0034] As used herein, “Variable region” or “variable domain” refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions both in the light-chain (VL) and the heavy-chain (VH) variable domains. The more highly conserved portions of variable domains are called the framework (FR). The variable configuration, connected by three CDRs, which form loops connecting, and in some cases forming FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen- binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, Md. (1991)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such asWSGR Docket No.47517-770.601 participation of the antibody in antibody-dependent cellular toxicity. ScFv fragments (for single chain fragment variable), which in some cases are obtained by genetic engineering, associates in a single polypeptide chain, the VH and the VL region of an antibody, separated by a peptide linker.
[0035] In some embodiments of this disclosure, the DLL3 binding domain, such as the DLL3 binding domain of the DLL3 targeting trispecific proteins comprise a single domain antibody, such as heavy chain only antibodies, such as VH or VHH domains, and comprise three CDRs. Such heavy chain only antibodies, in some embodiments, bind DLL3 as a monomer with no dependency on dimerisation with a VL (light chain variable) region for optimal binding affinity. In some embodiments of this disclosure, the CD3 binding domain of the DLL3 targeting trispecific proteins comprises an scFv. In some embodiments of this disclosure, the albumin binding domain of the DLL3 targeting trispecific proteins comprise a heavy chain only antibody, such as a single domain antibody comprising a VH domain or a VHH domain.
[0036] The assignment of amino acids to each domain, framework region and CDR is, in some embodiments, in accordance with one of the numbering schemes provided by Kabat et al. (1991) Sequences of Proteins of Immunological Interest (5th Ed.), US Dept. of Health and Human Services, PHS, NIH, NIH Publication no.91-3242; Chothia et al., 1987, PMID: 3681981; Chothia et al., 1989, PMID: 2687698; MacCallum et al., 1996, PMID: 8876650; or Dubel, Ed. (2007) Handbook of Therapeutic Antibodies, 3rd Ed., Wily-VCH Verlag GmbH and Co or AbM (Oxford Molecular / MSI Pharmacopia) unless otherwise noted. It is not intended that CDRs of the present disclosure necessarily correspond to the Kabat numbering convention. In some embodiments of this disclosure, the DLL3 binding proteins comprise single domain antibodies, such as heavy chain only antibodies, such as VH or VHH domains, and comprise three CDRs. Such heavy chain only antibodies, in some embodiments, bind DLL3 as a monomer with no dependency on dimerization with a VL (light chain variable) region for optimal binding affinity.
[0037] “Variable domain residue numbering as in Kabat” or “amino acid position numbering as in Kabat,” and variations thereof, refers to the numbering system used for heavy chain variable domains or light chain variable domains of the compilation of antibodies in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991). Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to a shortening of, or insertion into, a FR or CDR of the variable domain. For example, a heavy chain variable domain may include a single amino acid insert (residue 52a according to Kabat) after residue 52 of H2 and inserted residues (e.g., residues 82a, 82b, and 82c, etc according to Kabat) after heavy chain FR residue 82. TheWSGR Docket No.47517-770.601 Kabat numbering of residues may be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a “standard” Kabat numbered sequence.
[0038] The term “Framework” or “FR” residues (or regions) refer to variable domain residues other than the CDR or hypervariable region residues as herein defined. A “human consensus framework” is a framework which represents the most commonly occurring amino acid residue in a selection of human immunoglobulin VL or VH framework sequences.
[0039] As used herein, the term “Percent (%) amino acid sequence identity” with respect to a sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer softwares such as EMBOSS MATCHER, EMBOSS WATER, EMBOSS STRETCHER, EMBOSS NEEDLE, EMBOSS LALIGN, BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
[0040] As used herein, “elimination half-time” is used in its ordinary sense, as is described in Goodman and Gillman's The Pharmaceutical Basis of Therapeutics 21-25 (Alfred Goodman Gilman, Louis S. Goodman, and Alfred Gilman, eds., 6th ed.1980). Briefly, the term is meant to encompass a quantitative measure of the time course of drug elimination. The elimination of most drugs is exponential (i.e., follows first-order kinetics), since drug concentrations usually do not approach those required for saturation of the elimination process. The rate of an exponential process may be expressed by its rate constant, k, which expresses the fractional change per unit of time, or by its half-time, t1 / 2 the time required for 50% completion of the process. The units of of the reaction are simply related (k×t1 / 2=0.693) and may be interchanged accordingly. Since first- order elimination kinetics dictates that a constant fraction of drug is lost per unit time, a plot of the log of drug concentration versus time is linear at all times following the initial distribution phase (i.e. after drug absorption and distribution are complete). The half-time for drug elimination can be accurately determined from such a graph.
[0041] As used herein, the term “binding affinity” refers to the affinity of the proteins described in the disclosure to their binding targets, and is expressed numerically using “Kd” values. If two orWSGR Docket No.47517-770.601 more proteins are indicated to have comparable binding affinities towards their binding targets, then the Kd values for binding of the respective proteins towards their binding targets, are within ±2-fold of each other. If two or more proteins are indicated to have comparable binding affinities towards single binding target, then the Kd values for binding of the respective proteins towards said single binding target, are within ±2-fold of each other. If a protein is indicated to bind two or more targets with comparable binding affinities, then the Kd values for binding of said protein to the two or more targets are within ±2-fold of each other. In general, a higher Kd value corresponds to a weaker binding. In some embodiments, the “Kd” is measured by a radiolabeled antigen binding assay (RIA) or surface plasmon resonance assays using a BIAcore -2000 or a BIAcore -3000 (BIAcore, Inc., Piscataway, N.J.). In certain embodiments, an “on-rate” or “rate of association” or “association rate” or “kon” and an “off-rate” or “rate of dissociation” or “dissociation rate” or “koff” are also determined with the surface plasmon resonance technique using a BIAcore -2000 or a BIAcore -3000 (BIAcore, Inc., Piscataway, N.J.). In additional embodiments, the “Kd”, “kon”, and “koff” are measured using the OCTET® Systems (Pall Life Sciences). In an exemplary method for measuring binding affinity using the OCTET® Systems, the ligand, e.g., biotinylated human or cynomolgus DLL3, is immobilized on the OCTET® streptavidin capillary sensor tip surface which streptavidin tips are then activated according to manufacturer's instructions using about 20-50 µg / ml human or cynomolgus DLL3 protein. A solution of PBS / Casein is also introduced as a blocking agent. For association kinetic measurements, DLL3 binding protein variants are introduced at a concentration ranging from about 10 ng / mL to about 100 µg / mL, about 50 ng / mL to about 5 µg / mL, or about 2 ng / mL to about 20 µg / mL. In some embodiments, the DLL3 binding single domain proteins are used at a concentration ranging from about 2 ng / mL to about 20 µg / mL. Complete dissociation is observed in case of the negative control, assay buffer without the binding proteins. The kinetic parameters of the binding reactions are then determined using an appropriate tool, e.g., ForteBio software.
[0042] One embodiment provides a DLL3 binding protein (also referred to herein as an DLL3 binding domain, such as the DLL3 binding domain of a DLL3 trispecific antibody of this disclosure) that comprises a single domain antibody, comprising a CDR1 sequence comprising a sequence selected from the group consisting of SEQ ID Nos.443-884 and 1887, a CDR2 sequence comprising a sequence selected from the group consisting of SEQ ID Nos.885-1326 and 1888, and a CDR3 sequence comprising a sequence selected from the group consisting of SEQ ID Nos.1327- 1768 and 1889. It is contemplated that in some embodiments the DLL3 binding protein of this disclosure is fairly small and no more than 25 kD, no more than 20 kDa, no more than 15 kDa, orWSGR Docket No.47517-770.601 no more than 10 kDa in some embodiments. In certain instances, the EGFR binding is 5 kDa or less if it is a peptide or a small molecule entity.
[0043] In one aspect, the DLL3 targeting trispecific protein (also referred to herein as a DLL3 binding trispecific protein, a DLL3 trispecific protein, or a DLL3 TriTAC ) comprises (a) a first domain (A) which specifically binds to human CD3; (b) a second domain (B) which is a half-life extension domain; and (c) a third domain (C) which specifically binds to DLL3.The three domains in DLL3 targeting trispecific proteins are arranged in any order. Thus, it is contemplated that the domain order of the DLL3 targeting trispecific proteins are: H2N-(A)-(B)-(C)-COOH, H2N-(A)-(C)-(B)-COOH, H2N-(B)-(A)-(C)-COOH, H2N-(B)-(C)-(A)-COOH, H2N-(C)-(B)-(A)-COOH, or H2N-(C)-(A)-(B)-COOH.
[0044] In some embodiments, the DLL3 targeting trispecific proteins have a domain order of H2N- (A)-(B)-(C)-COOH. In some embodiments, the DLL3 targeting trispecific proteins have a domain order of H2N-(A)-(C)-(B)-COOH. In some embodiments, the DLL3 targeting trispecific proteins have a domain order of H2N-(B)-(A)-(C)-COOH. In some embodiments, the DLL3 targeting trispecific proteins have a domain order of H2N-(B)-(C)-(A)-COOH. In some embodiments, the DLL3 targeting trispecific proteins have a domain order of H2N-(C)-(B)-(A)-COOH. In some embodiments, the DLL3 targeting trispecific proteins have a domain order of H2N-(C)-(A)-(B)- COOH.
[0045] In some embodiments, the DLL3 targeting trispecific proteins have the HSA (also referred to herein as ALB) binding domain as the middle domain, such that the domain order is H2N-(A)- (B)-(C)-COOH or H2N-(C)-(B)-(A)-COOH. It is contemplated that in such embodiments where the HSA binding domain as the middle domain, the CD3 and DLL3 binding domains are afforded additional flexibility to bind to their respective targets.
[0046] In some embodiments, the trispecific binding protein comprises a third domain that specifically binds DLL3, which third domain is in some cases a DLL3 binding single domain antibody, which binds to DLL3 with equivalent or better affinity as that of a reference DLL3 binding parental molecule. The third domain in some embodiments comprises an affinity matured DLL3 binding molecule (e.g., an affinity matured DLL3 binding single domain antibody), and is derived from the DLL3 binding parental molecule, comprising one or more amino acid mutations (e.g., a stabilizing mutation, a destabilizing mutation) with respect to the DLL3 binding parentalWSGR Docket No.47517-770.601 molecule. In some embodiments, the affinity matured DLL3 binding molecule has superior stability with respect to selected destabilizing agents, as that of a reference DLL3 binding parental molecule. In some embodiments, the affinity matured DLL3 binding molecule is identified in a process comprising panning of one or more pre-candidate DLL3 binding molecules derived from one or more DLL3 binding parental molecule, expressed in a phage display library, against a DLL3 protein, such as a human DLL3 protein. The pre-candidate DLL3 binding molecule comprises, in some embodiments, amino acid substitutions in the variable regions, CDRs, or framework residues, relative to a parental molecule.
[0047] As used herein, “Phage display” refers to a technique by which variant polypeptides are displayed as fusion proteins to at least a portion of a coat protein on the surface of phage, filamentous phage, particles. A utility of phage display lies in the fact that large libraries of randomized protein variants can be rapidly and efficiently selected for those sequences that bind to a target molecule with high affinity. Display of peptide and protein libraries on phage has been used for screening millions of polypeptides for ones with specific binding properties. Polyvalent phage display methods have been used for displaying small random peptides and small proteins through Struct. Biol, 3:355-362 (1992), and references cited therein. In monovalent phage display, a protein or peptide library is fused to a gene III or a portion thereof, and expressed at low levels in the presence of wild type gene III protein so that phage particles display one copy or none of the fusion proteins. Avidity effects are reduced relative to polyvalent phage so that selection is on the basis of intrinsic ligand affinity, and phagemid vectors are used, which simplify DNA manipulations. Lowman and Wells, Methods: A companion to Methods in Enzymology, 3:205-0216 (1991).
[0048] In some embodiments, the panning comprises using varying binding times and concentrations to identify DLL3 binding molecules with increased or decreased on-rates, from pre- candidate DLL3 binding molecules. In some embodiments, the panning comprises using varying wash times to identify DLL3 binding molecules with increased or decreased off-rates, from pre- candidate DLL3 molecules. In some embodiments, the panning comprises using both varying binding times and varying wash times. In some embodiments, one or more stabilizing mutations are combined to increase the stability of the affinity matured DLL3 binding molecule, for example, by shuffling to create a second-stage combinatorial library from such mutants and conducting a second round of panning followed by a binding selection.
[0049] In some embodiments, the affinity matured DLL3 binding molecule comprises an equivalent or better affinity to a DLL3 protein (such as human DLL3 protein) as that of a DLL3 binding parental molecule, but that has reduced cross reactivity, or in some embodiments, increasedWSGR Docket No.47517-770.601 cross reactivity, with selected substances, such as ligands, proteins, antigens, or the like, other than the DLL3 epitope for which the DLL3 binding parental molecule is specific, or is designed to be specific for. In regard to the latter, an affinity matured DLL3 binding molecule, in some embodiments, is more successfully tested in animal models if the affinity matured DLL3 binding molecule is reacted with both human DLL3 and the corresponding target of the animal model, mouse DLL3 or cynomolgus DLL3. In some embodiments, the parental DLL3 binding molecule binds to human DLL3 with an affinity of about 10 nM or less, and to cynomolgus DLL3 with an affinity of about 15 nM or less. In some embodiments, the affinity matured DLL3 binding molecule, identified after one round of panning, binds to human DLL3 with an affinity of about 5 nM or less, and to cynomolgus DLL3 with an affinity of about 7.5 nM or less. In some embodiments, the affinity matured DLL3 binding molecule, identified after two rounds of panning, binds to human DLL3 with an affinity of about 2.5 nM or less, and to cynomolgus DLL3 with an affinity of about 3.5 nM or less.
[0050] In some embodiments, domain A, domain B, and domain C of the trispecific binding protein of this disclosure, are independently antigen-specific binding domain polypeptides that specifically bind to targets, such as targets on diseased cells, or targets on other cells that support the diseased state, such as targets on stromal cells that support tumor growth or targets on immune cells that support disease-mediated immunosuppression. In some examples, the antigen-specific binding domains include antibodies, heavy chain only antibodies, including single chain antibodies, Fabs, Fv, T-cell receptor binding domains, ligand binding domains, receptor binding domains, domain antibodies, single domain antibodies, minibodies, nanobodies, peptibodies, or various other antibody mimics (such as affimers, affitins, alphabodies, atrimers, CTLA4-based molecules, adnectins, anticalins, Kunitz domain-based proteins, avimers, knottins, fynomers, darpins, affibodies, affilins, monobodies and armadillo repeat protein-based proteins).
[0051] In some embodiments, the DLL3 targeting trispecific proteins described herein comprise a DLL binding polypeptide having a sequence selected from the group consisting of SEQ ID Nos.1- 442 and 1886, subsequences thereof, and variants thereof. In some embodiments, the trispecific antigen binding protein comprises a DLL3 binding polypeptide (i.e., the third domain (C)) having at least 70%-95% or more homology to a sequence selected from SEQ ID Nos.1-442 and 1886, subsequences thereof, and variants thereof. In some embodiments, the trispecific antigen binding protein comprises a DLL3 binding polypeptide (i.e., the third domain (C)) having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more homology to a sequence selected from the group consisting of SEQ ID Nos.1-442 and 1886, subsequences thereof, and variants thereof. In some embodiments, the trispecific antigen binding protein comprises a DLL3 bindingWSGR Docket No.47517-770.601 polypeptide (i.e., the third domain (C)) having at least 70%-95% or more identity to a sequence selected from SEQ ID Nos.1-442 and 1886, subsequences thereof, and variants thereof. In some embodiments, the trispecific antigen binding protein comprises a DLL3 binding polypeptide (i.e., the third domain (C)) having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to a sequence selected from the group consisting of SEQ ID Nos.1-442 and 1886, subsequences thereof, and variants thereof.
[0052] The DLL3 targeting trispecific proteins described herein are designed to allow specific targeting of cells expressing DLL3 by recruiting cytotoxic T cells. In some embodiments, this improves efficacy compared to ADCC (antibody dependent cell-mediated cytotoxicity), which is using full length antibodies directed to a sole antigen and is not capable of directly recruiting cytotoxic T cells. In contrast, by engaging CD3 molecules expressed specifically on these cells, the DLL3 targeting trispecific proteins can crosslink cytotoxic T cells with cells expressing DLL3 in a highly specific fashion, thereby directing the cytotoxic potential of the T cell towards the target cell. The DLL3 targeting trispecific proteins described herein engage cytotoxic T cells via binding to the surface-expressed CD3 proteins, which form part of the TCR. Simultaneous binding of several DLL3 trispecific antigen-binding protein to CD3 and to DLL3 expressed on the surface of particular cells causes T cell activation and mediates the subsequent lysis of the particular DLL3 expressing cell. Thus, DLL3 targeting trispecific proteins are contemplated to display strong, specific and efficient target cell killing. In some embodiments, the DLL3 targeting trispecific proteins described herein stimulate target cell killing by cytotoxic T cells to eliminate pathogenic cells (e.g., tumor cells expressing DLL3). In some of such embodiments, cells are eliminated selectively, thereby reducing the potential for toxic side effects.
[0053] The DLL3 targeting trispecific proteins described herein confer further therapeutic advantages over traditional monoclonal antibodies and other smaller bispecific molecules. Generally, the effectiveness of recombinant protein pharmaceuticals depends heavily on the intrinsic pharmacokinetics of the protein itself. One such benefit here is that the DLL3 targeting trispecific proteins described herein have extended pharmacokinetic elimination half-time due to having a half-life extension domain such as a domain that specifically binds to a serum albumin protein (e.g., a human serum albumin protein, HSA). In this respect, the DLL3 targeting trispecific proteins described herein have an extended serum elimination half-time of about two, three, about five, about seven, about 10, about 12, or about 14 days in some embodiments. This contrasts to other binding proteins such as BiTE or DART molecules which have relatively much shorter elimination half-times. For example, the BiTE CD19×CD3 bispecific scFv-scFv fusion molecule requires continuous intravenous infusion (i.v.) drug delivery due to its short elimination half-time.WSGR Docket No.47517-770.601 The longer intrinsic half-times of the DLL3 targeting trispecific proteins solve this issue thereby allowing for increased therapeutic potential such as low-dose pharmaceutical formulations, decreased periodic administration and / or novel pharmaceutical compositions.
[0054] The DLL3 targeting trispecific proteins described herein also have an optimal size for enhanced tissue penetration and tissue distribution. Larger sizes limit or prevent penetration or distribution of the protein in the target tissues. The DLL3 targeting trispecific proteins described herein avoid this by having a small size that allows enhanced tissue penetration and distribution. Accordingly, the DLL3 targeting trispecific proteins described herein, in some embodiments have a size of about 50 kDa to about 80 kDa, about 50 kDa to about 75 kDa, about 50 kDa to about 70 kDa, or about 50 kDa to about 65 kDa. In some embodiments, the size of the DLL3 targeting trispecific protein is smaller than about 60 kDa. Thus, the size of the DLL3 targeting trispecific proteins is advantageous over IgG antibodies which are about 150 kDa and the BiTE and DART diabody molecules which are about 55 kDa but are not half-life extended and therefore cleared quickly through the kidney.
[0055] In further embodiments, the DLL3 targeting trispecific proteins described herein have an optimal size for enhanced tissue penetration and distribution. In these embodiments, the DLL3 targeting trispecific proteins are constructed to be as small as possible, while retaining specificity toward its targets. Accordingly, in these embodiments, the DLL3 targeting trispecific proteins described herein have a size of about 20 kDa to about 40 kDa or about 25 kDa to about 35 kDa to about 40 kDa, to about 45 kDa, to about 50 kDa, to about 55 kDa, to about 60 kDa, to about 65 kDa. In some embodiments, the DLL3 targeting trispecific proteins described herein have a size of about 50kDa, 49, kDa, 48 kDa, 47 kDa, 46 kDa, 45 kDa, 44 kDa, 43 kDa, 42 kDa, 41 kDa, 40 kDa, about 39 kDa, about 38 kDa, about 37 kDa, about 36 kDa, about 35 kDa, about 34 kDa, about 33 kDa, about 32 kDa, about 31 kDa, about 30 kDa, about 29 kDa, about 28 kDa, about 27 kDa, about 26 kDa, about 25 kDa, about 24 kDa, about 23 kDa, about 22 kDa, about 21 kDa, or about 20 kDa. An exemplary approach to the small size is through the use of single domain antibody (sdAb) fragments for each of the domains. For example, a particular DLL3 trispecific antigen-binding protein has an anti-CD3 sdAb, anti-ALB sdAb and an sdAb for DLL3. This reduces the size of the exemplary DLL3 trispecific antigen-binding protein to under 60 kDa. Thus in some embodiments, the domains of the DLL3 targeting trispecific proteins are all single domain antibody (sdAb) fragments. It is contemplated that in some embodiments the DLL3 binding protein is fairly small and no more than 25 kDa, no more than 20 kDa, no more than 15 kDa, or no more than 10 kDa in some embodiments. In certain instances, the DLL3 binding protein is 5 kDa or less if it is a peptide or small molecule entity.WSGR Docket No.47517-770.601
[0056] In other embodiments, the DLL3 targeting trispecific proteins described herein comprise small molecule entity (SME) binders for ALB, DLL3, CD3, or all. SME binders are small molecules averaging about 500 to 2000 Da in size and are attached to the DLL3 targeting trispecific proteins by known methods, such as sortase ligation or conjugation. In these instances, one of the domains of DLL3 trispecific antigen-binding protein is a sortase recognition sequence, LPETG (SEQ ID No: 1896). To attach a SME binder to DLL3 trispecific antigen-binding protein with a sortase recognition sequence, the protein is incubated with a sortase and a SME binder whereby the sortase attaches the SME binder to the recognition sequence. In yet other embodiments, the domain which binds to DLL3 of DLL3 targeting trispecific proteins described herein comprise a knottin peptide for binding DLL3. Knottins are disufide-stabilized peptides with a cysteine knot scaffold and have average sizes about 3.5 kDa. Knottins have been contemplated for binding to certain tumor molecules such as DLL3. In further embodiments, the third domain which binds to DLL3 of DLL3 targeting trispecific proteins described herein comprise a natural DLL3 ligand.
[0057] Another feature of the DLL3 targeting trispecific proteins described herein is that they are of a single-polypeptide design with flexible linkage of their domains. This allows for facile production and manufacturing of the DLL3 targeting trispecific proteins as they can be encoded by single cDNA molecule to be easily incorporated into a vector. Further, because the DLL3 targeting trispecific proteins described herein are a monomeric single polypeptide chain, there are no chain pairing issues or a requirement for dimerization. It is contemplated that the DLL3 targeting trispecific proteins described herein have a reduced tendency to aggregate unlike other reported molecules such as bispecific proteins with Fc-gamma immunoglobulin domains.
[0058] In the DLL3 targeting trispecific proteins described herein, the domains are, in some embodiments, linked by internal linkers L1 and L2, where L1 links the first and second domain of the DLL3 targeting trispecific proteins and L2 links the second and third domains of the DLL3 targeting trispecific proteins. Linkers L1 and L2 have an optimized length and / or amino acid composition. In some embodiments, linkers L1 and L2 are the same length and amino acid composition. In other embodiments, L1 and L2 are different. In certain embodiments, internal linkers L1 and / or L2 are “short,” i.e., consist of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 amino acid residues. Thus, in certain instances, the internal linkers consist of about 12 or less amino acid residues. In the case of 0 amino acid residues, the internal linker is a peptide bond. In certain embodiments, internal linkers L1 and / or L2 are “long,” i.e., consist of 15, 20 or 25 amino acid residues. In some embodiments, these internal linkers consist of about 3 to about 15, for example 8, 9 or 10 contiguous amino acid residues. Regarding the amino acid composition of the internal linkers L1 and L2, peptides are selected with properties that confer flexibility to the DLL3 targetingWSGR Docket No.47517-770.601 trispecific proteins, do not interfere with the binding domains as well as resist cleavage from proteases. For example, glycine and serine residues generally provide protease resistance. Examples of internal linkers suitable for linking the domains in the DLL3 targeting trispecific proteins include but are not limited to (GS)n(SEQ ID No.1809), (GGS)n(SEQ ID No.1810), (GGGS)n (SEQ ID No.1811), (GGSG)n (SEQ ID No.1812), (GGSGG)n (SEQ ID No.1813), (GGGGS)n(SEQ ID No.1814), (GGGGG)n(SEQ ID No.1815), or (GGG)n(SEQ ID No.1816), wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment, internal linker L1 and / or L2 is (GGGGS)4 (SEQ ID No.1817) or (GGGGS)3 (SEQ ID No.1818). In another embodiment, internal linker L1 and / or L2 is GGGGSGGGS (SEQ ID No.1808).
[0059] In some cases, the domains within the DLL3 targeting trispecific protein are conjugated using an enzymatic site-specific conjugation method which involves the use of a mammalian or bacterial transglutaminase enzyme. Microbial transglutaminases (mTGs) are versatile tools in modern research and biotechnology. The availability of large quantities of relatively pure enzymes, ease of use, and lack of regulation by calcium and guanosine-5’-triphosphate (GTP) has propelled mTG to be the main cross-linking enzyme used in both the food industry and biotechnology. Currently, mTGs are used in many applications to attach proteins and peptides to small molecules, polymers, surfaces, DNA, as well as to other proteins. See Pavel Strp, Veracity of microbial transglutaminase, Bioconjugate Chem.25, 5, 855-862).
[0060] In some examples are provided DLL3 targeting trispecific protein wherein one of the domains comprises an acceptor glutamine in a constant region, which can then be conjugated to another domain via a lysine-based linker (e.g., any primary amine chain which is a substrate for TGase, comprising an alkylamine, oxoamine) wherein the conjugation occurs exclusively on one or more acceptor glutamine residues present in the targeting moiety outside of the antigen combining site (e.g., outside a variable region, in a constant region). Conjugation thus does not occur on a glutamine, an at least partly surface exposed glutamine, within the variable region. The trispecific protein, in some examples, is formed by reacting one of the domains with a lysine-based linker in the presence of a TGase.
[0061] In some embodiments, where one or more domains within the DLL3 targeting trispecific binding protein are directly joined, a hybrid vector is made where the DNA encoding the directly joined domains are themselves directly ligated to each other. In some embodiments, where linkers are used, a hybrid vector is made where the DNA encoding a first domain out of the three domains is ligated to the DNA encoding one end of a first linker moiety and the DNA encoding a second domain out of the three domains is ligated to the other end of the first linker moiety; further, the DNA encoding the second domain out of the three domains is linked to one end of a second linkerWSGR Docket No.47517-770.601 moiety and the DNA encoding a third domain out of the three domains is linked to the other end of the second linker moiety, wherein the first domain, the second domain, and the third domain are distinct and wherein the first domain, the second domain, and the third domain are independently selected from domain A, domain B, and domain C. Such ligation is performed, for example, either in series, or as a three way ligation. CD3 binding domain
[0062] The specificity of the response of T cells is mediated by the recognition of antigen (displayed in context of a major histocompatibility complex, MHC) by the TCR. As part of the Clustering of CD3 on T cells, such as by immobilized anti-CD3 antibodies leads to T cell activation similar to the engagement of the T cell receptor but independent of its clone-typical specificity.
[0063] In one aspect, the DLL3 targeting trispecific proteins described herein comprise a domain which specifically binds to CD3. In one aspect, the DLL3 targeting trispecific proteins described herein comprise a domain which specifically binds to human CD3. In some embodiments, the DLL3 targeting trispecific proteins described herein comprise a domain which specifically binds to
[0064] In further embodiments, the DLL3 targeting trispecific proteins described herein comprise a domain which specifically binds to the TCR. In certain instances, the DLL3 targeting trispecific certain instances, the DLL3 targeting trispecific proteins described herein comprise a domain which
[0065] In certain embodiments, the CD3 binding domain of the DLL3 targeting trispecific proteins described herein exhibit not only potent CD3 binding affinities with human CD3, but show also excellent cross reactivity with the respective cynomolgus monkey CD3 proteins.
[0066] In some embodiments, the CD3 binding domain of the DLL3 trispecific antigen-binding protein can be any domain that binds to CD3 including but not limited to domains from a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody. In some instances, it is beneficial for the CD3 binding domain to be derived from the same species in which the DLL3 trispecific antigen-binding protein will ultimately beWSGR Docket No.47517-770.601 used in. For example, for use in humans, it may be beneficial for the CD3 binding domain of the DLL3 trispecific antigen-binding protein to comprise human or humanized residues from the antigen binding domain of an antibody or antibody fragment.
[0067] Thus, in one aspect, the antigen-binding domain comprises a humanized or human antibody or an antibody fragment, or a murine antibody or antibody fragment. In one embodiment, the humanized or human anti-CD3 binding domain comprises one or more (e.g., all three) light chain complementary determining region 1 (LC CDR1), light chain complementary determining region 2 (LC CDR2), and light chain complementary determining region 3 (LC CDR3) of a humanized or human anti- CD3 binding domain described herein, and / or one or more (e.g., all three) heavy chain complementary determining region 1 (HC CDR1), heavy chain complementary determining region 2 (HC CDR2), and heavy chain complementary determining region 3 (HC CDR3) of a humanized or human anti-CD3 binding domain described herein, , a humanized or human anti-CD3 binding domain comprising one or more, , all three, LC CDRs and one or more, all three, HC CDRs.
[0068] In some embodiments, the humanized or human anti-CD3 binding domain comprises a humanized or human light chain variable region specific to CD3 where the light chain variable region specific to CD3 comprises human or non-human light chain CDRs in a human light chain framework.
[0069] In some embodiments, the humanized or human anti-CD3 binding domain comprises a humanized or human heavy chain variable region specific to CD3 where the heavy chain variable region specific to CD3 comprises human or non-human heavy chain CDRs in a human heavy chain framework region.
[0070] In certain instances, the complementary determining regions of the heavy chain and / or the light chain are derived from known anti-CD3 antibodies, such as, for example, muromonab-CD3 (OKT3), otelixizumab (TRX4), teplizumab (MGA031), visilizumab (Nuvion), SP34, TR-66 or X35-3, VIT3, BMA030 (BW264 / 56), CLB-T3 / 3, CRIS7, YTH12.5, F111-409, CLB-T3.4.2, TR- 66, WT32, SPv-T3b, 11D8, XIII-141, XIII-46, XIII-87, 12F6, T3 / RW2-8C8, T3 / RW2-4B6, OKT3D, M-T301, SMC2, F101.01, UCHT-1 and WT-31.
[0071] In one embodiment, the anti-CD3 binding domain is a single chain variable fragment (scFv) comprising a light chain and a heavy chain of an amino acid sequence provided herein. As used herein, “single chain variable fragment” or “scFv” refers to an antibody fragment comprising a variable region of a light chain and at least one antibody fragment comprising a variable region of a heavy chain, wherein the light and heavy chain variable regions are contiguously linked via a shortWSGR Docket No.47517-770.601 flexible polypeptide linker, and capable of being expressed as a single polypeptide chain, and wherein the scFv retains the specificity of the intact antibody from which it is derived. In an embodiment, the anti-CD3 binding domain comprises: a light chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions) of an amino acid sequence of a light chain variable region provided herein, or a sequence with 95-99% identity with an amino acid sequence provided herein; and / or a heavy chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions) of an amino acid sequence of a heavy chain variable region provided herein, or a sequence with 95-99% identity to an amino acid sequence provided herein. In some examples, the anti-CD3 binding domain comprises a sequence selected from SEQ ID Nos. 1793-1807, or a sequence that is at least about 60%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identity to a sequence selected from SEQ ID Nos.1793- 1807. In some examples, the anti-CD3 binding domain comprises three heavy chain CDRs (HC CDR1, HC CDR2, and HC CDR3), and three light chain CDRs. The heavy chain CDR1(HC CDR1) of the CD3 binding domain comprises a sequence selected from SEQ ID Nos.1820-1831, or a sequence comprising one or more modifications or substitutions in a sequence selected from SEQ ID Nos.1820-1831, or at least about 80% to about 99% . The heavy chain CDR2 (HC CDR2) of the CD3 binding domain comprises a sequence selected from SEQ ID Nos.1832-1841, or a sequence comprising one or more modifications or substitutions in a sequence selected from SEQ ID Nos.1832-1841. The heavy chain CDR3 (HC CDR3) of the CD3 binding domain comprises a sequence selected from SEQ ID Nos.1842-1853, or a sequence comprising one or more modifications or substitutions in a sequence selected from SEQ ID Nos.1842-1853. The light chain CDR1 (LC CDR1) of the CD3 binding domain comprises a sequence selected from SEQ ID Nos. 1852-1864, or a sequence comprising one or more modifications or substitutions in a sequence selected from SEQ ID Nos.1852-1864. The light chain CDR2 (LC CDR2) of the CD3 binding domain comprises a sequence selected from SEQ ID Nos.1865-1877, or a sequence comprising one or more modifications or substitutions in a sequence selected from SEQ ID Nos.1865-1877. The light chain CDR3 (LC CDR3) of the CD3 binding domain comprises a sequence selected from SEQ ID Nos.1878-1884, or a sequence comprising one or more modifications or substitutions in a sequence selected from SEQ ID Nos.1878-1884. In one embodiment, the humanized or human anti-CD3 binding domain is a scFv, and a light chain variable region comprising an amino acid sequence described herein, is attached to a heavy chain variable region comprising an amino acidWSGR Docket No.47517-770.601 sequence described herein, via a scFv linker. The light chain variable region and heavy chain variable region of a scFv can be in any of the following orientations: light chain variable region- scFv linker-heavy chain variable region or heavy chain variable region- scFv linker-light chain variable region.
[0072] In some instances, scFvs which bind to CD3 are prepared according to known methods. For example, scFv molecules can be produced by linking VH and VL regions together using flexible polypeptide linkers. The scFv molecules comprise a scFv linker (e.g.,a Ser-Gly linker) with an optimized length and / or amino acid composition. Accordingly, in some embodiments, the length of the scFv linker is such that the VH or VL domain can associate intermolecularly with the other variable domain to form the CD3 binding site. In certain embodiments, such scFv linkers are "short", i.e. consist of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 amino acid residues. Thus, in certain instances, the scFv linkers consist of about 12 or less amino acid residues. In the case of 0 amino acid residues, the scFv linker is a peptide bond. In some embodiments, these scFv linkers consist of about 3 to about 15, for example 8, 9 or 10 contiguous amino acid residues. Regarding the amino acid composition of the scFv linkers, peptides are selected that confer flexibility, do not interfere with the variable domains as well as allow inter-chain folding to bring the two variable domains together to form a functional CD3 binding site. For example, scFv linkers comprising glycine and serine residues generally provide protease resistance. In some embodiments, linkers in a scFv comprise glycine and serine residues. The amino acid sequence of the scFv linkers can be optimized, for example, by phage-display methods to improve the CD3 binding and production yield of the scFv. Examples of peptide scFv linkers suitable for linking a variable light domain and a variable heavy domain in a scFv include but are not limited to (GS)n (SEQ ID No.1809), (GGS)n (SEQ ID No.1810), (GGGS)n(SEQ ID No.1811), (GGSG)n(SEQ ID No.1812), (GGSGG)n(SEQ ID No.1813), (GGGGS)n(SEQ ID No.1814), (GGGGG)n(SEQ ID No.1815), or (GGG)n(SEQ ID No.1816), wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment, the scFv linker can be (GGGGS)4(SEQ ID No.1817) or (GGGGS)3(SEQ ID No.1818). In some embodiments, a linker comprises a sequence composed of any combinations of the linkers as set forth in SEQ ID Nos. 1809 to 1818, and the length of such a linker is in some examples up to 15 amino acids, or longer than 15 amino acids. Variation in the linker length may retain or enhance activity, giving rise to superior efficacy in activity studies.
[0073] In some embodiments, CD3 binding domain of DLL3 targeting trispecific antigen-binding protein has an affinity to CD3 on CD3 expressing cells with a KD of 1000 nM or less, 500 nM or less, 200 nM or less, 100 nM or less, 80 nM or less, 50 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 1 nM or less, or 0.5 nM or less. In some embodiments, the CD3 binding domain ofWSGR Docket No.47517-770.601 D of 1000 nM or less, 500 nM or less, 200 nM or less, 100 nM or less, 80 nM or less, 50 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 1 nM or less, or 0.5 nM or less. In further embodiments, CD3 binding domain of DLL3 targeting trispecific antigen-binding protein has low affinity to CD3, i.e., about 100 nM or greater.
[0074] The affinity to bind to CD3 can be determined, for example, by the ability of the DLL3 targeting trispecific antigen-binding protein itself or its CD3 binding domain to bind to CD3 coated on an assay plate; displayed on a microbial cell surface; in solution; etc. The binding activity of the DLL3 targeting trispecific antigen-binding protein itself or its CD3 binding domain of the present disclosure to CD3 can be assayed by immobilizing the ligand (e.g.,CD3) or the DLL3 targeting trispecific antigen-binding protein itself or its CD3 binding domain, to a bead, substrate, cell, etc. Agents can be added in an appropriate buffer and the binding partners incubated for a period of time at a given temperature. After washes to remove unbound material, the bound protein can be released with, for example, SDS, buffers with a high pH, and the like and analyzed, for example, by Surface Plasmon Resonance (SPR). Half-Life extension domain
[0075] Contemplated herein are domains which extend the half-life of an antigen-binding domain. Such domains are contemplated to include but are not limited to Albumin binding domains, Fc domains, small molecules, and other half-life extension domains known in the art.
[0076] Human albumin (ALB) (molecular mass 67 kDa) is the most abundant protein in plasma, to maintain plasma pH, contributes to colloidal blood pressure, functions as carrier of many metabolites and fatty acids, and serves as a major drug transport protein in plasma.
[0077] Noncovalent association with albumin extends the elimination half-time of short lived proteins. For example, a recombinant fusion of an albumin binding domain to a Fab fragment resulted in an in vivo clearance of 25- and 58-fold and a half-life extension of 26- and 37-fold when administered intravenously to mice and rabbits respectively as compared to the administration of the Fab fragment alone. In another example, when insulin is acylated with fatty acids to promote association with albumin, a protracted effect was observed when injected subcutaneously in rabbits or pigs. Together, these studies demonstrate a linkage between albumin binding and prolonged action.
[0078] In one aspect, the DLL3 targeting trispecific proteins described herein comprise a half-life extension domain, for example a domain which specifically binds to ALB. In some embodiments,WSGR Docket No.47517-770.601 the ALB binding domain of the DLL3 targeting trispecific antigen-binding protein can be any domain that binds to ALB including but not limited to domains from a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody. In some embodiments, the ALB binding domain is a single chain variable fragments (scFv), single-domain antibody such as a heavy chain variable domain (VH), a light chain variable domain (VL) and a variable domain (VHH) of camelid derived single domain antibody, peptide, ligand or small molecule entity specific for HSA. In certain embodiments, the ALB binding domain is a single- domain antibody. In other embodiments, the HSA binding domain is a peptide. In further embodiments, the HSA binding domain is a small molecule. It is contemplated that the HSA binding domain of DLL3 trispecific antigen-binding protein is fairly small and no more than 25 kD, no more than 20 kDa, no more than 15 kDa, or no more than 10 kDa in some embodiments. In certain instances, the ALB binding is 5 kDa or less if it is a peptide or small molecule entity.
[0079] The half-life extension domain of DLL3 targeting trispecific antigen-binding protein provides for altered pharmacodynamics and pharmacokinetics of the DLL3 targeting trispecific antigen-binding protein itself. As above, the half-life extension domain extends the elimination half-time. The half-life extension domain also alters pharmacodynamic properties including alteration of tissue distribution, penetration, and diffusion of the trispecific antigen-binding protein. In some embodiments, the half-life extension domain provides for improved tissue (including tumor) targeting, tissue distribution, tissue penetration, diffusion within the tissue, and enhanced efficacy as compared with a protein without a half-life extension domain. In one embodiment, therapeutic methods effectively and efficiently utilize a reduced amount of the trispecific antigen- binding protein, resulting in reduced side effects, such as reduced non-tumor cell cytotoxicity.
[0080] Further, the binding affinity of the half-life extension domain can be selected so as to target a specific elimination half-time in a particular trispecific antigen-binding protein. Thus, in some embodiments, the half-life extension domain has a high binding affinity. In other embodiments, the half-life extension domain has a medium binding affinity. In yet other embodiments, the half-life extension domain has a low or marginal binding affinity. Exemplary binding affinities include KD concentrations at 10 nM or less (high), between 10 nM and 100 nM (medium), and greater than 100 nM (low). As above, binding affinities to ALB are determined by known methods such as Surface Plasmon Resonance (SPR). In some embodiments, ALB binding domains described herein comprise a single domain antibody.
[0081] In some embodiments, the half-life extension domain comprises a sequence selected from SEQ ID Nos.1769-1778, or a sequence that is at least about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% identical to aWSGR Docket No.47517-770.601 sequence selected from SEQ ID Nos.1769-1778. In some examples, the half-life extension comprises three heavy chain CDRs (HC CDR1, HC CDR2, and HC CDR3), and three light chain CDRs. In some examples, the half-life extension comprises three heavy chain CDRs (HC CDR1, HC CDR2, and HC CDR3), or three light chain CDRs. The heavy chain CDR1(HC CDR1) of the half-life extension domain, in some embodiments, comprises a sequence selected from SEQ ID Nos..1782-1784, or a sequence comprising one or more modifications or substitutions in a sequence selected from SEQ ID Nos.1782-1784, or at least about 80% to about 99%. The heavy chain CDR2 (HC CDR2) of the half-life extension domain, in some embodiments, comprises a sequence selected from SEQ ID Nos.1785-1790, or a sequence comprising one or more modifications or substitutions in a sequence selected from SEQ ID Nos.1785-1790. The heavy chain CDR3 (HC CDR3) of the CD3 binding domain comprises a sequence selected from SEQ ID Nos.1791 or 1792, or a sequence comprising one or more modifications or substitutions in a sequence selected from SEQ ID Nos.1791 or 1792. DLL3 binding domain
[0082] DLL3 (also known as Delta-like Ligand 3 or SCDO1) is a member of the Delta-like family of Notch DSL ligands. Representative DLL3 protein orthologs include, but are not limited to, human (Accession Nos. NP_058637 and NP_982353), chimpanzee (Accession No. XP_003316395), mouse (Accession No. NP_031892), and rat (Accession No. NP_446118). In humans, the DLL3 gene consists of 8 exons spanning 9.5 kbp located on chromosome 19q13. Alternate splicing within the last exon gives rise to two processed transcripts, one of 2389 bases (Accession No. NM_016941) and one of 2052 bases (Accession No. NM_203486). The former transcript encodes a 618 amino acid protein (Accession No. NP_058637), whereas the latter encodes a 587 amino acid protein (Accession No. NP_982353). These two protein isoforms of DLL3 share overall 100% identity across their extracellular domains and their transmembrane domains, differing only in that the longer isoform contains an extended cytoplasmic tail containing 32 additional residues at the carboxy terminus of the protein. The extracellular region of the DLL3 protein, comprises six EGF-like domains, the single DSL domain and the N-terminal domain. Generally, the EGF domains are recognized as occurring at about amino acid residues 216-249 (domain 1), 274-310 (domain 2), 312-351 (domain 3), 353-389 (domain 4), 391-427 (domain 5) and 429-465 (domain 6), with the DSL domain at about amino acid residues 176-215 and the N- terminal domain at about amino acid residues 27-175 of hDLL3. Each of the EGF-like domains, the DSL domain and the N-terminal domain comprise part of the DLL3 protein as defined by a distinct amino acid sequence. The EGF-like domains are termed, in some embodiments, as EGF1 to EGF6WSGR Docket No.47517-770.601 with EGF1 being closest to the N-terminal portion of the protein. In general, DSL ligands are composed of a series of structural domains: a unique N-terminal domain, followed by a conserved DSL domain, multiple tandem epidermal growth factor (EGF)-like repeats, a transmembrane domain, and a cytoplasmic domain not highly conserved across ligands but one which contains multiple lysine residues that are potential sites for ubiquitination by unique E3 ubiquitin ligases. The DSL domain is a degenerate EGF-domain that is necessary but not sufficient for interactions with Notch receptors. Additionally, the first two EGF-like repeats of most DSL ligands contain a smaller protein sequence motif known as a DOS domain that co-operatively interacts with the DSL domain when activating Notch signaling.
[0083] In some embodiments, the disclosed DLL3 trispecific binding proteins of this disclosure are generated, fabricated, engineered or selected so as to react with a selected domain, motif or epitope within a DLL3 protein. In some embodiments, the DLL3 targeting trispecific protein binds to the DSL domain and, in some embodiments, binds to an epitope comprising G203, R205, P206 within the DSL domain.
[0084] The DLL3 binding domain of the DLL3 targeting trispecific proteins of the present disclosure are, in some embodiments, engineered fabricated and / or selected to react with both isoform(s) of DLL3 or a single isoform of the protein or, conversely, comprise a pan-DLL binding domain that reacts or associates with at least one additional DLL family member in addition to DLL3. In some embodiments, the DLL3 binding domain, such as DLL3 binding domain are engineered, fabricated, and / or selected so that they react with domains (or epitopes therein) that are exhibited by DLL3 only or with domains that are at least somewhat conserved across multiple or all DLL family members.
[0085] In some embodiments the DLL3 binding domain associates or binds to a specific epitope, portion, motif or domain of DLL3. Both DLL3 isoforms incorporate an identical extracellular region comprising at least an N-terminal domain, a DSL (Delta / Serrate / lag-2) domain and six EGF- like domains (i.e., EGF1-EGF6). Accordingly, in certain embodiments the DLL3 binding domain binds or associate with the N-terminal domain of DLL3 (amino acids 27-175 in the mature protein) while in other embodiments the DLL3 binding domain associates with the DSL domain (amino acids 176-215) or epitope therein. In other aspects of the present disclosure the DLL3 binding domain associates or bind to a specific epitope located in a particular EGF-like domain of DLL3. In some embodiments, the DLL3 binding domain associates or binds to an epitope located in EGF1 (amino acids 216-249), EGF2 (amino acids 274-310), EGF3 (amino acids 312-351), EGF4 (amino acids 353-389), EGF5 (amino acids 391.427) or EGF6 (amino acids 429-465). In some embodiments, each of the aforementioned domains comprises more than one epitope and / or moreWSGR Docket No.47517-770.601 than one bin. In some embodiments the DLL3 binding domain binds, reacts or associates with the DSL domain or an epitope therein. In other embodiments the DLL3 binding domain binds, reacts or associates with a particular EGF-like domain or an epitope therein. In some embodiments the DLL3 binding domain binds, reacts or associates with the N-terminal domain or an epitope therein.
[0086] In some embodiments, the DLL3 binding proteins of this disclosure, such as the DLL3 binding domain of the trispecific proteins of this disclosure binds to the full length DLL3 protein or to a fragment thereof, such as epitope containing fragments within the full length DLL3 protein, as described above. In some cases, the epitope containing fragment comprises antigenic or immunogenic fragments and derivatives thereof of the DLL3 protein. Epitope containing fragments, including antigenic or immunogenic fragments, are, in some embodiments, 12 amino acids or more, 20 amino acids or more, 50 or 100 amino acids or more. The DLL3 fragments, in some embodiments, comprises 95% or more of the length of the full protein, 90% or more, 75% or 50% or 25% or 10% or more of the length of the full protein. In some embodiments, the epitope- containing fragments of DLL3 including antigenic or immunogenic fragments are capable of eliciting a relevant immune response in a patient. Derivatives of DLL3 include, in some embodiments, variants on the sequence in which one or more (e.g.,1-20 such as 15 amino acids, or up to 20% such as up to 10% or 5% or 1% by number of amino acids based on the total length of the protein) deletions, insertions or substitutions have been made to the DLL3 sequence provided in SEQ ID No.1885 (UniProtKB Accession Q9NYJ7). In some embodiments, substitutions comprise conservative substitutions. Derivatives and variants of DLL3, in some examples, have essentially the same biological function as the DLL3 protein from which they are derived. For instance, derivatives and variants of DLL3 are, in some cases, comparably antigenic or immunogenic to the protein from which they are derived, have either the ligand-binding activity, or the active receptor- complex forming ability, or preferably both, of the protein from which they are derived, and have the same tissue distribution as DLL3.
[0087] The design of the DLL3 targeting trispecific proteins described herein allows the binding domain to DLL3 to be flexible in that the binding domain to DLL3 can be any type of binding domain, including but not limited to, domains from a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody. In some embodiments, the binding domain to DLL3 is a single chain variable fragments (scFv), a single-domain antibody such as a heavy chain variable domain (VH), a light chain variable domain (VL) and a variable domain (VHH) of camelid derived single domain antibody. In other embodiments, the binding domain to DLL3 is a non-Ig binding domain, i.e., an antibody mimetic, such as anticalins, affilins, affibody molecules, affimers, affitins, alphabodies, avimers, DARPins, fynomers, kunitz domain peptides,WSGR Docket No.47517-770.601 and monobodies. In further embodiments, the binding domain to DLL3 is a ligand or peptide that binds to or associates with DLL3. In yet further embodiments, the binding domain to DLL3 is a knottin. In yet further embodiments, the binding domain to DLL3 is a small molecular entity.
[0088] In some embodiments, the DLL3 binding domain binds to a protein comprising the sequence of SEQ ID No.1885 (UniProtKB Accession Q9NYJ7). In some embodiments, the DLL3 binding domain binds to a protein comprising a truncated sequence compared to SEQ ID No.1885 (UniProtKB Accession Q9NYJ7). In some embodiments, the DLL3 binding domain binds to a protein comprising the sequence of SEQ ID No.1892 or SEQ ID No.1893 (which is the mature extracellular domain of a DLL3 protein). In some embodiments, the DLL3 binding domain binds to a protein comprising amino acids 47-492 of SEQ ID No.1892. In some embodiments, the DLL3 binding domain recognizes an epitope within amino acids 47-4492 of SEQ ID No.1892.
[0089] In some embodiments, the DLL3 binding domain is an anti-DLL3 antibody or an antibody variant. As used herein, the term “antibody variant” refers to variants and derivatives of an antibody described herein. In certain embodiments, amino acid sequence variants of the anti-DLL3 antibodies described herein are contemplated. For example, in certain embodiments amino acid sequence variants of anti-DLL3 antibodies described herein are contemplated to improve the binding affinity and / or other biological properties of the antibodies. Exemplary method for preparing amino acid variants include, but are not limited to, introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions from, and / or insertions into and / or substitutions of residues within the amino acid sequences of the antibody.
[0090] Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, antigen- binding. In certain embodiments, antibody variants having one or more amino acid substitutions are provided. Sites of interest for substitution mutagenesis include the CDRs and framework regions. Examples of such substitutions are described below. Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, retained / improved antigen binding, decreased immunogenicity, or improved T-cell mediated cytotoxicity (TDCC). Both conservative and non-conservative amino acid substitutions are contemplated for preparing the antibody variants.
[0091] In another example of a substitution to create a variant anti-DLL3 antibody, one or more hypervariable region residues of a parent antibody are substituted. In general, variants are then selected based on improvements in desired properties compared to a parent antibody, for example, increased affinity, reduced affinity, reduced immunogenicity, increased pH dependence of binding.WSGR Docket No.47517-770.601
[0092] In some embodiments, the DLL3 binding domain of the DLL3 targeting trispecific protein is a single domain antibody such as a heavy chain variable domain (VH), a variable domain (VHH) of a llama derived sdAb, a peptide, a ligand or a small molecule entity specific for DLL3. In some embodiments, the DLL3 binding domain of the DLL3 targeting trispecific protein described herein is any domain that binds to DLL3 including but not limited to domains from a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody. In certain embodiments, the DLL3 binding domain is a single-domain antibody. In other embodiments, the DLL3 binding domain is a peptide. In further embodiments, the DLL3 binding domain is a small molecule.
[0093] Generally, it should be noted that the term single domain antibody as used herein in its broadest sense is not limited to a specific biological source or to a specific method of preparation. Single domain antibodies are antibodies whose complementary determining regions are part of a single domain polypeptide. Examples include, but are not limited to, heavy chain antibodies, antibodies naturally devoid of light chains, single domain antibodies derived from conventional 4- chain antibodies, engineered antibodies and single domain scaffolds other than those derived from antibodies. Single domain antibodies may be any of the art, or any future single domain antibodies. Single domain antibodies may be derived from any species including, but not limited to mouse, human, camel, llama, goat, rabbit, bovine. For example, in some embodiments, the single domain antibodies of the disclosure are obtained: (1) by isolating the VHH domain of a naturally occurring heavy chain antibody; (2) by expression of a nucleotide sequence encoding a naturally occurring VHH domain; (3) by “humanization” of a naturally occurring VHH domain or by expression of a nucleic acid encoding a such humanized VHH domain; (4) by “camelization” of a naturally occurring VH domain from any animal species, and in particular from a species of mammal, such as from a human being, or by expression of a nucleic acid encoding such a camelized VH domain; (5) by “camelisation” of a “domain antibody” or “Dab,” or by expression of a nucleic acid encoding such a camelized VH domain; (6) by using synthetic or semi-synthetic techniques for preparing proteins, polypeptides or other amino acid sequences; (7) by preparing a nucleic acid encoding a single domain antibody using techniques for nucleic acid synthesis known in the field, followed by expression of the nucleic acid thus obtained; and / or (8) by any combination of one or more of the foregoing.
[0094] In one embodiment, a single domain antibody corresponds to the VHH domains of naturally occurring heavy chain antibodies directed against DLL3. As further described herein, such VHH sequences can generally be generated or obtained by suitably immunizing a species of Llama with DLL3, (i.e., so as to raise an immune response and / or heavy chain antibodies directed againstWSGR Docket No.47517-770.601 DLL3), by obtaining a suitable biological sample from said Llama (such as a blood sample, serum sample or sample of B-cells), and by generating VHH sequences directed against DLL3, starting from said sample, using any suitable technique known in the field.
[0095] In another embodiment, such naturally occurring VHH domains against DLL3, are obtained from naïve libraries of Camelid VHH sequences, for example by screening such a library using DLL3, or at least one part, fragment, antigenic determinant or epitope thereof using one or more screening techniques known in the field. Such libraries and techniques are for example described in WO 99 / 37681, WO 01 / 90190, WO 03 / 025020 and WO 03 / 035694. Alternatively, improved synthetic or semi-synthetic libraries derived from naïve VHH libraries are used, such as VHH libraries obtained from naïve VHH libraries by techniques such as random mutagenesis and / or CDR shuffling, as for example described in WO 00 / 43507.
[0096] In a further embodiment, yet another technique for obtaining VHH sequences directed against DLL3, involves suitably immunizing a transgenic mammal that is capable of expressing heavy chain antibodies (i.e., so as to raise an immune response and / or heavy chain antibodies directed against DLL3), obtaining a suitable biological sample from said transgenic mammal (such as a blood sample, serum sample or sample of B-cells), and then generating VHH sequences directed against DLL3, starting from said sample, using any suitable technique known in the field. For example, for this purpose, the heavy chain antibody-expressing rats or mice and the further methods and techniques described in WO 02 / 085945 and in WO 04 / 049794 can be used.
[0097] In some embodiments, an anti-DLL3 single domain antibody of the DLL3 targeting trispecific protein comprises a single domain antibody with an amino acid sequence that corresponds to the amino acid sequence of a naturally occurring VHH domain, but that has been "humanized", i.e., by replacing one or more amino acid residues in the amino acid sequence of said naturally occurring VHH sequence (and in particular in the framework sequences) by one or more of the amino acid residues that occur at the corresponding position(s) in a VH domain from a conventional 4-chain antibody from a human being (e.g., as indicated above). This can be performed in a manner known in the field, which will be clear to the skilled person, for example on the basis of the further description herein. Again, it should be noted that such humanized anti-DLL3 single domain antibodies of the disclosure are obtained in any suitable manner known per se (i.e., as indicated under points (1)-(8) above) and thus are not strictly limited to polypeptides that have been obtained using a polypeptide that comprises a naturally occurring VHH domain as a starting material. In some additional embodiments, a single domain anti-DLL3 antibody, as described herein, comprises a single domain antibody with an amino acid sequence that corresponds to the amino acid sequence of a naturally occurring VH domain, but that has been “camelized,” i.e., byWSGR Docket No.47517-770.601 replacing one or more amino acid residues in the amino acid sequence of a naturally occurring VH domain from a conventional 4-chain antibody by one or more of the amino acid residues that occur at the corresponding position(s) in a VHH domain of a heavy chain antibody. Such “camelizing” substitutions are preferably inserted at amino acid positions that form and / or are present at the VH- VL interface, and / or at the so-called Camelidae hallmark residues (see for example WO 94 / 04678 and Davies and Riechmann (1994 and 1996)). Preferably, the VH sequence that is used as a starting material or starting point for generating or designing the camelized single domain is preferably a VH sequence from a mammal, more preferably the VH sequence of a human being, such as a VH3 sequence. However, it should be noted that such camelized anti-DLL3 single domain antibodies of the disclosure, in certain embodiments, are obtained in any suitable manner known in the field (i.e., as indicated under points (1)-(8) above) and thus are not strictly limited to polypeptides that have been obtained using a polypeptide that comprises a naturally occurring VH domain as a starting material. For example, as further described herein, both “humanization” and “camelization” is performed by providing a nucleotide sequence that encodes a naturally occurring VHH domain or VH domain, respectively, and then changing, one or more codons in said nucleotide sequence in such a way that the new nucleotide sequence encodes a “humanized” or “camelized” single domain antibody, respectively. This nucleic acid can then be expressed, so as to provide a desired anti- DLL3 single domain antibody of the disclosure. Alternatively, in other embodiments, based on the amino acid sequence of a naturally occurring VHH domain or VH domain, respectively, the amino acid sequence of the desired humanized or camelized anti-DLL3 single domain antibody of the disclosure, respectively, are designed and then synthesized de novo using known techniques for peptide synthesis. In some embodiments, based on the amino acid sequence or nucleotide sequence of a naturally occurring VHH domain or VH domain, respectively, a nucleotide sequence encoding the desired humanized or camelized anti-DLL3 single domain antibody of the disclosure, respectively, is designed and then synthesized de novo using known techniques for nucleic acid synthesis, after which the nucleic acid thus obtained is expressed in using known expression techniques, so as to provide the desired anti-DLL3 single domain antibody of the disclosure.
[0098] Other suitable methods and techniques for obtaining the anti-DLL3 single domain antibody of the disclosure and / or nucleic acids encoding the same, starting from naturally occurring VH sequences or VHH sequences for example comprises combining one or more parts of one or more naturally occurring VH sequences (such as one or more framework (FR) sequences and / or complementarity determining region (CDR) sequences), one or more parts of one or more naturally occurring VHH sequences (such as one or more FR sequences or CDR sequences), and / or one or more synthetic or semi-synthetic sequences, in a suitable manner, so as to provide an anti-DLL3WSGR Docket No.47517-770.601 single domain antibody of the disclosure or a nucleotide sequence or nucleic acid encoding the same.
[0099] In some embodiments, the DLL3 binding domain is an anti-DLL3 specific antibody comprising a heavy chain variable complementarity determining region CDR1, a heavy chain variable CDR2, a heavy chain variable CDR3, a light chain variable CDR1, a light chain variable CDR2, and a light chain variable CDR3. In some embodiments, the DLL3 binding domain comprises any domain that binds to DLL3 including but not limited to domains from a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody, fragments, fragments comprised of one or more CDRs, single-chain antibodies (e.g., single chain Fv fragments (scFv)), disulfide stabilized (dsFv) Fv fragments, heteroconjugate antibodies (e.g., bispecific antibodies), pFv fragments, heavy chain monomers or dimers, light chain monomers or dimers, and dimers consisting of one heavy chain and one light chain. In some embodiments, the DLL3 binding domain is a single domain antibody. In some embodiments, the anti-DLL3 single domain antibody comprises heavy chain variable complementarity determining regions (CDR), CDR1, CDR2, and CDR3.
[0100] In some embodiments, the DLL3 binding domain is a polypeptide comprising an amino acid sequence that is comprised of four framework regions / sequences (f1-f4) interrupted by three complementarity determining regions / sequences, as represented by the formula: f1-r1-f2-r2-f3-r3- f4, wherein r1, r2, and r3 are complementarity determining regions CDR1, CDR2, and CDR3, respectively, and f1, f2, f3, and f4 are framework residues. The framework residues of the DLL3 binding protein of the present disclosure comprise, for example, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, or 94 amino acid residues, and the complementarity determining regions comprise, for example, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 amino acid residues. In some embodiments, the DLL3 binding domain comprises an amino acid sequence selected from SEQ ID Nos.1-442 and 1886. In some embodiments, CDR1 of the DLL3 binding domain comprises a sequence selected from SEQ ID Nos.443-884 and 1887, or one or more amino acid substitutions relative to a sequence selected from the group consisting of SEQ ID Nos.443-884 and 1887. In some embodiments, CDR2 comprises a sequence selected from the group consisting of SEQ ID Nos.885-1326 and 1888, or one or more amino acid substitutions relative to a sequence selected from the group consisting of SEQ ID Nos.885-1326 and 1888. In some embodiments, the CDR3 comprises a sequence selected from the group consisting of SEQ ID Nos.1327-1768 and 1889, or one or more substitutions relative to a sequence selected from SEQ ID Nos.1327-1768 and 1889.WSGR Docket No.47517-770.601
[0101] In some embodiments, the CDR1 comprises an amino acid sequence selected from SEQ ID Nos.443-884 and 1887 or a variant having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions in an amino acid selected from SEQ ID Nos.443-884 and 1887. In some embodiments, the CDR2 comprises an amino acid sequence selected from SEQ ID Nos.885-1326 and 1888 or a variant having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions in an amino acid sequence selected from SEQ ID Nos.885-1326 and 1888. In some embodiments, the CDR3 comprises an amino acid sequence selected from SEQ ID Nos.1327-1768 and 1889 or a variant having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions in a sequence selected from SEQ ID Nos.1327-1768 and 1889.
[0102] In some embodiments, the CDR1 comprises an amino acid sequence selected from SEQ ID Nos.495-528 or a variant having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions in an amino acid selected from SEQ ID Nos.495-528. In some embodiments, the CDR2 comprises an amino acid sequence selected from SEQ ID Nos.937-970 or a variant having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions in an amino acid sequence selected from SEQ ID Nos.937-970. In some embodiments, the CDR3 comprises an amino acid sequence selected from SEQ ID Nos.1379-1412 or a variant having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions in a sequence selected from SEQ ID Nos.1379-1412.
[0103] In some embodiments, the CDR1 comprises an amino acid sequence selected from SEQ ID Nos.529-809 or a variant having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions in an amino acid selected from SEQ ID Nos.529-809. In some embodiments, the CDR2 comprises an amino acid sequence selected from SEQ ID Nos.971 to 1251 or a variant having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions in an amino acid sequence selected from SEQ ID Nos.971 to 1251. In some embodiments, the CDR3 comprises an amino acid sequence selected from SEQ ID Nos.1379 to 1412 or a variant having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions in a sequence selected from SEQ ID Nos.1379-1412.
[0104] In some embodiments, the CDR1 comprises an amino acid sequence selected from SEQ ID Nos.810-884 or a variant having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions in an amino acid selected from SEQ ID Nos.810-884. In some embodiments, the CDR2 comprises an amino acid sequence selected from SEQ ID Nos.1252 to 1326 or a variant having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions in an amino acid sequence selected from SEQ ID Nos.1252 to 1326. In some embodiments, the CDR3 comprises an amino acid sequence selected from SEQ ID Nos.1692 to 1768 or a variant havingWSGR Docket No.47517-770.601 one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions in a sequence selected from SEQ ID Nos.1692 to 1768.
[0105] In various embodiments, the DLL3 binding domain of the present disclosure is at least about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to an amino acid sequence selected from SEQ ID Nos.1-442 and 1886.In various embodiments, the DLL3 binding domain of the present disclosure is at least about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to an amino acid sequence selected from SEQ ID Nos.53-86.
[0106] In various embodiments, the DLL3 binding domain of the present disclosure is at least about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to an amino acid sequence selected from SEQ ID Nos.87-367.
[0107] In various embodiments, the DLL3 binding domain of the present disclosure is at least about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to SEQ ID No.68, or a sequence derived from SEQ ID No.68.
[0108] In various embodiments, the DLL3 binding domain of the present disclosure is at least about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to SEQ ID No.75, or a sequence derived from SEQ ID No.75.
[0109] In some embodiments, the DLL3 binding domain of the DLL3 targeting trispecific binding protein is cross-reactive with human and cynomolgus DLL3. In some embodiments, the DLL3 binding domain is specific for human DLL3. In certain embodiments, the DLL3 binding domain disclosed herein binds to human DLL3 with a human Kd (hKd). In certain embodiments, the DLL3 binding domain disclosed herein binds to cynomolgus DLL3 with a cynomolgus Kd (cKd). In certain embodiments, the DLL3 binding domain disclosed herein binds to both cynomolgus DLL3 and a human DLL3,with a cyno Kd (cKd) and a human Kd, respectively (hKd). In someWSGR Docket No.47517-770.601 embodiments, the DLL3 binding protein binds to human and cynomolgus DLL3 with comparable binding affinities (i.e., hKd and cKd values do not differ by more than ± 10%). In some embodiments, the hKd and the cKd range from about 0.001 nM to about 500 nM. In some embodiments, the hKd and the cKd range from about 0.001 nM to about 450 nM. In some embodiments, the hKd and the cKd range from about 0.001 nM to about 400 nM. In some embodiments, the hKd and the cKd range from about 0.001 nM to about 350 nM. In some embodiments, the hKd and the cKd range from about 0.001 nM to about 300 nM . In some embodiments, the hKd and the cKd range from about 0.001 nM to about 250 nM. In some embodiments, the hKd and the cKd range from about 0.001 nM to about 200 nM. In some embodiments, the hKd and the cKd range from about 0.001 nM to about 150 nM. In some embodiments, the hKd and the cKd range from about 0.001 nM to about 100 nM. In some embodiments, the hKd and the cKd range from about 0.1 nM to about 90 nM. In some embodiments, the hKd and the cKd range from about 0.2 nM to about 80 nM. In some embodiments, the hKd and the cKd range from about 0.3 nM to about 70 nM. In some embodiments, the hKd and the cKd range from about 0.4 nM to about 50 nM. In some embodiments, the hKd and the cKd range from about 0.5 nM to about 30 nM. In some embodiments, the hKd and the cKd range from about 0.6 nM to about 10 nM. In some embodiments, the hKd and the cKd range from about 0.7 nM to about 8 nM. In some embodiments, the hKd and the cKd range from about 0.8 nM to about 6 nM. In some embodiments, the hKd and the cKd range from about 0.9 nM to about 4 nM. In some embodiments, the hKd and the cKd range from about 1 nM to about 2 nM.
[0110] In certain embodiments, the DLL3 binding domains of the present disclosure preferentially bind membrane bound DLL3 over soluble DLL3. Membrane bound DLL3 refers to the presence of DLL3 in or on the cell membrane surface of a cell that expresses DLL3. Soluble DLL3 refers to DLL3 that is no longer on in or on the cell membrane surface of a cell that expresses or expressed DLL3. In certain instances, the soluble DLL3 is present in the blood and / or lymphatic circulation in a subject. In one embodiment, the DLL3 binding proteins bind membrane-bound DLL3 at least 5 fold, 10 fold, 15 fold, 20 fold, 25 fold, 30 fold, 40 fold, 50 fold, 100 fold, 500 fold, or 1000 fold greater than soluble DLL3. In one embodiment, the antigen binding proteins of the present disclosure preferentially bind membrane-bound DLL330 fold greater than soluble DLL3. Determining the preferential binding of an antigen binding protein to membrane bound DLL3 over soluble DLL3 can be readily determined using assays well known in the art.
[0111] In some embodiments, any of the foregoing DLL3 binding domains (e.g., anti-DLL3 single domain antibodies of SEQ ID Nos.1-442 and 1886) are affinity peptide tagged for ease ofWSGR Docket No.47517-770.601 purification. In some embodiments, the affinity peptide tag is six consecutive histidine residues, also referred to as 6X-his (SEQ ID No.1819).
[0112] In some embodiments, any of the foregoing DLL3 binding domains (e.g., anti-DLL3 single domain antibodies of SEQ ID Nos.1-442 and 1886) are affinity peptide tagged for ease of purification. In some embodiments, the affinity peptide tag is six consecutive histidine residues, also referred to as 6X-his (SEQ ID No.1819). Integration into chimeric antigen receptors (CAR)
[0113] The DLL3 targeting trispecific antigen binding proteins of the present disclosure can, in certain examples, be incorporated into a chimeric antigen receptor (CAR). An engineered immune effector cell, a T cell or NK cell, can be used to express a CAR that includes an anti-DLL3 targeting trispecific protein containing an anti-DLL3 single domain antibody as described herein. In one embodiment, the CAR including an anti-DLL3 targeting trispecific protein as described herein is connected to a transmembrane domain via a hinge region, and further a costimulatory domain, a functional signaling domain obtained from OX40, CD27, CD28, CD5, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), or 4-1BB. In some embodiments, the CAR further comprises a sequence encoding an intracellular signaling domain, such as 4-1BB and / or CD3 zeta. Tumor growth reduction properties
[0114] In certain embodiments, the DLL3 targeting trispecific proteins of the disclosure reduce the growth of tumor cells in vivo when administered to a subject who has tumor cells that express DLL3. Measurement of the reduction of the growth of tumor cells can be determined by multiple different methodologies well known in the art. Non-limiting examples include direct measurement of tumor dimension, measurement of excised tumor mass and comparison to control subjects, measurement via imaging techniques (e.g.,CT or MRI) that may or may not use isotopes or luminescent molecules (e.g. luciferase) for enhanced analysis, and the like.
[0115] In specific embodiments, administration of the trispecific proteins of the disclosure results in a reduction of in vivo growth of tumor cells as compared to a control antigen binding agent by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%, with an about 100% reduction in tumor growth indicating a complete response and disappearance of the tumor. In further embodiments, administration of the trispecific proteins of the disclosure results in a reduction of in vivo growth of tumor cells as compared to a control antigen binding agent by about 50-100%, about 75-100% or about 90-100%. In further embodiments, administration of the trispecific proteins of the disclosure results in a reduction of in vivo growth of tumor cells asWSGR Docket No.47517-770.601 compared to a control antigen binding agent by about 50-60%, about 60-70%, about 70-80%, about 80-90%, or about 90-100%. DLL3 Targeting Trispecific Protein Modifications
[0116] The DLL3 targeting trispecific proteins described herein encompass derivatives or analogs in which (i) an amino acid is substituted with an amino acid residue that is not one encoded by the genetic code, (ii) the mature polypeptide is fused with another compound such as polyethylene glycol, or (iii) additional amino acids are fused to the protein, such as a leader or secretory sequence or a sequence for purification of the protein.
[0117] Typical modifications include, but are not limited to, acetylation, acylation, ADP- ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.
[0118] Modifications are made anywhere in DLL3 targeting trispecific proteins described herein, including the peptide backbone, the amino acid side-chains, and the amino or carboxyl termini. Certain common peptide modifications that are useful for modification of DLL3 targeting trispecific proteins include glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation, blockage of the amino or carboxyl group in a polypeptide, or both, by a covalent modification, and ADP-ribosylation.
[0119] In some embodiments, a derivative of the DLL3 targeting trispecific protein as described herein comprises immunoreactive modulator derivatives and antigen binding molecules comprising one or more modifications.
[0120] In some embodiments, the trispecific DLL3 binding molecules of the disclosure are monovalent or multivalent, bivalent, trivalent, etc. As used herein, the term “valency” refers to the number of potential target binding sites associated with an antibody. Each target binding site specifically binds one target molecule or specific position or locus on a target molecule. When an antibody is monovalent, each binding site of the molecule will specifically bind to a single antigen position or epitope. When an antibody comprises more than one target binding site (multivalent),WSGR Docket No.47517-770.601 each target binding site may specifically bind the same or different molecules (e.g., may bind to different ligands or different antigens, or different epitopes or positions on the same antigen).
[0121] In some embodiments, the DLL3 targeting trispecific proteins of this disclosure contain inter alia one or more additional amino acid residue substitutions, mutations and / or modifications which result in a compound with preferred characteristics including, but not limited to: altered pharmacokinetics, increased serum half-life, increase binding affinity, reduced immunogenicity, increased production, altered Fc ligand binding to an Fc receptor (FcR), enhanced or reduced “ADCC” (antibody-dependent cell mediated cytotoxicity) or “CDC” (complement-dependent cytotoxicity) activity, altered glycosylation and / or disulfide bonds and modified binding specificity. In some cases these DLL3 targeting trispecific protein variants are advantageously used to enhance the effective anti-neoplastic properties of the disclosed DLL3 targeting trispecific proteins.
[0122] In some embodiments, the DLL3 targeting trispecific proteins of the disclosure have half- lives in a mammals, such as in a human, or in a cynomolgus monkey of less than about 5 days, about 5 days, greater than about 5 days, greater than 10 days, greater than about 15 days, greater than about 20 days, greater than about 25 days, greater than about 30 days, greater than about 35 days, greater than about 40 days, greater than about 45 days, greater than about 2 months, greater than about 3 months, greater than about 4 months, or greater than about 5 months. The increased half-life, in some cases, results in a higher serum titer which thus reduces the frequency of the administration of the DLL3 targeting trispecific proteins, reduces the concentration of the antibodies to be administered, or both.
[0123] Still other embodiments comprise one or more engineered glycoforms, i.e., a DLL3 targeting trispecific binding protein comprising an altered glycosylation pattern or altered carbohydrate composition that is covalently attached to the protein. Engineered glycoforms are useful, in some cases, for a variety of purposes, including but not limited to enhancing or reducing effector function, increasing the affinity of the trispecific protein for a target or facilitating production of the trispecific protein. In certain embodiments where reduced effector function is desired, the molecule is engineered to express an aglycosylated form. Substitutions that result in elimination of one or more variable region framework glycosylation sites to thereby eliminate glycosylation at that site, are included in some embodiments. Conversely, enhanced effector functions or improved binding is imparted to the Fc containing trispecific proteins of this disclosure by engineering in one or more additional glycosylation sites, in some cases.
[0124] The DLL3 targeting trispecific proteins, in some cases, are differentially modified during or after production, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting / blocking groups, proteolytic cleavage, linkage to an antibody molecule or otherWSGR Docket No.47517-770.601 cellular ligand, etc. Any of numerous chemical modifications are carried out by techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH4, acetylation, formylation, oxidation, reduction, metabolic synthesis in the presence of tunicamycin etc.
[0125] Various post-translational modifications also encompassed by the disclosure include, for example, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends, attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of prokaryotic host cell expression. Moreover, the DLL3 targeting trispecific binding proteins are, in some cases, modified with a detectable label, such as an enzymatic, fluorescent, radioisotopic or affinity label to allow for detection and isolation of the modulator. Polynucleotides Encoding DLL3 targeting trispecific proteins
[0126] Also provided, in some embodiments, are polynucleotide molecules encoding an anti-DLL3 trispecific binding protein described herein. In some embodiments, the polynucleotide molecules are provided as a DNA construct. In other embodiments, the polynucleotide molecules are provided as a messenger RNA transcript.
[0127] The polynucleotide molecules are constructed by known methods such as by combining the genes encoding the three binding domains either separated by peptide linkers or, in other embodiments, directly linked by a peptide bond, into a single genetic construct operably linked to a suitable promoter, and optionally a suitable transcription terminator, and expressing it in bacteria or other appropriate expression system such as, for example CHO cells. In the embodiments where the DLL3 binding domain is a small molecule, the polynucleotides contain genes encoding the CD3 binding domain and the half-life extension domain. In the embodiments where the half-life extension domain is a small molecule, the polynucleotides contain genes encoding the domains that bind to CD3 and DLL3. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. The promoter is selected such that it drives the expression of the polynucleotide in the respective host cell.
[0128] In some embodiments, the polynucleotide is inserted into a vector, preferably an expression vector, which represents a further embodiment. This recombinant vector can be constructed according to known methods. Vectors of particular interest include plasmids, phagemids, phage derivatives, virii (e.g., retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, lentiviruses, and the like), and cosmids.WSGR Docket No.47517-770.601
[0129] A variety of expression vector / host systems may be utilized to contain and express the polynucleotide encoding the polypeptide of the described trispecific antigen-binding protein. Examples of expression vectors for expression in E.coli are pSKK (Le Gall et al., J Immunol Methods. (2004) 285(1):111-27) or pcDNA5 (Invitrogen) for expression in mammalian cells.
[0130] Thus, the DLL3 targeting trispecific proteins as described herein, in some embodiments, are produced by introducing a vector encoding the protein as described above into a host cell and culturing said host cell under conditions whereby the protein domains are expressed, may be isolated and, optionally, further purified. Pharmaceutical Compositions
[0131] Also provided, in some embodiments, are pharmaceutical compositions comprising an anti- DLL3 trispecific binding protein described herein, a vector comprising the polynucleotide encoding the polypeptide of the DLL3 targeting trispecific proteins or a host cell transformed by this vector and at least one pharmaceutically acceptable carrier. The term “pharmaceutically acceptable carrier” includes, but is not limited to, any carrier that does not interfere with the effectiveness of the biological activity of the ingredients and that is not toxic to the patient to whom it is administered. Examples of suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil / water emulsions, various types of wetting agents, sterile solutions etc. Such carriers can be formulated by conventional methods and can be administered to the subject at a suitable dose. Preferably, the compositions are sterile. These compositions may also contain adjuvants such as preservative, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents. A further embodiment provides one or more of the above described DLL3 targeting trispecific proteins packaged in lyophilized form, or packaged in an aqueous medium.
[0132] In some embodiments of the pharmaceutical compositions, the DLL3 targeting trispecific proteins described herein are encapsulated in nanoparticles. In some embodiments, the nanoparticles are fullerenes, liquid crystals, liposome, quantum dots, superparamagnetic nanoparticles, dendrimers, or nanorods. In other embodiments of the pharmaceutical compositions, the DLL3 targeting trispecific protein is attached to liposomes. In some instances, the DLL3 targeting trispecific proteins are conjugated to the surface of liposomes. In some instances, the DLL3 trispecific antigen-binding protein are encapsulated within the shell of a liposome. In some instances, the liposome is a cationic liposome.WSGR Docket No.47517-770.601
[0133] The DLL3 targeting trispecific proteins described herein are contemplated for use as a medicament. Administration is effected by different ways, by intravenous, intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration. In some embodiments, the route of administration depends on the kind of therapy and the kind of compound contained in the pharmaceutical composition. The dosage regimen will be determined by the attending physician and other clinical factors. Dosages for any one patient depends on many factors, including the patient´s size, body surface area, age, sex, the particular compound to be administered, time and route of administration, the kind of therapy, general health and other drugs being administered concurrently. An “effective dose” refers to amounts of the active ingredient that are sufficient to affect the course and the severity of the disease, leading to the reduction or remission of such pathology and may be determined using known methods.
[0134] In some embodiments, the DLL3 targeting trispecific proteins of this disclosure are administered at a dosage of up to 10 mg / kg at a frequency of once a week. In some cases, the dosage ranges from about 1 ng / kg to about 10 mg / kg. In some embodiments, the dose is from about 1 ng / kg to about 10 ng / kg, about 5 ng / kg to about 15 ng / kg, about 12 ng / kg to about 20 ng / kg, about 18 ng / kg to about 30 ng / kg, about 25 ng / kg to about 50 ng / kg, about 35 ng / kg to about 60 ng / kg, about 45 ng / kg to about 70 ng / kg, about 65 ng / kg to about 85 ng / kg, about 80 ng / kg to about 1 µg / kg, about 0.5 µg / kg to about 5 µg / kg, about 2 µg / kg to about 10 µg / kg, about 7 µg / kg to about 15 µg / kg, about 12 µg / kg to about 25 µg / kg, about 20 µg / kg to about 50 µg / kg, about 35 µg / kg to about 70 µg / kg, about 45 µg / kg to about 80 µg / kg, about 65 µg / kg to about 90 µg / kg, about 85 µg / kg to about 0.1 mg / kg, about 0.095 mg / kg to about 10 mg / kg. In some cases, the dosage is about 0.1 mg / kg to about 0.2 mg / kg; about 0.25 mg / kg to about 0.5 mg / kg, about 0.45 mg / kg to about 1 mg / kg, about 0.75 mg / kg to about 3 mg / kg, about 2.5 mg / kg to about 4 mg / kg, about 3.5 mg / kg to about 5 mg / kg, about 4.5 mg / kg to about 6 mg / kg, about 5.5 mg / kg to about 7 mg / kg, about 6.5 mg / kg to about 8 mg / kg, about 7.5 mg / kg to about 9 mg / kg, or about 8.5 mg / kg to about 10 mg / kg. The frequency of administration, in some embodiments, is about less than daily, every other day, less than once a day, twice a week, weekly, once in 7 days, once in two weeks, once in two weeks, once in three weeks, once in four weeks, or once a month. In some cases, the frequency of administration is weekly. In some cases, the frequency of administration is weekly and the dosage is up to 10 mg / kg. In some cases, duration of administration is from about 1 day to about 4 weeks or longer.
[0135] In some embodiments, the DLL3 targeting trispecific proteins of this disclosure are administered at a dosage of about 1µg to about 100µg, about 1 µg to about 500 µg, about 1 µg to about 1mg, about 1 µg to about 2mg, about 1 µg to about 5mg, about 1 µg to about 10mg, about 1WSGR Docket No.47517-770.601 µg to about 100mg, about 100 µg to about 500 µg, about 100 µg to about 1mg, about 100 µg to about 2mg, about 100 µg to about 5mg, about 100 µg to about 10mg, about 100 µg to about 100mg, about 500 µg to about 1mg, about 500 µg to about 2mg, about 500 µg to about 5mg, about 500 µg to about 10mg, about 500 µg to about 100mg, about 1mg to about 2mg, about 1mg to about 5mg, about 1 mg to about 10 mg, about 1mg to about 100 mg, about 2mg to about 5mg, about 2 mg to about 10 mg, about 2mg to about 100 mg, about 5 mg to about 10 mg, about 5mg to about 100 mg, or about 10 mg to about 100 mg. In some embodiments, the DLL3 targeting trispecific proteins of this disclosure are administered at a dosage of about 15 µg to about 45 µg, about 15 µg to about 135 µg, about 15 µg to about 405 µg, about 15 µg to about 1215 µg, about 15 µg to about 3600 µg, about 45 µg to about 135 µg, about 45 µg to about 405 µg, about 45 µg to about 1215 µg, about 45 µg to about 3600 µg, about 135 µg to about 405 µg, about 135 µg to about 1215 µg, about 135 µg to about 3600 µg, about 405 µg to about 1215 µg, about 405 µg to about 3600 µg, or about 1215 µg to about 3600 µg. In some embodiments, the first dose is about 5 mg. In some embodiments, the dose is about 7 mg. In some embodiments, the dose is about 10 mg. In some embodiments, the dose is about 12 mg. In some embodiments, the dose is about 15 mg. In some embodiments, the dose is about 20 mg. In some embodiments, the dose is about 30 mg. In some embodiments, the dose is about 40 mg. In some embodiments, the dose is about 50 mg. In some embodiments, the dose is about 70 mg. In some embodiments, the dose is about 100 mg.
[0136] The DLL3 targeting trispecific protein described herein can be administered using different dosages. In some embodiments, the DLL3 targeting trispecific protein of this disclosure is administered according to a schedule comprising the following steps: (i) administration of a first dose of the DLL3 targeting trispecific protein, and (ii) administration of a second dose of the DLL3 targeting trispecific protein, wherein the second dose is higher than the first dose. In some embodiments, the schedule further comprises step (iii) administration of a third dose of the DLL3 targeting trispecific protein, wherein the third dose is higher than the second dose. In some embodiments, the schedule further comprises step (iv) administration of a fourth dose of the DLL3 targeting trispecific protein, wherein the fourth dose is higher than the third dose. In some embodiments, the schedule further comprises step (v) administration of a fifth dose of the DLL3 targeting trispecific protein, wherein the fifth dose is higher than the fourth dose.
[0137] In some embodiments, the first dose is about 1 µg to about 100 µg, about 1 µg to about 500 µg, about 1 µg to about 1 mg, about 1 µg to about 2 mg, about 1 µg to about 5 mg, about 1 µg to about 5 mg, about 1 µg to about 8 mg, about 1 µg to about 10 mg, about 1 µg to about 50 mg, about 1 µg to about 100 mg about 100 µg to about 500 µg, about 100 µg to about 1 mg, about 100 µg to about 2 mg, about 100 µg to about 5 mg, about 100 µg to about 5 mg, about 100 µg to about 8 mg,WSGR Docket No.47517-770.601 about 100 µg to about 10 mg, about 100 µg to about 50 mg, about 100 µg to about 100 mg, about 500 µg to about 1 mg, about 500 µg to about 2 mg, about 500 µg to about 5 mg, about 500 µg to about 5 mg, about 500 µg to about 8 mg, about 500 µg to about 10 mg, about 500 µg to about 50 mg, about 500 µg to about 100 mg, about 1 mg to about 2 mg, about 1 mg to about 5 mg, about 1 mg to about 8 mg, about 1 mg to about 10 mg, about 1 mg to about 50 mg, about 1 mg to about 100 mg, about 2 mg to about 5 mg, about 2 mg to about 8 mg, about 2 mg to about 10 mg, about 2 mg to about 50 mg, about 2 mg to about 100 mg, about 5 mg to about 8 mg, about 5 mg to about 10 mg, about 5 mg to about 50 mg, about 5 mg to about 100 mg, about 8 mg to about 10 mg, about 8 mg to about 50 mg, about 8 mg to about 100 mg, about 10 mg to about 50 mg, or about 50 mg to about 100 mg. In some embodiments, the first dose is about 5 µg. In some embodiments, the first dose is about 15 µg. In some embodiments, the first dose is about 45 µg. In some embodiments, the first dose is about 135 µg. In some embodiments, the first dose is about 405 µg. In some embodiments, the first dose is about 1215 µg. In some embodiments, the first dose is about 1500 µg. In some embodiments, the first dose is about 2000 µg. In some embodiments, the first dose is about 2500 µg. In some embodiments, the first dose is about 3600 µg. In some embodiments, the first dose is about 3 mg. In some embodiments, the first dose is about 4 mg. In some embodiments, the first dose is about 5 mg. In some embodiments, the first dose is about 6 mg. In some embodiments, the first dose is about 7 mg. In some embodiments, the first dose is about 8 mg. In some embodiments, the first dose is about 9 mg. In some embodiments, the first dose is about 10 mg. In some embodiments, the first dose is about 11 mg. In some embodiments, the first dose is about 12 mg. In some embodiments, the first dose is about 15 mg. In some embodiments, the first dose is about 20 mg. In some embodiments, the first dose is about 30 mg. In some embodiments, the first dose is about 40 mg. In some embodiments, the first dose is about 50 mg. In some embodiments, the first dose is about 70 mg. In some embodiments, the first dose is about 100 mg.
[0138] In some embodiments, the first dose is administered for about 1 week to about 5 weeks, about 1 week to about 10 weeks, about 1 week to about 20 weeks, about 1 week to about 50 weeks, about 1 week to about 80 weeks, about 1 week to about 100 weeks, about 5 weeks to about 10 weeks, about 5 weeks to about 20 weeks, about 5 weeks to about 50 weeks, about 5 weeks to about 80 weeks, about 5 weeks to about 100 weeks, about 10 weeks to about 20 weeks, about 10 weeks to about 50 weeks, about 10 weeks to about 80 weeks, about 10 weeks to about 100 weeks, about 20 weeks to about 50 weeks, about 20 weeks to about 80 weeks, about 20 weeks to about 100 weeks, about 50 weeks to about 80 weeks, about 50 weeks to about 100 weeks, about 80 weeks to about 100 weeks, about 1 week to about 9 weeks, about 1 week to about 18 weeks, about 1 week to about 27 weeks, about 1 week to about 36 weeks, about 9 weeks to about 18 weeks, about 9 weeks toWSGR Docket No.47517-770.601 about 27 weeks, about 9 weeks to about 36 weeks, about 18 weeks to about 27 weeks, about 18 weeks to about 36 weeks, or about 27 weeks to about 36 weeks.
[0139] In some embodiments, the first dose is administered once per day, twice per day, three times per day, four times per day, five times per day, six times per day, seven times per day, eight times per day, nine times per day or ten times per day. In some embodiments, the first dose is administered once per week, twice per week, three times per week, four times per week, five times per week, six times per week, once every other week, once every three weeks, once every four week or once every five weeks.
[0140] In some embodiments, the second dose is about 1 µg to about 100 µg, about 1 µg to about 500 µg, about 1 µg to about 1 mg, about 1 µg to about 2 mg, about 1 µg to about 5 mg, about 1 µg to about 5 mg, about 1 µg to about 8 mg, about 1 µg to about 10 mg, about 1 µg to about 50 mg, about 1 µg to about 100 mg about 100 µg to about 500 µg, about 100 µg to about 1 mg, about 100 µg to about 2 mg, about 100 µg to about 5 mg, about 100 µg to about 5 mg, about 100 µg to about 8 mg, about 100 µg to about 10 mg, about 100 µg to about 50 mg, about 100 µg to about 100 mg, about 500 µg to about 1 mg, about 500 µg to about 2 mg, about 500 µg to about 5 mg, about 500 µg to about 5 mg, about 500 µg to about 8 mg, about 500 µg to about 10 mg, about 500 µg to about 50 mg, about 500 µg to about 100 mg, about 1 mg to about 2 mg, about 1 mg to about 5 mg, about 1 mg to about 8 mg, about 1 mg to about 10 mg, about 1 mg to about 50 mg, about 1 mg to about 100 mg, about 2 mg to about 5 mg, about 2 mg to about 8 mg, about 2 mg to about 10 mg, about 2 mg to about 50 mg, about 2 mg to about 100 mg, about 5 mg to about 8 mg, about 5 mg to about 10 mg, about 5 mg to about 50 mg, about 5 mg to about 100 mg, about 8 mg to about 10 mg, about 8 mg to about 50 mg, about 8 mg to about 100 mg, about 10 mg to about 50 mg, or about 50 mg to about 100 mg. In some embodiments, the second dose is about 1.2 mg. In some embodiments, the second dose is about 2 mg. In some embodiments, the second dose is about 3 mg. In some embodiments, the second dose is about 4 mg. In some embodiments, the second dose is about 5 mg. In some embodiments, the second dose is about 6 mg. In some embodiments, the second dose is about 7 mg. In some embodiments, the second dose is about 8 mg. In some embodiments, the second dose is about 9 mg. In some embodiments, the second dose is about 10 mg. In some embodiments, the second dose is about 11 mg. In some embodiments, the second dose is about 12 mg. In some embodiments, the second dose is about 13 mg. In some embodiments, the second dose is about 14 mg. In some embodiments, the second dose is about 15 mg. In some embodiments, the second dose is about 20 mg. In some embodiments, the second dose is about 30 mg. In some embodiments, the second dose is about 40 mg. In some embodiments, the second dose is about 50 mg. In some embodiments, the second dose is about 70 mg. In some embodiments, the second doseWSGR Docket No.47517-770.601 is about 100 mg. In some embodiments, the second dose is about 3.6 mg. In some embodiments, the second dose is about 7.2 mg. In some embodiments, the second dose is about 12 mg. In some embodiments, the second dose is about 24 mg. In some embodiments, the second dose is about 36 mg. In some embodiments, the second dose is about 48 mg. In some embodiments, the second dose is about 60 mg. In some embodiments, the second dose is about 72 mg. In some embodiments, the second dose is about 84 mg. In some embodiments, the second dose is about 96 mg.
[0141] In some embodiments, the second dose is administered for about 1 week to about 5 weeks, about 1 week to about 10 weeks, about 1 week to about 20 weeks, about 1 week to about 50 weeks, about 1 week to about 80 weeks, about 1 week to about 100 weeks, about 5 weeks to about 10 weeks, about 5 weeks to about 20 weeks, about 5 weeks to about 50 weeks, about 5 weeks to about 80 weeks, about 5 weeks to about 100 weeks, about 10 weeks to about 20 weeks, about 10 weeks to about 50 weeks, about 10 weeks to about 80 weeks, about 10 weeks to about 100 weeks, about 20 weeks to about 50 weeks, about 20 weeks to about 80 weeks, about 20 weeks to about 100 weeks, about 50 weeks to about 80 weeks, about 50 weeks to about 100 weeks, about 80 weeks to about 100 weeks, about 1 week to about 9 weeks, about 1 week to about 18 weeks, about 1 week to about 27 weeks, about 1 week to about 36 weeks, about 9 weeks to about 18 weeks, about 9 weeks to about 27 weeks, about 9 weeks to about 36 weeks, about 18 weeks to about 27 weeks, about 18 weeks to about 36 weeks, or about 27 weeks to about 36 weeks.
[0142] In some embodiments, the second dose is administered once per day, twice per day, three times per day, four times per day, five times per day, six times per day, seven times per day, eight times per day, nine times per day or ten times per day. In some embodiments, the first dose is administered once per week, twice per week, three times per week, four times per week, five times per week, six times per week, once every other week, once every three weeks, once every four week or once every five weeks.
[0143] In some embodiments, the first dose is about 3.6 mg and the second dose is about 7.2 mg. In some embodiments, the first dose is about 3 mg and the second dose is about 14 mg, which is administered weekly. In some embodiments, the first dose is about 3 mg and the second dose is about 7 mg, which is administered weekly. In some embodiments, the first dose is about 3 mg and the second dose is about 7 mg, which is administered every other week. Methods of treatment
[0144] In some embodiments, the DLL3 targeting trispecific proteins of the present disclosure is administered to treat a neoplastic condition. Neoplastic conditions, in some cases, are benign or malignant; solid tumors or other blood neoplasia; and, in some cases, are selected from the groupWSGR Docket No.47517-770.601 including, but not limited to: adrenal gland tumors, AIDS-associated cancers, alveolar soft part sarcoma, astrocytic tumors, autonomic ganglia tumors, bladder cancer (squamous cell carcinoma and transitional cell carcinoma), blastocoelic disorders, bone cancer (adamantinoma, aneurismal bone cysts, osteochondroma, osteosarcoma), brain and spinal cord cancers, metastatic brain tumors, breast cancer including triple negative breast cancer, carotid body tumors, cervical cancer, chondrosarcoma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, colon cancer, colorectal cancer, cutaneous benign fibrous histiocytomas, desmoplastic small round cell tumors, ependymomas, epithelial disorders, Ewing's tumors, extraskeletal myxoid chondrosarcoma, fibrogenesis imperfecta ossium, fibrous dysplasia of the bone, gallbladder and bile duct cancers, gastric cancer, gastrointestinal, gestational trophoblastic disease, germ cell tumors, glandular disorders, head and neck cancers, hypothalamic, intestinal cancer, islet cell tumors, Kaposi's Sarcoma, kidney cancer (nephroblastoma, papillary renal cell carcinoma), leukemias, lipoma / benign lipomatous tumors, liposarcoma / malignant lipomatous tumors, liver cancer (hepatoblastoma, hepatocellular carcinoma), lymphomas, lung cancers (small cell carcinoma, adenocarcinoma, squamous cell carcinoma, large cell carcinoma etc.), macrophagal disorders, medulloblastoma, melanoma, meningiomas, multiple endocrine neoplasia, multiple myeloma, myelodysplastic syndrome, neuroblastoma, neuroendocrine tumors, ovarian cancer, pancreatic cancers, papillary thyroid carcinomas, parathyroid tumors, pediatric cancers, peripheral nerve sheath tumors, phaeochromocytoma, pituitary tumors, prostate cancer, posterious unveal melanoma, rare hematologic disorders, renal metastatic cancer, rhabdoid tumor, rhabdomysarcoma, sarcomas, skin cancer, soft-tissue sarcomas, squamous cell cancer, stomach cancer, stromal disorders, synovial sarcoma, testicular cancer, thymic carcinoma, thymoma, thyroid metastatic cancer, and uterine cancers (carcinoma of the cervix, endometrial carcinoma, and leiomyoma).
[0145] In some cases, the DLL3 targeting trispecific proteins of the present disclosure is used as a front-line therapy and administered to subjects who have not previously been treated for the cancerous condition. In some cases, the DLL3 targeting trispecific proteins of the present disclosure are used to treat subjects that have previously been treated (with a DLL3 targeting trispecific protein of this disclosure or with other anti-cancer agent) and have relapsed or determined to be refractory to the previous treatment. In some cases, the DLL3 targeting trispecific proteins of the present disclosure are used to treat subjects that have recurrent tumors.
[0146] In some aspects, the DLL3 targeting trispecific proteins of the present disclosure are administered to treat a proliferative disorder comprising a solid tumor including, but not limited to, adrenal, liver, kidney, bladder, breast, gastric, ovarian, cervical, uterine, esophageal, colorectal,WSGR Docket No.47517-770.601 prostate, pancreatic, lung (both small cell and non-small cell), thyroid, carcinomas, sarcomas, glioblastomas and various head and neck tumors.
[0147] In some cases, the DLL3 targeting trispecific proteins of the present disclosure are administered to a subject suffering from melanoma. In some embodiments, the DLL3 targeting trispecific proteins of the present disclosure are used to diagnose, monitor, treat or prevent melanoma. The term “melanoma,” as used herein, includes all types of melanoma including, but not limited to, primary melanoma, malignant melanoma, cutaneous melanoma, extracutaneous melanoma, superficial spreading melanoma, polypoid melanoma, melanocarcinomas, melanoepitheliomas, melanosarcomas, melanoma in situ, nodular malignant melanoma, lentigo maligna melanoma, lentiginous melanoma, lentiginous malignant melanoma, mucosal lentiginous melanoma, mucosal melanoma, acral lentiginous melanoma, soft tissue melanoma, ocular melanoma, invasive melanoma, familial atypical mole and melanoma (FAM-M) syndrome, desmoplastic malignant melanoma or uveal melanoma.
[0148] DLL3 is an effective tumor marker that is expressed on a number of different cancers and has been found to be associated with cancer stem cells. Thus, in some embodiments where the DLL3 binding proteins, or the DLL3 targeting trispecific proteins of the disclosure are incorporated in a chimeric antigen receptor expressed on lymphocytes, the resulting “DLL3 sensitized lymphocytes” (e.g., natural killer cells or T cells that immunospecifically recognize a DLL3 determinant) are able to effectively mount an immune response directed to aberrant DLL3 positive cells including cancer stem cells. This ability to effectively eliminate tumorigenic “seed” cells is often critical in reducing the possibility of tumor recurrence or metastasis. In some embodiments, such DLL3 sensitized lymphocytes are used in combination with other therapeutic agents or as part of a maintenance regimen following standard of care treatments.
[0149] More generally a chimeric antigen receptor is an artificially constructed hybrid protein or polypeptide containing or comprising an antigen binding domain of an antibody linked to a signaling domain (e.g., T-cell signaling or T-cell activation domains). In some embodiments, CARs comprising the DLL3 targeting trispecific binding protein of the present disclosure have the ability to redirect the specificity and reactivity of sensitized lymphocytes (e.g., T-cells) toward DLL3 positive target cells in a non-MHC-restricted manner by exploiting the antigen-binding properties of antibodies or antigen binding fragments thereof. The non-MHC-restricted antigen recognition gives T-cells expressing DLL3 CARs the ability to recognize tumorigenic DLL3 independent of antigen processing, thus bypassing a major mechanism of tumor escape. Moreover, when expressed in T-cells, CARs advantageously do not dimerize with endogenous T cell receptor (TCR) alpha and beta chains.WSGR Docket No.47517-770.601
[0150] In selected aspects, the DLL3 targeting trispecific proteins of the disclosure is incorporated into a chimeric antigen receptor (CAR) and the DLL3 CAR is administered in a CAR based therapy effective at treating lung cancer, including the following subtypes: small cell lung cancer, non- small cell lung cancer (e.g., squamous cell non-small cell lung cancer or squamous cell small cell lung cancer) and large cell neuroendocrine carcinoma (LCNEC).
[0151] In some embodiments, the DLL3 sensitive lymphocytes are administered to patients exhibiting limited stage disease or extensive stage disease. In other embodiments the disclosed DLL3 targeting trispecific antibodies are administered to refractory patients (i.e., those whose disease recurs during or shortly after completing a course of initial therapy); sensitive patients (i.e., those whose relapse is longer than 2-3 months after primary therapy); or patients exhibiting resistance to a platinum-based agent (e.g., carboplatin, cisplatin, oxaliplatin) and / or a taxane (e.g., docetaxel, paclitaxel, larotaxel or cabazitaxel). In another embodiment the disclosed DLL3 CAR treatments are effective at treating ovarian cancer, including ovarian-serous carcinoma and ovarian- papillary serous carcinoma.
[0152] The disclosed DLL3 targeting trispecific binding proteins, in some embodiments, are used to prevent, treat or diagnose tumors with neuroendocrine features or phenotypes including neuroendocrine tumors. True or canonical neuroendocrine tumors (NETs) arising from the dispersed endocrine system are relatively rare, with an incidence of 2-5 per 100,000 people, but highly aggressive. Neuroendocrine tumors occur in the kidney, genitourinary tract (bladder, prostate, ovary, cervix, and endometrium), gastrointestinal tract (colon, stomach), thyroid (medullary thyroid cancer), and lung (small cell lung carcinoma and large cell neuroendocrine carcinoma). These tumors may secrete several hormones including serotonin and / or chromogranin A that can cause debilitating symptoms known as carcinoid syndrome. Such tumors can be denoted by positive immunohistochemical markers such as neuron-specific enolase (NSE, also known as gamma enolase, gene symbol=ENO2), CD56 (or NCAM1), chromogranin A (CHGA), and synaptophysin (SYP) or by genes known to exhibit elevated expression such as ASCL1. Traditional chemotherapies have not been particularly effective in treating neuroendocrine tumors and liver metastasis is a common outcome. In some embodiments the disclosed DLL3 targeting trispecific antibodies are advantageously used to treat neuroendocrine tumors, and in some embodiments they are used to treat, prevent or diagnose pseudo neuroendocrine tumors (pNETs) that genotypically or phenotypically mimic, resemble or exhibit common traits with canonical neuroendocrine tumors. Pseudo neuroendocrine tumors or tumors with neuroendocrine features are tumors that arise from cells of the diffuse neuroendocrine system or from cells in which a neuroendocrine differentiation cascade has been aberrantly reactivated during the oncogenic process. Such pNETs commonlyWSGR Docket No.47517-770.601 share certain phenotypic or biochemical characteristics with traditionally defined neuroendocrine tumors, including the ability to produce subsets of biologically active amines, neurotransmitters, and peptide hormones. Histologically, such tumors (NETs and pNETs) share a common appearance often showing densely connected small cells with minimal cytoplasm of bland cytopathology and round to oval stippled nuclei. In some embodiments of the present disclosure commonly expressed histological markers or genetic markers that are used to define neuroendocrine and pseudo neuroendocrine tumors include, but are not limited to, chromogranin A, CD56, synaptophysin, PGP9.5, ASCL1 and neuron-specific enolase (NSE). Accordingly, in some embodiments, the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof, of the present disclosure, are beneficially used to treat both pseudo neuroendocrine tumors and canonical neuroendocrine tumors, such as to treat neuroendocrine tumors (both NET and pNET) arising in the kidney, genitourinary tract (bladder, prostate, ovary, cervix, and endometrium), gastrointestinal tract (colon, stomach), thyroid (medullary thyroid cancer), and lung (small cell lung carcinoma and large cell neuroendocrine carcinoma). Moreover, in some embodiments, the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof are used to treat tumors expressing one or more markers such as NSE, CD56, synaptophysin, chromogranin A, ASCL1, or PGP9.5 (UCHL1). In some embodiments, the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof are used to treat a subject suffering from a tumor that is NSE+ or CD56+ or PGP9.5+ or ASCL1+ or SYP+ or CHGA+ or any combination thereof.
[0153] In another embodiment the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof are used in maintenance therapy to reduce or eliminate the chance of tumor recurrence following the initial presentation of the disease. In some cases, the disorder has been treated and the initial tumor mass eliminated, reduced or otherwise ameliorated so the patient is asymptomatic or in remission. At such time the subject is administered pharmaceutically effective amounts of the disclosed the DLL3 binding proteins, the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof one or more times regardless of if there is little or no indication of disease using standard diagnostic procedures. In some embodiments, the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof is administered on a regular schedule over a period of time, such as weekly, every two weeks, monthly, every six weeks, every two months, every three months every six months or annually, for example, to reduce the potential of disease recurrence. Moreover suchWSGR Docket No.47517-770.601 treatments are in some embodiments continued for a period of weeks, months, years or even indefinitely depending on the patient response and clinical and diagnostic parameters.
[0154] In yet another embodiment the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof are used to prophylactically or as an adjuvant therapy to prevent or reduce the possibility of tumor metastasis following a debulking procedure. As used in the present disclosure a “debulking procedure” is defined broadly and means any procedure, technique or method that eliminates, reduces, treats or ameliorates a tumor or tumor proliferation. Exemplary debulking procedures include, but are not limited to, surgery, radiation treatments (i.e., beam radiation), chemotherapy, immunotherapy or ablation. In some embodiments, at appropriate times, the DLL3 binding proteins, the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof are administered as suggested by clinical, diagnostic or theranostic procedures to reduce tumor metastasis. In some embodiments, the dosing regimen is accompanied by appropriate diagnostic or monitoring techniques that allow it to be modified.
[0155] Yet other embodiments of the disclosure comprise administering the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof to subjects that are asymptomatic but at risk of developing a proliferative disorder. That is, in some embodiments, the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof are used in preventative sense and given to patients that have been examined or tested and have one or more noted risk factors (e.g., genomic indications, family history, in vivo or in vitro test results, etc.) but have not developed neoplasia. In such cases those skilled in the art would be able to determine an effective dosing regimen through empirical observation or through accepted clinical practices.
[0156] As used herein, in some embodiments, “treatment” or “treating” or “treated” refers to therapeutic treatment wherein the object is to slow (lessen) an undesired physiological condition, disorder or disease, or to obtain beneficial or desired clinical results. For the purposes described herein, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of the extent of the condition, disorder or disease; stabilization (i.e., not worsening) of the state of the condition, disorder or disease; delay in onset or slowing of the progression of the condition, disorder or disease; amelioration of the condition, disorder or disease state; and remission (whether partial or total), whether detectable or undetectable, or enhancement or improvement of the condition, disorder or disease. Treatment includes eliciting a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment. In other embodiments,WSGR Docket No.47517-770.601 “treatment” or “treating” or “treated” refers to prophylactic measures, wherein the object is to delay onset of or reduce severity of an undesired physiological condition, disorder or disease, such as, for example is a person who is predisposed to a disease (e.g., an individual who carries a genetic marker for a disease such as breast cancer).
[0157] In some embodiments of the methods described herein, the DLL3 targeting trispecific proteins, or compositions as described herein are administered in combination with an agent for treatment of the particular disease, disorder or condition. Agents include but are not limited to, therapies involving antibodies, small molecules (e.g., chemotherapeutics), hormones (steroidal, microwaves, UV radiation and the like), gene therapies (e.g., antisense, retroviral therapy and the like) and other immunotherapies. In some embodiments, an anti-DLL3 targeting trispecific protein as described herein is administered in combination with anti-diarrheal agents, anti-emetic agents, analgesics, opioids and / or non-steroidal anti-inflammatory agents. In some embodiments, an anti- DLL3 targeting trispecific protein as described herein is administered in combination with anti- cancer agents. Non-limiting examples of anti-cancer agents that can be used in the various embodiments of the disclosure, including pharmaceutical compositions and dosage forms and kits of the disclosure, include: acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cisplatin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; dactinomycin; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; docetaxel; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflornithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; ilmofosine; interleukin II (including recombinant interleukin II, or rIL2), interferon alpha-2a; interferon alpha-2b; interferon alpha-n1 interferon alpha-n3; interferon beta-I a; interferon gamma-I b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexolWSGR Docket No.47517-770.601 sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazole; nogalamycin; ormaplatin; oxisuran; paclitaxel; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinzolidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride. Other examples of anti-cancer drugs include, but are not limited to: 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR / ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorins; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin AWSGR Docket No.47517-770.601 derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5- docetaxel; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflornithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor-I receptor inhibitor; interferon agonists; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; HMG-CoA reductase inhibitor (such as but not limited to, Lovastatin, Pravastatin, Fluvastatin, Statin, Simvastatin, and Atorvastatin); loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; paclitaxel; paclitaxel analogues; paclitaxelWSGR Docket No.47517-770.601 derivatives; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen binding protein; sizofiran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; Vitaxin®; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer. Additional anti-cancer drugs are 5- fluorouracil and leucovorin. These two agents are particularly useful when used in methods employing thalidomide and a topoisomerase inhibitor. In some embodiments, the DLL3 targeting trispecific protein of the present disclosure is used in combination with gemcitabine. In some embodiments, the DLL3 targeting trispecific protein as described herein is administered before, during, or after surgery.WSGR Docket No.47517-770.601 Methods of enhancing anti-tumor immunity
[0158] Also disclosed herein are methods for inducing long term immunity in a subject, comprising administering an effective amount of the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof to the subject. Further disclosed herein are methods for inducing epitope spreading in a subject, comprising administering an effective amount of the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof to the subject. Further disclosed herein are methods for increasing memory T cells in a subject, comprising administering an effective amount of the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof to the subject, wherein the memory T cells are increased in the subject as compared to a subject without the administration.
[0159] Further disclosed herein are methods for treating a subject in need thereof, comprising administering an effective amount of the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof to the subject, wherein the subject in need thereof is prone to cancer relapse. Further disclosed herein are methods for enhancing immunity and immune response in a subject in need thereof, comprising administering an effective amount of the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof to the subject.
[0160] Further disclosed herein are methods for treating a subject in need thereof, comprising determining the subject is prone to cancer relapse; and administering an effective amount of the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof to the subject.
[0161] Further disclosed herein are methods for treating a subject in need thereof, comprising administering an effective amount of the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof to the subject, and wherein the subject is determined to be prone to cancer relapse.
[0162] In some instances, the subject has a cancer. In some instance, the subject is prone to have a cancer. In some instances, the subject is prone to cancer relapse. In some instances, the subject has a cancer that is a cancer prone to relapse. In some instances, the cancer prone to relapse is a cancer prone to relapse after conventional treatment, for example, platinum-based, taxane-based or anti- angiogenic therapy, or combinations thereof. In some instances, the cancer prone to relapse is aWSGR Docket No.47517-770.601 cancer prone to relapse after treated with cell-based therapy such as T cell therapy, for example, CAR-T or T cell engagers. In some instances, the cancer comprises a cancer associated with DLL3.
[0163] In some instances, the cancer is determined to be prone to relapse. Various biomarkers or imaging can be used for the determination. Additional description for determining cancer relapse can be found in, e.g., Edward R. Sauter, Reliable Biomarkers to Identify New and Recurrent Cancer, Eur J Breast Health.2017 Oct; 13(4): 162–167.
[0164] In some instances, the memory T cells are increased in the subject post administering the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof as compared to a subject without the administration. In some instances, the memory T cells are increased in the subject post administering the DLL3 targeting trispecific protein of the disclosure as compared to a subject without the administration. In some instances, the memory T cells comprises central memory T cells, effector memory T cells, tissue-resident memory T cells, or stem cell-like memory T cells. In some instances, the memory T cells comprises central memory T cells. In some instances, the memory T cells comprises effector memory T cells. In some instances, the memory T cells comprises tissue-resident memory T cells. In some instances, the memory T cells comprises stem cell-like memory T cells.
[0165] In some instances, the central memory T cells comprise T cells expressing at least one marker selected from the group consisting of CCR7+, CD45RA-, CD45RO+, CD62L+, and CD27+. In some instances, the central memory T cells comprise T cells expressing CCR7+, CD45RA-, CD45RO+, CD62L+, and CD27+. In some instances, the effector memory T cells comprise T cells expressing at least one marker selected from the group consisting of CCR7-, CD45RA-, CD45RO+, CD62L-, and CD27-. In some instances, the effector memory T cells comprise T cells expressing CCR7-, CD45RA-, CD45RO+, CD62L-, and CD27-. In some instances, the tissue-resident memory T cells comprise T cells expressing at least one marker selected from the group consisting of CD69+and CD103+. In some instances, the tissue-resident memory T cells comprise T cells expressing CD69+and CD103+. In some instances, the stem cell-like memory T cells comprise T cells expressing at least one marker selected from the group consisting of CCR7+, CD95+, CD45RO-, CD27+, CD45RA+, CD62L+, and CD122+. In some instances, the stem cell-like memory T cells comprise T cells expressing CCR7+, CD95+, CD45RO-, CD27+, CD45RA+, CD62L+, and CD122+.
[0166] In some instances, the memory T cells are increased by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or atWSGR Docket No.47517-770.601 least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, or at least 80% as compared to the subject without the administration.
[0167] In some instances, the memory T cells are increased by at least 0.5%, at least 1%, at least 1.5%, at least 2%, at least 2.5%, at least 3%, at least 3.5%, at least 4%, at least 4.5%, at least 5%, at least 5.5%, at least 6%, at least 6.5%, at least 7%, at least 7.5%, at least 8%, at least 8.5%, at least 9%, at least 9.5%, at least 10%, at least 10.5%, at least 11%, at least 11.5%, at least 12%, at least 12.5%, at least 13%, at least 13.5%, at least 14%, at least 14.5%, at least 15%, at least 15.5%, at least 16%, at least 16.5%, at least 17%, at least 17.5%, at least 18%, at least 18.5%, at least 19%, at least 19.5%, at least 20%, at least 20.5%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, or at least 50% as compared to the subject without the administration.
[0168] In some instances, the memory T cells are increased by at most 1%, at most 2%, at most 3%, at most 4%, at most 5%, at most 6%, at most 7%, at most 8%, at most 9%, at most 10%, at most 11%, at most 12%, at most 13%, at most 14%, at most 15%, at most 16%, at most 17%, at most 18%, at most 19%, at most 20%, at most 25%, at most 30%, at most 35%, at most 40%, at most 45%, or at most 50%, at most 55%, at most 60%, at most 65%, at most 70%, at most 75%, at most 80%, at most 85%, or at most 90% as compared to the subject without the administration.
[0169] In some instances, the memory T cells are increased by at most 0.5%, at most 1%, at most 1.5%, at most 2%, at most 2.5%, at most 3%, at most 3.5%, at most 4%, at most 4.5%, at most 5%, at most 5.5%, at most 6%, at most 6.5%, at most 7%, at most 7.5%, at most 8%, at most 8.5%, at most 9%, at most 9.5%, at most 10%, at most 10.5%, at most 11%, at most 11.5%, at most 12%, at most 12.5%, at most 13%, at most 13.5%, at most 14%, at most 14.5%, at most 15%, at most 15.5%, at most 16%, at most 16.5%, at most 17%, at most 17.5%, at most 18%, at most 18.5%, at most 19%, at most 19.5%, at most 20%, at most 20.5%, at most 21%, at most 22%, at most 23%, at most 24%, at most 25%, at most 26%, at most 27%, at most 28%, at most 29%, at most 30%, at most 31%, at most 32%, at most 33%, at most 34%, at most 35%, at most 36%, at most 37%, at most 38%, at most 39%, at most 40%, at most 41%, at most 42%, at most 43%, at most 44%, at most 45%, at most 46%, at most 47%, at most 48%, at most 49%, at most 50%, at most 55%, at most 60%, at most 65%, at most 70%, at most 75%, at most 80%, or at most 85% as compared to the subject without the administration.WSGR Docket No.47517-770.601
[0170] In some instances, the memory T cells are increased by from about 1% to about 90%, from about 5% to about 80%, from about 10% to about 70%, from about 15% to about 65%, from about 20% to about 60%, from about 25% to about 55%, from about 30% to about 50%, from about 20% to about 55%, from about 20% to about 50%, from about 20% to about 45%, from about 20% to about 40%, from about 20% to about 35%, or from about 20% to about 30% as compared to the subject without the administration. In some instances, the memory T cells are increased by from about 20% to about 60% as compared to the subject without the administration. In some instances, the memory T cells are increased by from about 20% to about 50% as compared to the subject without the administration. In some instances, the memory T cells are increased by from about 20% to about 40% as compared to the subject without the administration. In some instances, the memory T cells are increased by from about 20% to about 30% as compared to the subject without the administration.
[0171] In some instances, the memory T cells are increased by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, or about 80% as compared to the subject without the administration. In some instances, the memory T cells are increased by about 15% as compared to the subject without the administration. In some instances, the memory T cells are increased by about 20% as compared to the subject without the administration. In some instances, the memory T cells are increased by about 25% as compared to the subject without the administration. In some instances, the memory T cells are increased by about 30% as compared to the subject without the administration. In some instances, the memory T cells are increased by about 40% as compared to the subject without the administration. In some instances, the memory T cells are increased by about 50% as compared to the subject without the administration. In some instances, the memory T cells are increased by about 60% as compared to the subject without the administration.
[0172] In some instances, a population of T cells in the subject is increased after the administration of the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof as compared to a subject without the administration. In some instances, a population of T cells in the subject is increased after the administration of the DLL3 targeting trispecific protein of the disclosure as compared to a subject without the administration. In some instances, the CD8+ / CD69+T cells in the subject are increased after the administration as compared to CD8+ / CD69+T cells in a subject without the administration. In someWSGR Docket No.47517-770.601 instances, the CD8+ / CD25+T cells in the subject are increased after the administration as compared to CD8+ / CD25+T cells in a subject without the administration.
[0173] In some instances, the CD8+ / CD69+T cells are increased by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, or at least 80% as compared to the subject without the administration.
[0174] In some instances, the CD8+ / CD69+T cells are increased by at least 0.5%, at least 1%, at least 1.5%, at least 2%, at least 2.5%, at least 3%, at least 3.5%, at least 4%, at least 4.5%, at least 5%, at least 5.5%, at least 6%, at least 6.5%, at least 7%, at least 7.5%, at least 8%, at least 8.5%, at least 9%, at least 9.5%, at least 10%, at least 10.5%, at least 11%, at least 11.5%, at least 12%, at least 12.5%, at least 13%, at least 13.5%, at least 14%, at least 14.5%, at least 15%, at least 15.5%, at least 16%, at least 16.5%, at least 17%, at least 17.5%, at least 18%, at least 18.5%, at least 19%, at least 19.5%, at least 20%, at least 20.5%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, or at least 50% as compared to the subject without the administration.
[0175] In some instances, the CD8+ / CD69+T cells are increased by at most 1%, at most 2%, at most 3%, at most 4%, at most 5%, at most 6%, at most 7%, at most 8%, at most 9%, at most 10%, at most 11%, at most 12%, at most 13%, at most 14%, at most 15%, at most 16%, at most 17%, at most 18%, at most 19%, at most 20%, at most 25%, at most 30%, at most 35%, at most 40%, at most 45%, or at most 50%, at most 55%, at most 60%, at most 65%, at most 70%, at most 75%, at most 80%, at most 85%, or at most 90% as compared to the subject without the administration.
[0176] In some instances, the CD8+ / CD69+T cells are increased by at most 0.5%, at most 1%, at most 1.5%, at most 2%, at most 2.5%, at most 3%, at most 3.5%, at most 4%, at most 4.5%, at most 5%, at most 5.5%, at most 6%, at most 6.5%, at most 7%, at most 7.5%, at most 8%, at most 8.5%, at most 9%, at most 9.5%, at most 10%, at most 10.5%, at most 11%, at most 11.5%, at most 12%, at most 12.5%, at most 13%, at most 13.5%, at most 14%, at most 14.5%, at most 15%, at most 15.5%, at most 16%, at most 16.5%, at most 17%, at most 17.5%, at most 18%, at most 18.5%, at most 19%, at most 19.5%, at most 20%, at most 20.5%, at most 21%, at most 22%, at most 23%, at most 24%, at most 25%, at most 26%, at most 27%, at most 28%, at most 29%, at most 30%, atWSGR Docket No.47517-770.601 most 31%, at most 32%, at most 33%, at most 34%, at most 35%, at most 36%, at most 37%, at most 38%, at most 39%, at most 40%, at most 41%, at most 42%, at most 43%, at most 44%, at most 45%, at most 46%, at most 47%, at most 48%, at most 49%, at most 50%, at most 55%, at most 60%, at most 65%, at most 70%, at most 75%, at most 80%, or at most 85% as compared to the subject without the administration.
[0177] In some instances, the CD8+ / CD69+T cells are increased by from about 1% to about 90%, from about 5% to about 80%, from about 10% to about 70%, from about 15% to about 65%, from about 20% to about 60%, from about 25% to about 55%, from about 30% to about 50%, from about 20% to about 55%, from about 20% to about 50%, from about 20% to about 45%, from about 20% to about 40%, from about 20% to about 35%, or from about 20% to about 30% as compared to the subject without the administration. In some instances, the CD8+ / CD69+T cells are increased by from about 20% to about 60% as compared to the subject without the administration. In some instances, the CD8+ / CD69+T cells are increased by from about 20% to about 50% as compared to the subject without the administration. In some instances, the CD8+ / CD69+T cells are increased by from about 20% to about 40% as compared to the subject without the administration. In some instances, the CD8+ / CD69+T cells are increased by from about 20% to about 30% as compared to the subject without the administration.
[0178] In some instances, the CD8+ / CD69+T cells are increased by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, or about 80% as compared to the subject without the administration. In some instances, the CD8+ / CD69+T cells are increased by about 15% as compared to the subject without the administration. In some instances, the CD8+ / CD69+T cells are increased by about 20% as compared to the subject without the administration. In some instances, the CD8+ / CD69+T cells are increased by about 25% as compared to the subject without the administration. In some instances, the CD8+ / CD69+T cells are increased by about 30% as compared to the subject without the administration. In some instances, the CD8+ / CD69+T cells are increased by about 40% as compared to the subject without the administration. In some instances, the CD8+ / CD69+T cells are increased by about 50% as compared to the subject without the administration. In some instances, the CD8+ / CD69+T cells are increased by about 60% as compared to the subject without the administration.
[0179] In some instances, the CD8+ / CD25+T cells are increased by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at leastWSGR Docket No.47517-770.601 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, or at least 80% as compared to the subject without the administration.
[0180] In some instances, the CD8+ / CD25+T cells are increased by at least 0.5%, at least 1%, at least 1.5%, at least 2%, at least 2.5%, at least 3%, at least 3.5%, at least 4%, at least 4.5%, at least 5%, at least 5.5%, at least 6%, at least 6.5%, at least 7%, at least 7.5%, at least 8%, at least 8.5%, at least 9%, at least 9.5%, at least 10%, at least 10.5%, at least 11%, at least 11.5%, at least 12%, at least 12.5%, at least 13%, at least 13.5%, at least 14%, at least 14.5%, at least 15%, at least 15.5%, at least 16%, at least 16.5%, at least 17%, at least 17.5%, at least 18%, at least 18.5%, at least 19%, at least 19.5%, at least 20%, at least 20.5%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, or at least 50% as compared to the subject without the administration.
[0181] In some instances, the CD8+ / CD25+T cells are increased by at most 1%, at most 2%, at most 3%, at most 4%, at most 5%, at most 6%, at most 7%, at most 8%, at most 9%, at most 10%, at most 11%, at most 12%, at most 13%, at most 14%, at most 15%, at most 16%, at most 17%, at most 18%, at most 19%, at most 20%, at most 25%, at most 30%, at most 35%, at most 40%, at most 45%, or at most 50%, at most 55%, at most 60%, at most 65%, at most 70%, at most 75%, at most 80%, at most 85%, or at most 90% as compared to the subject without the administration.
[0182] In some instances, the CD8+ / CD25+T cells are increased by at most 0.5%, at most 1%, at most 1.5%, at most 2%, at most 2.5%, at most 3%, at most 3.5%, at most 4%, at most 4.5%, at most 5%, at most 5.5%, at most 6%, at most 6.5%, at most 7%, at most 7.5%, at most 8%, at most 8.5%, at most 9%, at most 9.5%, at most 10%, at most 10.5%, at most 11%, at most 11.5%, at most 12%, at most 12.5%, at most 13%, at most 13.5%, at most 14%, at most 14.5%, at most 15%, at most 15.5%, at most 16%, at most 16.5%, at most 17%, at most 17.5%, at most 18%, at most 18.5%, at most 19%, at most 19.5%, at most 20%, at most 20.5%, at most 21%, at most 22%, at most 23%, at most 24%, at most 25%, at most 26%, at most 27%, at most 28%, at most 29%, at most 30%, at most 31%, at most 32%, at most 33%, at most 34%, at most 35%, at most 36%, at most 37%, at most 38%, at most 39%, at most 40%, at most 41%, at most 42%, at most 43%, at most 44%, at most 45%, at most 46%, at most 47%, at most 48%, at most 49%, at most 50%, at most 55%, atWSGR Docket No.47517-770.601 most 60%, at most 65%, at most 70%, at most 75%, at most 80%, or at most 85% as compared to the subject without the administration.
[0183] In some instances, the CD8+ / CD25+T cells are increased by from about 1% to about 90%, from about 5% to about 80%, from about 10% to about 70%, from about 15% to about 65%, from about 20% to about 60%, from about 25% to about 55%, from about 30% to about 50%, from about 20% to about 55%, from about 20% to about 50%, from about 20% to about 45%, from about 20% to about 40%, from about 20% to about 35%, or from about 20% to about 30% as compared to the subject without the administration. In some instances, the CD8+ / CD25+T cells are increased by from about 20% to about 60% as compared to the subject without the administration. In some instances, the CD8+ / CD25+T cells are increased by from about 20% to about 50% as compared to the subject without the administration. In some instances, the CD8+ / CD25+T cells are increased by from about 20% to about 40% as compared to the subject without the administration. In some instances, the CD8+ / CD25+T cells are increased by from about 20% to about 30% as compared to the subject without the administration.
[0184] In some instances, the CD8+ / CD25+T cells are increased by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, or about 80% as compared to the subject without the administration. In some instances, the CD8+ / CD25+T cells are increased by about 15% as compared to the subject without the administration. In some instances, the CD8+ / CD25+T cells are increased by about 20% as compared to the subject without the administration. In some instances, the CD8+ / CD25+T cells are increased by about 25% as compared to the subject without the administration. In some instances, the CD8+ / CD25+T cells are increased by about 30% as compared to the subject without the administration. In some instances, the CD8+ / CD25+T cells are increased by about 40% as compared to the subject without the administration. In some instances, the CD8+ / CD25+T cells are increased by about 50% as compared to the subject without the administration. In some instances, the CD8+ / CD25+T cells are increased by about 60% as compared to the subject without the administration.
[0185] In some instances, the memory T cells, such as central memory T cells, effector memory T cells, tissue-resident memory T cells, or stem cell-like memory T cells, are increased about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 12 hours, about 18 hours, about 24 hours, about 36 hours, about 48 hours, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12WSGR Docket No.47517-770.601 days, about 13 days, about 14 days, or about 15 days post the administration of the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof to the subject.
[0186] In some instances, the CD8+ / CD69+T cells are increased about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 12 hours, about 18 hours, about 24 hours, about 36 hours, about 48 hours, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, or about 15 days post the administration of the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof to the subject. In some instances, the CD8+ / CD69+T cells are increased within 1 hour, within 2 hours, within 3 hours, within 4 hours, within 5 hours, within 6 hours, within 12 hours, within 18 hours, within 24 hours, within 36 hours, within 48 hours, within 3 days, within 4 days, within 5 days, within 6 days, within 7 days, within 8 days, within 9 days, within 10 days, within 11 days, within 12 days, within 13 days, within 14 days, or within 15 days upon the administration of the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof to the subject.
[0187] In some instances, the CD8+ / CD25+T cells are increased about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 12 hours, about 18 hours, about 24 hours, about 36 hours, about 48 hours, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, or about 15 days post the administration of the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof to the subject. In some instances, the CD8+ / CD25+T cells are increased within 1 hour, within 2 hours, within 3 hours, within 4 hours, within 5 hours, within 6 hours, within 12 hours, within 18 hours, within 24 hours, within 36 hours, within 48 hours, within 3 days, within 4 days, within 5 days, within 6 days, within 7 days, within 8 days, within 9 days, within 10 days, within 11 days, within 12 days, within 13 days, within 14 days, or within 15 days upon the administration of the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof to the subject.
[0188] In some instances, the subject has an increased level of a cytokine after the administration of the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof as compared to a subject without the administration. In instances, the cytokine comprises interleukin-2 (IL-2), IL-7, or IL-15. In some instances, theWSGR Docket No.47517-770.601 cytokine comprises a proinflammatory cytokine or a chemokine. In some instances, the cytokine
[0189] The administration of the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof to a subject can induce epitope spreading. In some instances, tumor antigens from cancer cells of the subject are released from the cancer cells after the administration. In some instances, the endogenous T cell response of the subject is activated after the administration. In some instances, the long-term immunity of the subject is induced after the administration.
[0190] The subject receiving the administration of the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof can be a subject had cancer and the cancer had regressed. In some instances, the cancer regression is a result of a treatment. The treatment can be a conventional cancer treatment. The conventional cancer treatment can be a chemo-therapy, a radio-therapy, a surgery, or a cell therapy. In some instances, the treatment comprises administering an effective amount of the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof. In some instances, the treatment comprises administering a therapeutic agent as disclosed herein. In some instances, the subject had a cancer that had regressed to an undetectable size. In some instances, the subject had been clinically diagnosed as cancer free before the administration of the DLL3 targeting trispecific protein of the disclosure, the DLL3 CAR, or the DLL3 sensitized lymphocytes, or any combination thereof. In some instances, the subject has cancer relapse after the administration of the DLL3 targeting trispecific protein and the relapsed cancer develops slower than a relapsed cancer in a subject without the administration. In some instances, the subject is prone to cancer relapse and the subject is clinically cancer free after the administration of the DLL3 targeting trispecific protein. In some instances, the subject is clinically cancer free for at least 5 days, at least 10 days, at least 15 days, at least 20 days, at least 30 days, at least 40 days, at least 50 days, at least 60 days, at least 70 days, at least 80 days, at least 90 days, at least 100 days, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, or at least 12 months. Methods of detection of DLL3 expression and diagnosis of DLL3 associated cancer
[0191] According to another embodiment of the disclosure, kits for detecting expression of DLL3 in vitro or in vivo are provided. The kits include the foregoing DLL3 binding proteins, DLL3 targeting trispecific proteins (e.g., a trispecific protein containing a labeled anti-DLL3 singleWSGR Docket No.47517-770.601 domain antibody or antigen binding fragments thereof), and one or more compounds for detecting the label. In some embodiments, the label is selected from the group consisting of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.
[0192] In some cases, DLL3 expression is detected in a biological sample. The sample can be any sample, including, but not limited to, tissue from biopsies, autopsies and pathology specimens. Biological samples also include sections of tissues, for example, frozen sections taken for histological purposes. Biological samples further include body fluids, such as blood, serum, plasma, sputum, spinal fluid or urine. A biological sample is typically obtained from a mammal, such as a human or non-human primate.
[0193] In one embodiment, provided is a method of determining if a subject has cancer by contacting a sample from the subject with an anti-DLL3 single domain antibody or an anti-DLL3 trispecific protein as disclosed herein; and detecting binding of the single domain antibody to the sample. An increase in binding of the antibody to the sample as compared to binding of the antibody to a control sample identifies the subject as having cancer.
[0194] In another embodiment, provided is a method of confirming a diagnosis of cancer in a subject by contacting a sample from a subject diagnosed with cancer with an anti-DLL3 single domain antibody or an anti-DLL3 trispecific protein as disclosed herein; and detecting binding of the antibody to the sample. An increase in binding of the antibody to the sample as compared to binding of the antibody to a control sample confirms the diagnosis of cancer in the subject.
[0195] In some examples of the disclosed methods, the DLL3 binding protein, or the DLL3 binding single domain antibody of the trispecific protein is directly labeled. In some examples, the methods further include contacting a second antibody that specifically binds an anti-DLL3 single domain antibody or an anti-DLL3 trispecific protein with the sample; and detecting the binding of the second antibody. An increase in binding of the second antibody to the sample as compared to binding of the second antibody to a control sample detects cancer in the subject or confirms the diagnosis of cancer in the subject. In some cases, the cancer is a neuroendocrine cancer, prostate cancer, lung cancer, stomach cancer, squamous cell carcinoma, pancreatic cancer, cholangiocarcinoma, triple negative breast cancer or ovarian cancer, or any other type of cancer that expresses DLL3. In some examples, the control sample is a sample from a subject without cancer. In particular examples, the sample is a blood or tissue sample.
[0196] In some cases, the antibody that binds (for example specifically binds) DLL3 is directly labeled with a detectable label. In another embodiment, the antibody that binds (for example, specifically binds) DLL3 (the first antibody) is unlabeled and a second antibody or other moleculeWSGR Docket No.47517-770.601 that can bind the antibody that specifically binds DLL3 is labeled. A second antibody is chosen such that it is able to specifically bind the specific species and class of the first antibody. For example, if the first antibody is a llama IgG, then the secondary antibody may be an anti-llama-IgG. Other molecules that can bind to antibodies include, without limitation, Protein A and Protein G, both of which are available commercially. Suitable labels for the antibody or secondary antibody are described above, and include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, magnetic agents and radioactive materials. Non-limiting examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase. Non-limiting examples of suitable prosthetic group complexes include streptavidin / biotin and avidin / biotin. Non-limiting examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin. A non-limiting exemplary luminescent material is luminol; a non-limiting exemplary a magnetic agent is gadolinium, and non-limiting exemplary radioactive labels include 125I, 131I, 35S or 3H.
[0197] In an alternative embodiment, DLL3 can be assayed in a biological sample by a competition immunoassay utilizing DLL3 standards labeled with a detectable substance and an unlabeled antibody that specifically binds DLL3. In this assay, the biological sample, the labeled DLL3 standards and the antibody that specifically bind DLL3 are combined and the amount of labeled DLL3 standard bound to the unlabeled antibody is determined. The amount of DLL3 in the biological sample is inversely proportional to the amount of labeled DLL3 standard bound to the antibody that specifically binds DLL3.
[0198] The immunoassays and method disclosed herein can be used for a number of purposes. In one embodiment, the antibody that specifically binds DLL3 may be used to detect the production of DLL3 in cells in cell culture. In another embodiment, the antibody can be used to detect the amount of DLL3 in a biological sample, such as a tissue sample, or a blood or serum sample. In some examples, the DLL3 is cell-surface DLL3. In other examples, the DLL3 is soluble DLL3 (e.g., DLL3 in a cell culture supernatant or soluble DLL3 in a body fluid sample, such as a blood or serum sample).
[0199] In one embodiment, a kit is provided for detecting DLL3 in a biological sample, such as a blood sample or tissue sample. For example, to confirm a cancer diagnosis in a subject, a biopsy can be performed to obtain a tissue sample for histological examination. Alternatively, a blood sample can be obtained to detect the presence of soluble DLL3 protein or fragment. Kits for detecting a polypeptide will typically comprise a single domain antibody, according to the present disclosure, that specifically binds DLL3. In some embodiments, an antibody fragment, such as anWSGR Docket No.47517-770.601 scFv fragment, a VH domain, or a Fab is included in the kit. In a further embodiment, the antibody is labeled (for example, with a fluorescent, radioactive, or an enzymatic label).
[0200] In one embodiment, a kit includes instructional materials disclosing means of use of an antibody that binds DLL3. The instructional materials may be written, in an electronic form (such as a computer diskette or compact disk) or may be visual (such as video files), or provided through an electronic network, for example, over the internet, World Wide Web, an intranet, or other network. The kits may also include additional components to facilitate the particular application for which the kit is designed. Thus, for example, the kit may additionally contain means of detecting a label (such as enzyme substrates for enzymatic labels, filter sets to detect fluorescent labels, appropriate secondary labels such as a secondary antibody, or the like). The kits may additionally include buffers and other reagents routinely used for the practice of a particular method. Such kits and appropriate contents are well known to those of skill in the art.
[0201] In one embodiment, the diagnostic kit comprises an immunoassay. Although the details of the immunoassays may vary with the particular format employed, the method of detecting DLL3 in a biological sample generally includes the steps of contacting the biological sample with an antibody which specifically reacts, under immunologically reactive conditions, to a DLL3 polypeptide. The antibody is allowed to specifically bind under immunologically reactive conditions to form an immune complex, and the presence of the immune complex (bound antibody) is detected directly or indirectly.
[0202] Methods of determining the presence or absence of a cell surface marker are well known in the art. For example, the antibodies can be conjugated to other compounds including, but not limited to, enzymes, magnetic beads, colloidal magnetic beads, haptens, fluorochromes, metal compounds, radioactive compounds or drugs. The antibodies can also be utilized in immunoassays such as but not limited to radioimmunoassays (RIAs), ELISA, or immunohistochemical assays. The antibodies can also be used for fluorescence activated cell sorting (FACS). FACS employs a plurality of color channels, low angle and obtuse light-scattering detection channels, and impedance channels, among other more sophisticated levels of detection, to separate or sort cells (see U.S. Patent No.5,061,620). Any of the single domain antibodies that bind DLL3, as disclosed herein, can be used in these assays. Thus, the antibodies can be used in a conventional immunoassay, including, without limitation, an ELISA, an RIA, FACS, tissue immunohistochemistry, Western blot or imunoprecipitation.WSGR Docket No.47517-770.601 EXAMPLES
[0203] The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, cell biology, biochemistry, nucleic acid chemistry, and immunology, which are well known to those skilled in the art. Such techniques are explained fully in the literature cited herein.
[0204] Additional embodiments are disclosed in further detail in the following examples, which are provided by way of illustration and are not in any way intended to limit the scope of this disclosure or the claims. Generation of the mouse model
[0205] FIG.2A). Flow cytometry was used to FIG.2B).
[0206] incubated with a secondary antibody (anti-trispecific antibody), which is able to recognize the anti- albumin domain in the exemplary trispecific molecules, conjugated to Alexa Fluor 647. Binding of the anti-trispecific antibody was measured by flow cytometry. The results show that the exemplary cells (FIG.2C). TriTACs can engage and activate endogenous T cells In Vivo and display anti-tumor activity and toxicity
[0207] 6MC38-huEGFR cells and dosed with 1mg / kg DLL3-targeting trispecific proteins (anti-huEGFR TriTAC, anti-mu / huEGFR TriTAC) for 10 days. Measurements taken twice weekly for tumor volume and weight. (FIG.3A TriTAC was used as a negative control. Significant inhibition of tumor growth was observed in the wild-type mice (FIG.3A KI mice treated with anti-mu / huEGFR TriTAC which had weight loss, no weight loss was wild-type mice treated with anti-mu / huEGFR TriTAC, and wild-type mice treated with anti- huEGFR TriTAC. GFP TriTAC was used as a negative control (FIG.3B).WSGR Docket No.47517-770.601
[0208] day 8 when tumors reached about 280 mm3. An exemplary anti-DLL3 trispecific protein (anti- 100 µg / kg, 40 µg / kg, and 8 µg / kg) once a day on days 9-18 (FIG.4). Vehicle was used as a negative control. The results suggest that the exemplary anti-DLL3 trispecific protein has a dose Increased activation in CD8+ TILs
[0209] with the exemplary anti-DLL3 trispecific protein. Vehicle was used as negative control. Two days after dosing, tumors were dissociated, T cell populations were collected, CD69 and CD25 expression on the T cells was measured by flow cytometry (FIG.5). Increased expression of CD69 anti-DLL3 trispecific protein as compared to the negative control. Example 3: HPN328 Treatment Induces Long-Term Immunity in Immunocompetent Mouse Model Mechanism of TriTAC-induced long-term immunity and epitope spread
[0210] Without being bound by any particular theory, the TriTAC molecules may induce long-term immunity and epitope spread by activating the T cells to initiate cytokine cascade. As shown in FIG.6, when a tumor associated antigen from the tumor cell is presented to the T cell expressing the TriTAC, two pathways are activated to induce the long-term immunity: the first pathway is direct tumor cell death, and the second pathway is amplification of tumor killing. In the first pathway, after T cell activation by the TriTAC molecule, the T cell releases perforin / granzyme B, leading to the lysis of the tumor cell. The tumor cell lysis allows the release of more tumor antigens, activating endogenous T cell response and inducing the long-term immunity. In the second pathway, after T cell activation by the TriTAC molecule, the activated T cell increases cytokine release. The increased cytokine release activates endogenous T cell response and induce the long-term immunity. Long-term immunity induced in mice cured by an exemplary anti-DLL3 trispecific protein
[0211] In this study, as shown in FIG.7A one flank with 2 × 106Mice were measured. On day 8, the mice were randomized and an exemplary anti-DLL3 trispecificWSGR Docket No.47517-770.601 protein (anti-DLL3 TriTAC) was used to treat the mice by i.p. injection at different doses (1000 µg / kg, 200 µg / kg, and 100 µg / kg) once a day on days 8-17. As shown in FIG.7B, consistent with the earlier observation, the exemplary anti-DLL3 trispecific protein showed a dose response anti- tumor activity. The treatment with all three doses (1000 µg / kg, 200 µg / kg, and 100 µg / kg) reduced the tumor volume and with the highest tested dose (i.e., 1000 µg / kg), the tumor volume significantly decreased and reduced to minimal at the end of the treatment period. On day 30, the tumor free mice after the treatment were rechallenged with 2 × 106parental MC38 cells on the opposite flank. As shown in FIG.7C, after the rechallenge, the tumor volume in naïve mice increased significantly. However, the tumor volume in the mice with previous 200 µg / kg dose treatment showed a slower tumor group than the naïve mice. The tumor in the mice with previous 1000 µg / kg dose treatment did not grow. On day 60, spleens from the rechallenged mice in were processed and CD8+ memory T cells were analyzed by flow cytometry (FIG.7D). The results suggest that the previous treatment with the exemplary anti-DLL3 trispecific protein resulted in an increase in the CD8+ memory T cells in spleens from the rechallenged mice previously treated with the exemplary anti-DLL3 trispecific protein.
[0212] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby. SEQ. ID NO. name sequence 1DL1QVQLQESGGGLVQAGGSLRLSCAASGSIFSIASMGWYRQAPGKQRELVAVITSFSSTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTGVYYCNARYFERTDWGQGTQVTVSS2 DL74QVQLQESGGGLVQAGGSLRLSCAAPGSIFSIASMGWYRQAPGKQRELVAVITSFSSTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTGVYYCNARYFERTDWGQGTQVTVSS3 DL31QVQLQESGGGLVQAGGSLRLSCAASGSIFSIASMAWYRQAPGKQRELVAAITSFSSTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTGVYYCNARYFERTDWGQGTQVTVSS4 DL3QVQLQESGGGLVQAGGSLRLSCAASESIFSINVMAWHRQAPGKQRELVARITSGGSTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTGVYYCGAYQGLYAYWGQGTQVTVSS5 DL80QVQLQESGGGLVQAGGSLRLSCVASGSSFSITSMAWYRQAPGKQRDLVAAITSFGSTNYADSVKDRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNGRVFDHVYWGQGTQVTVSS6 DL18QVQLQESGGGLVQAGGSLKLSCAASSSIFSISSMSWYRQAPGKQRELVAAITTFDYTNYADSVKGRFTISRDNAKNMMYLQMNSLKPEDTAVYLCNARAFGRDYWGQGTQVTVSS7 DL94QVQLQESGGGLVQAGGSLKLSCAASSSIFSISSMSWYRQAPGKQRELVAAITSFGSTNYADSVKGRFTISRDNAKNMMYLQMNSLKPEDTAVYRCNARTMGRDYWGQGTQVTVSS8 DL17QVQLQESGGGLVQPGGSLRLSCAASGSTLNIKIMAWHRQAPGKQRELVATLTSGGNTNYADSVKGRFTISRDNAKNTVYLQMNSLQPEDTAVYYCGLWDGVGGAYWGRGTQVTVSSWSGR Docket No.47517-770.601 9 DL46QVQLQESGGGLVQPGGSLRISCAASGSTLNIKIMAWHRQAPGKQRELVATLTSGGNTNYADSVKGRFTISRDNAKNTVYLQMNSLQPEDTAVYYCGLWDGVGGAYWGRGTQVTVSS10 DL15QVQLQESGGGLVQAGGSLRLSCAASGSTFNIKTMAWHRQAPGNQRELVATLTSGGNTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCGLWNGVGGAYWGRGTQVTVSS11 DL26QVQLQDGGGLVQPGGSLRLSCAASGSTFNIKLMAWHRQAPGNQRELVATLTSGGNTNYADSVKGRFTISRDNASNIVYLQMNSLKPEDTAVYYCGLWDGVGGAYWGRGTQVTVSS12 DL83QVQLQESGGGLVQAGGSLRLSCAASGSTFNFKIMAWHRQAPGKQRELVASLTSEGLTNYRDSVKGRFTISRDNAKNTVYLQMNNLKPEDTAVYYCGLWDGVGGAYWGRGTQVTVSS13 DL5QVQLQESGGGLVQPGGSLRLSCAASGFMFSSYSMSWYRQAPGKQRELVAAITTWGSTNYADSVKGRFTISRDNAKNTVWLQMNSLEPEDTAVYFCNARSWNNYWGQGTQVTVSS14 DL22QVQLQESGGGLVQVGGSLRLSCAASGFMFSSYSMSWYRQAPGKQRELVAAITSYGSTNYADSVKGRFTISRDNAKNTVWLQMNSLKPEDTAVYFCNARSWNNYWGQGTQVTVSS15 DL85QVQLQESGGGLVQPGGSLRLSCAASGFTFSSHSMSWYRQAPGKQRELVAAITTYGSTNYIDSVKGRFTISRDNTKNTVYLQMNSLKPEDTAVYFCNARSWNNYWGQGTQVTVSS16 DL69QVQLQESGGGLVQAGGSLRLSCVASGSSFSHNTMGWYRQAPGKQRDLVARITTFGTTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNGESFGRIWYNWGQGTQVTVSS17 DL27QVQLQESGGGLVQAGASLRLTCTASGGRFSYATMGWSRQAPGKQREMVARITSSGFSTNYADSVKGRFTISRDNAKNAVYLQMDSLKPEDTAVYYCNAQHFGTDSWGQGTQVTVSS18 DL51QVQLQESGGGLVQAGASLRLTCTASGSRFSYATMGWSRQAPGKQRELVARITSSGFSTNYADSVKGRFTISRDNAKNAVYLQMDSLKPEDTAVYYCNAQQFGTDSWGQGTQVTVSS19 DL54QVQLQESGGGLVQAGGSLRLSCAASGSTFTSNVMGWHRQAPGKQRELVANMHSGGSTNYADSVKGRFTISRDNAKNIVYLQMNNLKIEDTAVYYCRWYGIQRAEGYWGQGTQVTVSS20 DL11QVQLQESGGGLVVAGGSLRLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISVDGSTNYADSVKGRFTVSRDNAKNTVYLQMNSLQPEDTAVYYCYAYRWVGRDTYWGQGTQVTVSS21 DL19QVQLQESGGGLVVAGGSLRLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISVDGSTNYADSVKGRFTISRDNAKNTVYLQMNSLQPEDTAVYYCYAYRWVGRDTYWGQGTQVTVSS22 DL68QVQLQESGGGLVVSGGSLRLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISVDGSTNYADSVKGRFTISRDNAKNTVYLQMNSLQPEDTAAYYCYAYRWVGRDTYWGQGTQVTVSS23 DL14QVQLQESGGGLVVAGGSLRLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISVDGSTNYADSVKGRFTISRDNAENTVYLQMNSLQPEDTAVYYCYAYRWEGRDTYWGQGTQVTVSS24 DL67QVQLQESGGGLVVAGGSLRLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISVDGSTNYADSVKGRFTISRDNAENTVYLQMNSLQPEDTAVYYCYAYRWEGRNTYWGQGTQVTVSS25 DL56QVQLQESGGGLVQPGGSLRLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISTDGSTNYVDSVKGRFTISRDNAKNTVYLQMNSLQPEDTAVYYCYAYRWVGRYTYWGQGTQVTVSS26 DL13QVQLQESGGGLVVAGGSLRLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISTDGTTNYVDSVKDRFTISRDNAKNTVYLQMNSLQPEDTAAYYCYAYRWVGRDTYWGQGTQVTVSS27 DL77QVQLQESGGGLVVAGGSLRLSCAASGSSVSFLSIAWYRQAPGKKRELVAGISTDGTTNYVDSVKDRFTISRDNAKNTVYLQMNSLQPEDTAAYYCYAYRWVGRDTYWGQGTQVTVSS28 DL79QVQLQESGGGLVQAGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISTDGTTNYVDSVKDRFTISRDNAKNTVYLQMNSLQPEDTAAYYCYAYRWVGRDTYWGQGTQVTVSS29 DL20QVQLQESGGGLVQAGGSLRLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISTDGSTNYADSVKGRFTISEGNAKNTVDLQMNSLQPEDTAVYYCYAYRWVDRYTYWGQGTQVTVSS30 DL41QVQLQESGGGLVVAGGSLRLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISTDGSTNYADSVKGRFTISEDNAKNTVDLQMNSLQPEDTAVYYCYAYRWIDRYTYWGQGTQVTVSS31 DL59QVQLQESGGGLVQPGGSLRLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISTDGSTNYADSVKGRFTISEDNAKNTVDLQMNSLQPEDTAVYYCYAYRWVDRYTYWGQGTQVTVSS32 DL16QVQLQESGGGLVVAGGSLRLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISSDGSTNYVDSVKGRFTISRDNAKNIVFLQMNSLQPQDTAVYYCYAYRWVGRDTYWGQGTQVTVSS33 DL6QVQLQESGGGLVVAGGSLRLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISADGSTDYIDSVKGRFTISRDSANNTMYLQMNSLQPEDTAVYYCYAYRWTTRYTYWGQGTQVTVSS34 DL84QVQLQESGGGLVQPGGSLRLSCAASGFTLDYYAIGWYRQAPGKKRELVAGISSDGSTHYVDSVKGRFAISRDNAENTVYLQMNDLQPDDTAVYYCYAYRWVGGYTYWGQGTQVTVSS35 DL2QVQLQESGGGLVQAGGSLRLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDGSKNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCYYFRTVAASSMQYWGQGTQVTVSS36 DL43 QVQLQESGGGLVQAGGSLRLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVFYCYYFRTVSGSSMRYWGQGTQVTVSS37 DL92 QVQLQESGGGLVQAGGSLRLSCAASGITSSVYSMGWYRQAPGKQRELVAGSSSDGSTHYVDSVRGRFTISRDNAKNTVYLQMSSLKPEDTAVYYCYANRGFAGAPSYWGQGTQVTVSS38 DL10QVQLQESGGGLVQAGGSLRLSCAASGRTSMFNSMGWHRQAPGKQRELVAIIRSGGSSNYADTVKGRFTISRDNTKNTVYLQMNDLKPEDTAVYYCFYYFQSSYWGQGTQVTVSSWSGR Docket No.47517-770.60139 DL82QVQLQESGGGLVQAGGSLRLSCAASGRTSMVNSMGWHRQAPGKQRELVALITSGGSSNYADTVKGRFTISRDNTKNTVYLQMNDLKPEDTAVYYCFYYFQSSYWGQGTQVTVSS40 DL23QVQLQESGGGLVQAGGSLRLSCAASGSVSMFNSMGWHRQPPGKQRELVAIITSGGSSNYADTVKGRFTISRDNTKNTVYLQMNDLKPEDTAVYYCFYYFQSSYWGQGTQVTVSS41 DL42 QVQLQESGGGLVQAGGSLRLSCTASGSIFSIAVMGWYRQVPGKRREWVATIFDGSYTNYADSVKGRFTISRDNARNKVYLQMNNLKPEDTAVYYCQTHWTQGSVPKESWGQGTQVTVSS42 DL45QVQLQESGGGLVQAGGSLRLSCVASSGIFSDMSMVWYRQAPGKQRELVASITTFGSTNYADPVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCSGRSYSSDYWGRGTQVTVSS43 DL58QVQLQESGGGLVQAGGSLRLSCVASGSISSIIVMGWSRQAPGKQRESVATITRDGTRNYADSLKGRFTISRDNAKNTSYLQINSLKPEDTAVYSCYARYGDINYWGKGTQVTVSS44 DL70QVQLQESGGGLVQAGGSLRLSCVASGSISSIIVMGWSRQAPGKQRESLATISRGGTRTYADSVKGRFTISRDNAKNTSYLQMNSLKPEDTAVYSCYARYGDINYWGKGTQVTVSS45 DL89QVQLQESGGGLVQAGGSLRLSCVASGSIFTTNSMGWHRQGPGKQRELVALIGSAGSTKYADSVKGRFTISRDNAKNTVSLQMDSLKPEDTAVYYCFYYDSRSYWGQGTQVTVSS46 DL38QVQLQESGGGMVQPGGSLRLSCAASGSREISTMGWHRQAPGKQRELAARITSGGITKYADSVKGRFTISRDNAKKTVYLQMNSLKSEDTAVYYCFAYDNINAYWGQGTQVTVSS47 DL52QVQLQESGGGWVQAGGSLRLSCAASGSREISTMGWHRQAPGKQRELAARITSGGITKYADSVKGRFTISRDNAKKTVYLQMNSLKSEDTAVYYCFAYDNINAYWGQGTQVTVSS48 DL64QVQLQESGGGWVQAGGSLRLSCTASGSREISTMGWHRQAPGKQRELAARITSGGITKYADSVKGRFTISRDNAKKTVYLQMDSLKSEDTAVYYCFAYDNINAYWGQGTQVTVSS49 DL33QVQLQESGGGSVQAGRSLGLSCAASGSREISTMGWHRQAPGKQRELAARITSGGITKYADSVKGRFTISRDNAKKTVYLQMNSLKSEDTAVYYCFAYDNINAYWGQGTQVTVSS50 DL12QVQLQESGGGLVQAGGSLRLSCTASGSIFRGAAMYWHRQAPGKQRELVAAITTSGNTSYADSVKGRFTISRDNAKNTMYLQIISLKPEDTAVYYCAFWIAGKAYWGQGTQVTVSS51 DL29QVQLQESGGGLVQPGGSLRLSCAASGSISSFNFMSWHRQAPGKERELAGVITRGGATNYADSVKGRFTISRDNVKNTVYLQMNGLKPEDTAVYYCHGRSQLGSTWGQGTQVTVSS52 DL61QVQLQESGGGLVQAGGSLRLSCLASGTIFTASTMGWHRQPPGKQRELVASIAGDGRTNYAESTEGRFTISRDDAKNTMYLQMNSLKPEDTAVYYCYAYYLDTYAYWGQGTQVTVSS53 DH1EVQLVESGGGLVQPGGSLTLSCAASGSIFSIASMGWYRQAPGKQRELVAVITSFSSTNYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCNARYFERTDWGQGTLVTVSS54 DH10EVQLVESGGGLVQPGGSLTLSCAASGRTSMFNSMGWHRQAPGKQRELVAIIRSGGSSNYADTVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCFYYFQSSYWGQGTLVTVSS55 DH11EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISVDGSTNYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWVGRDTYWGQGTLVTVSS56 DH12EVQLVESGGGLVQPGGSLTLSCTASGSIFRGAAMYWHRQAPGKQRELVAAITTSGNTSYADSVKGRFTISRDNAKNSMYLQMNSLRAEDTAVYYCAFWIAGKAYWGQGTLVTVSS57 DH15EVQLVESGGGLVQPGGSLTLSCAASGSTFNIKTMAWHRQAPGNQRELVATLTSGGNTNYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCGLWNGVGGAYWGQGTLVTVSS58 DH17EVQLVESGGGLVQPGGSLTLSCAASGSTLNIKIMAWHRQAPGKQRELVATLTSGGNTNYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCGLWDGVGGAYWGQGTLVTVSS59 DH18EVQLVESGGGLVQPGGSLTLSCAASSSIFSISSMSWYRQAPGKQRELVAAITTFDYTNYADSVKGRFTISRDNAKNSMYLQMNSLRAEDTAVYYCNARAFGRDYWGQGTLVTVSS60 DH2 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDGSKNYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVAASSMQYWGQGTLVTVSS61 DH22EVQLVESGGGLVQPGGSLTLSCAASGFMFSSYSMSWYRQAPGKQRELVAAITSYGSTNYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCNARSWNNYWGQGTLVTVSS62 DH23EVQLVESGGGLVQPGGSLTLSCAASGSVSMFNSMGWHRQPPGKQRELVAIITSGGSSNYADTVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCFYYFQSSYWGQGTLVTVSS63 DH27EVQLVESGGGLVQPGGSLTLSCTASGGRFSYATMGWSRQAPGKQREMVARITSSGFSTNYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCNAQHFGTDSWGQGTLVTVSS64 DH29EVQLVESGGGLVQPGGSLTLSCAASGSISSFNFMSWHRQAPGKERELAGVITRGGATNYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCHGRSQLGSTWGQGTLVTVSS65 DH3EVQLVESGGGLVQPGGSLTLSCAASESIFSINVMAWHRQAPGKQRELVARITSGGSTNYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCGAYQGLYAYWGQGTLVTVSS66 DH38EVQLVESGGGLVQPGGSLTLSCAASGSREISTMGWHRQAPGKQRELAARITSGGITKYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCFAYDNINAYWGQGTLVTVSS67 DH42 EVQLVESGGGLVQPGGSLTLSCTASGSIFSIAVMGWYRQVPGKRREWVATIFDGSYTNYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCQTHWTQGSVPKESWGQGTLVTVSS68 DH43EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMRYWGQGTLVTVSSWSGR Docket No.47517-770.601 69 DH45EVQLVESGGGLVQPGGSLTLSCVASSGIFSDMSMVWYRQAPGKQRELVASITTFGSTNYADPVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCSGRSYSSDYWGQGTLVTVSS70 DH5EVQLVESGGGLVQPGGSLTLSCAASGFMFSSYSMSWYRQAPGKQRELVAAITTWGSTNYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCNARSWNNYWGQGTLVTVSS71 DH51EVQLVESGGGLVQPGGSLTLSCTASGSRFSYATMGWSRQAPGKQRELVARITSSGFSTNYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCNAQQFGTDSWGQGTLVTVSS72 DH54EVQLVESGGGLVQPGGSLTLSCAASGSTFTSNVMGWHRQAPGKQRELVANMHSGGSTNYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCRWYGIQRAEGYWGQGTLVTVSS73 DH56EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISTDGSTNYVDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWVGRYTYWGQGTLVTVSS74 DH58EVQLVESGGGLVQPGGSLTLSCVASGSISSIIVMGWSRQAPGKQRESVATITRDGTRNYADSLKGRFTISRDNAKNSSYLQMNSLRAEDTAVYYCYARYGDINYWGQGTLVTVSS75 DH6EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISADGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYTYWGQGTLVTVSS76 DH61EVQLVESGGGLVQPGGSLTLSCLASGTIFTASTMGWHRQPPGKQRELVASIAGDGRTNYAESTEGRFTISRDNAKNSMYLQMNSLRAEDTAVYYCYAYYLDTYAYWGQGTLVTVSS77 DH67EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISVDGSTNYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWEGRNTYWGQGTLVTVSS78 DH69EVQLVESGGGLVQPGGSLTLSCVASGSSFSHNTMGWYRQAPGKQRDLVARITTFGTTNYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCNGESFGRIWYNWGQGTLVTVSS79 DH70EVQLVESGGGLVQPGGSLTLSCVASGSISSIIVMGWSRQAPGKQRESLATISRGGTRTYADSVKGRFTISRDNAKNSSYLQMNSLRAEDTAVYYCYARYGDINYWGQGTLVTVSS80 DH80EVQLVESGGGLVQPGGSLTLSCVASGSSFSITSMAWYRQAPGKQRDLVAAITSFGSTNYADSVKDRFTISRDNAKNSVYLQMNSLRAEDTAVYYCNGRVFDHVYWGQGTLVTVSS81 DH82EVQLVESGGGLVQPGGSLTLSCAASGRTSMVNSMGWHRQAPGKQRELVALITSGGSSNYADTVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCFYYFQSSYWGQGTLVTVSS82 DH83EVQLVESGGGLVQPGGSLTLSCAASGSTFNFKIMAWHRQAPGKQRELVASLTSEGLTNYRDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCGLWDGVGGAYWGQGTLVTVSS83 DH84EVQLVESGGGLVQPGGSLTLSCAASGFTLDYYAIGWYRQAPGKKRELVAGISSDGSTHYVDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWVGGYTYWGQGTLVTVSS84 DH89EVQLVESGGGLVQPGGSLTLSCVASGSIFTTNSMGWHRQGPGKQRELVALIGSAGSTKYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCFYYDSRSYWGQGTLVTVSS85 DH92EVQLVESGGGLVQPGGSLTLSCAASGITSSVYSMGWYRQAPGKQRELVAGSSSDGSTHYVDSVRGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYANRGFAGAPSYWGQGTLVTVSS86 DH94EVQLVESGGGLVQPGGSLTLSCAASSSIFSISSMSWYRQAPGKQRELVAAITSFGSTNYADSVKGRFTISRDNAKNSMYLQMNSLRAEDTAVYYCNARTMGRDYWGQGTLVTVSS87 1A01EVQLVESGGGLVQPGGSLTLSCVASGFTSSINAMGWYRRAPGKQRELVAGISSDGSFVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRHVSGSSMRYWGQGTLVTVSS88 1A03EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSSRYWGQGTLVTVSS89 1A04 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDGSKVYEDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMRYWGQGTLVTVSS90 1A05 EVQLVESGGGLVQPGGSLTLSCVASGSPSSINAMGWYRRAPGKQRELSAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVRGSSMSYWGQGTLVTVSS91 1A06EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELAAGISSDGSSVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSKRYWGQGTLVTVSS92 1A07EVQLVESGGGLVQPGGSLTLSCVASGSISSINAMGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRMVSGSSMRYWGQGTLVTVSS93 1A09EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDGSKLYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVQGSSMRYWGQGTLVTVSS94 1A010EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAYGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVYGSSMRYWGQGTLVTVSS95 1A011EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAIGWYRRAPGKQRELVAGISSDGSKVYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSYRYWGQGTLVTVSS96 1A012 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDGSKVYSDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVLGSSMRYWGQGTLVTVSS97 1B01 EVQLVESGGGLVQPGGSLTLSCVASGSTSIINAMGWYRRAPGKQRELAAGISSDGSKVIADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRRVSGSSMRYWGQGTLVTVSS98 1B02EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDGSKIYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMRYWGQGTLVTVSSWSGR Docket No.47517-770.601 99 1B03EVQLVESGGGLVQPGGSLTLSCVASGKTSSINAMAWYRRAPGKQRELVAGISSDGSKVYTDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSARYWGQGTLVTVSS100 1B04 EVQLVESGGGLVQPGGSLTLSCVASGTTSSINAMGWYRRAPGKQRELVAGISSDGSLVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRIVRGSSMRYWGQGTLVTVSS101 1B05 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYYRTVSGSSMRYWGQGTLVTVSS102 1B07EVQLVESGGGLVQPGGSLTLSCVASGSGSSINAMGWYRRAPGKQRELVAGISSDGSKVYSDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRHVSGSSMRYWGQGTLVTVSS103 1B08EVQLVESGGGLVQPGGSLTLSCVASGTTSSINAMGWYRRAPGKQRELVAGISSDGSKVYVDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRFVSGSSMRYWGQGTLVTVSS104 1B09EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDGSKVYVDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMRYWGQGTLVTVSS105 1B010EVQLVESGGGLVQPGGSLTLSCVASGSTSRINAMGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTKSGSSMRYWGQGTLVTVSS106 1B011 EVQLVESGGGLVQPGGSLTLSCVASGSTSRINAMGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVYGSSMRYWGQGTLVTVSS107 1C01 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDGSKVYRDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMGYWGQGTLVTVSS108 1C02 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDGSKVYSDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMRSWGQGTLVTVSS109 1C03EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDNSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVGGSSMRYWGQGTLVTVSS110 1C04EVQLVESGGGLVQPGGSLTLSCVASGNTSSINAMAWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMRYWGQGTLVTVSS111 1C05EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSHMRYWGQGTLVTVSS112 1C06EVQLVESGGGLVQPGGSLTLSCVASGSTSIINAMGWYRRAPGKQRELVAGISSDGSKVYEDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRAVSGSSMRYWGQGTLVTVSS113 1C07 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMRYWGQGTLVTVSS114 1C08 EVQLVESGGGLVQPGGSLTLSCVASGSTSRINAMGWYRRAPGKQRELPAGISSDGSKVYAVSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSPMRYWGQGTLVTVSS115 1C010EVQLVESGGGLVQPGGSLTLSCVASGSTSRINAMGWYRRAPGKQRELVAGVSSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMSYWGQGTLVTVSS116 1C011EVQLVESGGGLVQPGGSLTLSCVASGTTSSINAMGWYRRAPGKQRELVAGISSDGSKVYEDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMRYWGQGTLVTVSS117 1C012EVQLVESGGGLVQPGGSLTLSCVASGITSSINAMGWYRRAPGKQRELVAGISSDGSKVYAGSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVRGSSMRYWGQGTLVTVSS118 1D01EVQLVESGGGLVQPGGSLTLSCVASGSTSDINAMGWYRRAPGKQRELVAGISSDKSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVRGSSMRYWGQGTLVTVSS119 1D02 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSNGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRQVSGSSMRYWGQGTLVTVSS120 1D03 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAIGWYRRAPGKQRELVAGISSDGSKVLADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRIVSGSSMGYWGQGTLVTVSS121 1D04EVQLVESGGGLVQPGGSLTLSCVASGSTSSKNAMGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGASMRYWGQGTLVTVSS122 1D06EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDNSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVHGSSMRYWGQGTLVTVSS123 1D08EVQLVESGGGLVQPGGSLTLSCVASGLTSSINAMGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRMVSGSSMRYWGQGTLVTVSS124 1D09EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDGSKVYTDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTISGSSMRYWGQGTLVTVSS125 1D010EVQLVESGGGLVQPGGSLTLSCVASGSTSSNNAMAWYRRAPGKQRELVAGISSDGSKVYTDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTRSGSSMRYWGQGTLVTVSS126 1D011 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDNSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGHSMRYWGQGTLVTVSS127 1D012 EVQLVESGGGLVQPGGSLTLSCVASGSTSHINAMGWYRRAPGKQRELVAGISSDGSRVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGGSMRYWGQGTLVTVSS128 1E02EVQLVESGGGLVQPGGSLTLSCVASGQTSSINAMGWYRRAPGKQRELVAGISSDGSQVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTKSGSSMRYWGQGTLVTVSSWSGR Docket No.47517-770.601 129 1E04EVQLVESGGGLVQPGGSLTLSCVASGSTSRINGMGWYRRAPGKQRELPAGISSDGSKAYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTASGTSMRYWGQGTLVTVSS130 1E05 EVQLVESGGGLVQPGGSLTLSCVASGSTSVINAMAWYRRAPGKQRELAAGISSDGSKVYAKSAKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFNTVSGSSMRYWGQGTLVTVSS131 1E07 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDGSKVYNDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVRGSSQRYWGQGTLVTVSS132 1E08EVQLVESGGGLVQPGGSLTLSCVASGKTSSINAMGWYRRAPGKQRELVAGISSDGSKVIADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVLGSSMRYWGQGTLVTVSS133 1E09EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDGSKVYTDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTRSGSSMRYWGQGTLVTVSS134 1E010EVQLVESGGGLVQPGGSLTLSCVASGSVSSINAMGWYRRAPGKQRELVAGISSDGSKVYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGLSMRYWGQGTLVTVSS135 1E011EVQLVESGGGLVQPGGSLTLSCVASGNTSSINAMGWYRRAPGKQRELVAGISSDGSKVYYDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVRGSSQRYWGQGTLVTVSS136 1E012 EVQLVESGGGLVQPGGSLTLSCVASGSTSSTNAMGWYRRAPGKQRELVAGISSDGSKVYVDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMVYWGQGTLVTVSS137 1F01 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDGSKVYGDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSRSSMRYWGQGTLVTVSS138 1F02 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELAAGISSDQSKVYADSAKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMSYWGQGTLVTVSS139 1F04EVQLVESGGGLVQPGGSLTLSCVASGGTSSINAMGWYRRAPGKQRELVAGISSDGSKVYSDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSARYWGQGTLVTVSS140 1F05EVQLVESGGGLVQPGGSLTLSCVASGSTRSINAMGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFHTVSGSSMRYWGQGTLVTVSS141 1F06EVQLVESGGGLVQPGGSLTLSCVASGTTSSINAMGWYRRAPGKQRELVAGISSDGSKVIADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVLGSSMRYWGQGTLVTVSS142 1F07EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDGSKVDADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMRYWGQGTLVTVSS143 1F08 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDGSKVYKDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRNVSGSSMRYWGQGTLVTVSS144 1F09 EVQLVESGGGLVQPGGSLTLSCVASGNTSSINAMGWYRRAPGKQRELVAGISSNGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVTGSSMRYWGQGTLVTVSS145 1F010EVQLVESGGGLVQPGGSLTLSCVASGSTSRINAMGWYRRAPGKQRELVAGISSDGSKVYKDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMRYWGQGTLVTVSS146 1F011EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAIGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVKGSSMRYWGQGTLVTVSS147 1F012EVQLVESGGGLVQPGGSLTLSCVASGLTSSINAMGWYRRAPGKQRELVAGISSDGSKVYQDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTNSGSSMRYWGQGTLVTVSS148 1G01EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDGSKVYAESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGASMRYWGQGTLVTVSS149 1G04 EVQLVESGGGLVQPGGSLTLSCVASGSTSSTNAMGWYRRAPGKQRELVAGISSDGSKVLADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVNLSSMRYWGQGTLVTVSS150 1G05 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAIGWYRRAPGKQRELVAGISSDGSKYYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVTGSSMRYWGQGTLVTVSS151 1G06EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAIGWYRRAPGKQRELVAGISSDGSKVYAVSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRKVSGSSARYWGQGTLVTVSS152 1G07EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDGSKVVADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTYSGSSMRYWGQGTLVTVSS153 1G09EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSKSSMRYWGQGTLVTVSS154 1G011EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFKTVSGSSMRYWGQGTLVTVSS155 1H01EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELAAGISSDNSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTRSGSSMRYWGQGTLVTVSS156 1H02 EVQLVESGGGLVQPGGSLTLSCVASGSKSSINAMGWYRRAPGKQRELAAGISSDGSKVYAQSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTSSGSSMRYWGQGTLVTVSS157 1H06 EVQLVESGGGLVQPGGSLTLSCVASGTTSSINAMGWYRRAPGKQRELVAGISSDGSKVYVDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRFLSGSSMRYWGQGTLVTVSS158 1H07EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAFGWYRRAPGKQRELVAGISSDGSKVYSDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMRYWGQGTLVTVSSWSGR Docket No.47517-770.601 159 1H08EVQLVESGGGLVQPGGSLTLSCVASGSTFSINAMGWYRRAPGKQRELVAGISSDGSKVLADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRLVSGSSMRYWGQGTLVTVSS160 1H010 EVQLVESGGGLVQPGGSLTLSCVASGSTRSINAMGWYRRAPGKQRELVAGISSDGSKVYNDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMRFWGQGTLVTVSS161 1H011 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAIGWYRRAPGKQRELVAGISSDGSKVYNDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTQSGSSMRYWGQGTLVTVSS162 1H012EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDGSKVYVDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMPYWGQGTLVTVSS163 2A01EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDGSKVVADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTLSGSSMRYWGQGTLVTVSS164 2A03EVQLVESGGGLVQPGGSLTLSCVASGTTSSINAMGWYRRAPGKQRELVAGISSDGSKVYGDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSAMRYWGQGTLVTVSS165 2A04EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDGSKVYTDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTTSGSSMRYWGQGTLVTVSS166 2A05 EVQLVESGGGLVQPGGSLTLSCVASGRTSSINAMGWYRRAPGKQRELVAGISSDGSKVYNDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGTSMRYWGQGTLVTVSS167 2A06 EVQLVESGGGLVQPGGSLTLSCVASGSTSSRNAMGWYRRAPGKQRELVAGISSDGSKVTADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTRSGSSMRYWGQGTLVTVSS168 2A08 EVQLVESGGGLVQPGGSLTLSCVASGSTKSINAMGWYRRAPGKQRELVAGISSDGSKVYRDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTSSGSSMRYWGQGTLVTVSS169 2A09EVQLVESGGGLVQPGGSLTLSCVASGSTSSRNAMGWYRRAPGKQRELVAGISSNGSKVYSDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMSYWGQGTLVTVSS170 2A011EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAIGWYRRAPGKQRELVAGISSDGSKVYSDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRPVSGSSMRYWGQGTLVTVSS171 2B01EVQLVESGGGLVQPGGSLTLSCVASGSTSLINAMGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRHVSGSSMRYWGQGTLVTVSS172 2B02EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTKSGSSMRYWGQGTLVTVSS173 2B03 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDGSLVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFTTVSGSSMRYWGQGTLVTVSS174 2B05 EVQLVESGGGLVQPGGSLTLSCVASGTTSSINAMGWYRRAPGKQRELVAGISSDGTKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFHTVSGSSMRYWGQGTLVTVSS175 2B07EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAFGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVRGSSMRYWGQGTLVTVSS176 2B010EVQLVESGGGLVQPGGSLTLSCVASGSTSSRNAMGWYRRAPGKQRELVAGISSDGSKLYLDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVLGSSMRYWGQGTLVTVSS177 2B011EVQLVESGGGLVQPGGSLTLSCVASGNTSSINAMGWYRRAPGKQRELVAGISSDGSRVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMRSWGQGTLVTVSS178 2B012EVQLVESGGGLVQPGGSLTLSCVASGTTSSINAMGWYRRAPGKQRELVAGISSDGSKVYNDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVRGSSMRYWGQGTLVTVSS179 2C01 EVQLVESGGGLVQPGGSLTLSCVASGSTASINAMGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRYVSGSSMRYWGQGTLVTVSS180 2C02 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAVGWYRRAPGKQRELVAGISSDGSKVYVDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVYGSSMRYWGQGTLVTVSS181 2C04EVQLVESGGGLVQPGGSLTLSCVASGSTSSRNAMGWYRRAPGKQRELVAGISSDGSKLYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVLGSSMRYWGQGTLVTVSS182 2C06EVQLVESGGGLVQPGGSLTLSCVASGSTNSINAMGWYRRAPGKQRELVAGISSDGSKVYKDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYYRTVSGSSMRYWGQGTLVTVSS183 2C07EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRSVSGSSMRYWGQGTLVTVSS184 2C08EVQLVESGGGLVQPGGSLTLSCVASGSTSRINAMGWYRRAPGKQRELVAGISSDGSKVYQDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRRVSGSSMRYWGQGTLVTVSS185 2C09EVQLVESGGGLVQPGGSLTLSCVPSGSTSNINAMGWYRRAPGKQRELPAGISSDGTKIYADSAKVPFTITRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGTSMRYWGQGTLVTVSS186 2C010 EVQLVESGGGLVQPGGSLTLSCVASGSTSKINAMGWYRRAPGKQRELVAGISSDRSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVAGSSMRYWGQGTLVTVSS187 2D02 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINALGWYRRAPGKQRELVAGISSDGSLVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRIVSGSSMRYWGQGTLVTVSS188 2D03EVQLVESGGGLVQPGGSLTLSCVASGKTSSINAMGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGVSMRYWGQGTLVTVSSWSGR Docket No.47517-770.601 189 2D04EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAVGWYRRAPGKQRELVAGISSDGSKVYRDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVQGSSMRYWGQGTLVTVSS190 2D05 EVQLVESGGGLVQPGGSLTLSCVASGSTSRINAMGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTASGSSMRYWGQGTLVTVSS191 2D06 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDGSKVYSDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSSRYWGQGTLVTVSS192 2D07EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAVGWYRRAPGKQRELVAGISSDGTKVYRDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVQGSSMRYWGQGTLVTVSS193 2D09EVQLVESGGGLVQPGGSLTLSCVASGTTSSINAMGWYRRAPGKQRELAAGISSDGSKVYNDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVRGSSMRYWGQGTLVTVSS194 2D010EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTKSGSSMRYWGQGTLVTVSS195 2D011EVQLVESGGGLVQPGGSLTLSCVASGTTSSINAMGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVWGSSMRYWGQGTLVTVSS196 2D012 EVQLVESGGGLVQPGGSLTLSCVASGKTSSINAMGWYRRAPGKQRELVAGISSDGSKVYTDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTRSGSSMRYWGQGTLVTVSS197 2E01 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPFKQGELPAGISPDGTKAYADSAKVRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFHTVCGTSMGYWGQGTLVTVSS198 2E02 EVQLVESGGGLVQPGGSLTLSCVASGSTSAINAMGWYRRAPGKQRELVAGISSDGSKVYVDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSQRYWGQGTLVTVSS199 2E05EVQLVESGGGLVQPGGSLTLSCVASGSPSSINAYGWYRRAPGKQRELVAGISSDGSKVYSDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMSYWGQGTLVTVSS200 2E06EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDGSKVYASSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVRGSSMRYWGQGTLVTVSS201 2E08EVQLVESGGGLVQPGGSLTLSCVASGSRSSINAMGWYRRAPGKQRELVAGISADGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTQSGSSMRYWGQGTLVTVSS202 2E09EVQLVESGGGLVQPGGSLTLSCVASGSVSSINAMGWYRRAPGKQRELVAGISSDGSKVYASSAKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTLSGSSMRYWGQGTLVTVSS203 2E010 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFHTVSGSSMRYWGQGTLVTVSS204 2E011 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAIGWYRRAPGKQRELVAGISSDGSSVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRRVSGSSMRYWGQGTLVTVSS205 2F01EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDGSKVYSDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRLVSGSSMRYWGQGTLVTVSS206 2F02EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAVGWYRRAPGKQRELVAGISSDGSKVYAGSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSYMRYWGQGTLVTVSS207 2F03EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELAAGISSDNSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVGGSSMRYWGQGTLVTVSS208 2F06EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAYGWYRRAPGKQRELVAGISSDGSAVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTHSGSSMRYWGQGTLVTVSS209 2F07 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAVGWYRRAPGKQRELVAGISSDGSSVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSTSSMRYWGQGTLVTVSS210 2F08 EVQLVESGGGLVQPGGSLTLSCVASGSKSSINAMGWYRRAPGKQRELPAGISSNGTKVYADSAKVRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVLGTSMRYWGQGTLVTVSS211 2F09EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDGSKLYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMRYWGQGTLVTVSS212 2F11EVQLVESGGGLVQPGGSLTLSCVASGSVSSINAMGWYRRAPGKQRELVAGISSDGSKVYKDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMGYWGQGTLVTVSS213 2G03EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDGSLVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMRAWGQGTLVTVSS214 2G04EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDGSLVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRILSGSSMRYWGQGTLVTVSS215 2G07EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVQGSSMRYWGQGTLVTVSS216 2G08 EVQLVESGGGLVQPGGSLTLSCVASGSTSYINAMGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGQSMGYWGQGTLVTVSS217 2G09 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGVSSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSARYWGQGTLVTVSS218 2G011EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELPAGISRDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRYVSGSSMRYWGQGTLVTVSSWSGR Docket No.47517-770.601 219 2H010EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELAAGISSDGSKLYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSMRYWGQGTLVTVSS220 2H011 EVQLVESGGGLVQPGGSLTLSCVASGSTSRINAMGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRRVSGSSMRYWGQGTLVTVSS221 2H02 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELAAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFHTVSGSSMRYWGQGTLVTVSS222 2H03EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRQVSGSSMRYWGQGTLVTVSS223 2H04EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDTSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSYMRYWGQGTLVTVSS224 2H06EVQLVESGGGLVQPGGSLTLSCVASGSTSTINAMGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTASGSSMRYWGQGTLVTVSS225 2H07EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAVGWYRRAPGKQRELVAGISSDGSTVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGHSMRYWGQGTLVTVSS226 2H08 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELAAGISKDGSKVYADSAKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSSRYWGQGTLVTVSS2E0EVQLVESGGGLVQPGGSLTLSCVASGSPSSINAYGWYRRAPGKQRELVAGISSDGSKVYSD227 5-M106YSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSYSYWGQGTLVTVSS 2E05EVQLVESGGGLVQPGGSLTLSCVASGSPSSINAYGWYRRAPGKQRELVAGISSDGSKVYSD228 -M106QSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSQSYWGQGTLVTVSS229 3A01EVQLVESGGGLVQPGGSLTLSCAASGSSVKFLSMAWYRQAPGKKRELVAGISADGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTRRYTYWGQGTLVTVSS230 3A02EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSLAWYRQAPGKKRELVAGISADGSTAYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS231 3A03EVQLVESGGGLVQPGGSLTLSCAASGSRVSFLSMAWYRQAPGKKRELVAGISRDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRRTYWGQGTLVTVSS232 3A04EVQLVESGGGLVQPGGSLTLSCAASGSQVSFLSMAWYRQAPGKKRELVAGISRDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYIYWGQGTLVTVSS233 3A05EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISEAGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS234 3A06EVQLVESGGGLVQPGGSLTLRCAASGSKVSFLSMAWYRQAPGKKRELVAGISADGSTDYVDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTRRYTYWGQGTLVTVSS235 3A08EVQLVESGGGLVQPGGSLTLSCAASGSSVGFLSMAWYRQAPGKKRELVAGISADGSTDYIRSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS236 3A09EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISADGSVDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYIYWGQGTLVTVSS237 3A010EVQLVESGGGLVQPGGSLTLSCAASGSRVSFLSMAWYRQAPGKKRELVAGISADGSTLYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRRTYWGQGTLVTVSS238 3A011EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSLAWYRQAPGKKRELVAGISTDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS239 3B01EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISGDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYTYWGQGTLVTVSS240 3B02EVQLVESGGGLVQPGGSLTLSCAASGSSVQFLSMAWYRQAPGKKRELVAGISADGSTDYINSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS241 3B04EVQLVESGGGLVQPGGSLTLSCAASGSNVSFLSMAWYRQAPGKKRELVAGISARGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYHWTTRYTYWGQGTLVTVSS242 3B05EVQLVESGGGLVQPGGSLTLSCVASGSSVKFLSMAWYRQAPGKKRELVAGISADGSTTYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRRTYWGQGTLVTVSS243 3B06EVQLVESGGGLVQPGGSLTLSCAASGKSVSFLSMAWYRQAPGKKRELVAGISKDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYTYWGQGTLVTVSS244 3B07EVQLVESGGGLVQPGGSLTLSCAASGSRVSFLSMAWYRQAPGKKRELVAGISADGSTTYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYTYWGQGTLVTVSS245 3B09EVQLVESGGGLVQPGGSLTLSCAASGSHVSFLSMAWYRQAPGKKRELVAGISANGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYAYWGQGTLVTVSS246 3B010EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISRDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWVTRYTYWGQGTLVTVSS247 3B011EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISADGSADYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWVTRYTYWGQGTLVTVSS248 3C01EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISAHGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWSTRYTYWGQGTLVTVSSWSGR Docket No.47517-770.601 249 3C02EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISADGSTIYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS250 3C03EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISRDGSTVYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRGTYWGQGTLVTVSS251 3C04EVQLVESGGGLVQPGGSLTLSCAASGSHVSFLSMAWYRQAPGKKRELVAGISADGPTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWDTRYTYWGQGTLVTVSS252 3C05EVQLVESGGGLVQPGGSLTLSCVASGTSVSFLSMAWYRQAPGKKRELVAGISADGSTTYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRRTYWGQGTLVTVSS253 3C06EVQLVESGGGLVQPGGSLTLSCAASGTSVSFLSIAWYRQAPGKKRELVAGISADGSTDYIASVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS254 3C08EVQLVESGGGLVQPGGSLTLSCAASGSSVKFLSMAWYRQAPGKKRELVAGISLDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTGRYTYWGQGTLVTVSS255 3C09EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISADGSTIYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS256 3C011EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISAHGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS257 3D01EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISRDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWITRYTYWGQGTLVTVSS258 3D02EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISRDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWITRYTYWGQGTLVTVSS259 3D03EVQLVESGGGLVQPGGSLTLSCAASGSSVVFLSMAWYRQAPGKKRELVAGISADGSMDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS260 3D05EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISADGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTRRYTYWGQGTLVTVSS261 3D07EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISADGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYSWTTRYTYWGQGTLVTVSS262 3D08EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISANGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTNRYTYWGQGTLVTVSS263 3D09EVQLVESGGGLVQPGGSLTLSCAASGSSVSRLSMAWYRQAPGKKRELVAGISANGSTTYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYRYWGQGTLVTVSS264 3D010EVQLVESGGGLVQPGGSLTLSCAASGSSKSFLSMAWYRQAPGKKRELVAGISADGSTSYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYTYWGQGTLVTVSS265 3D011EVQLVESGGGLVQPGGSLTLSCAASGSSVSRLSMAWYRQAPGKKRELVAGISADGSRDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYKYWGQGTLVTVSS266 3E01EVQLVESGGGLVQPGGSLTLSCAASGSSVKFLSMAWYRQAPGKKRELVAGISADGSTMYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWHTRYTYWGQGTLVTVSS267 3E02EVQLVESGGGLVQPGGSLTLSCAASGSGVRFLSMAWYRQAPGKKRELVAGISPDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTRRYTYWGQGTLVTVSS268 3E03EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISGDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWMTRYTYWGQGTLVTVSS269 3E04EVQLVESGGGLVQPGGSLTLSCAASGSSVHFLSMAWYRQAPGKKRELVAGISRDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYRYWGQGTLVTVSS270 3E09EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISRDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWSTRYTYWGQGTLVTVSS271 3E011EVQLVESGGGLVQPGGSLTLSCAASGSKVSFLSMAWYRQAPGKKRELVAGISRDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYTFWGQGTLVTVSS272 3F03EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISADGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS273 3F05EVQLVESGGGLVQPGGSLTLSCAASGSKVSFLSMAWYRQAPGKKRELVAGISTDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRRTYWGQGTLVTVSS274 3F06EVQLVESGGGLVQPGGSLTLSCAASGSRVSFLSMAWYRQAPGKKRELVAGISADGSTSYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWATRYTYWGQGTLVTVSS275 3F08EVQLVESGGGLVQPGGSLTLSCAASGSRVSFLSMAWYRQAPGKKRELVAGISADGSTLYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWHTRYTYWGQGTLVTVSS276 3F09EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISRDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWGTRYTYWGQGTLVTVSS277 3F010EVQLVESGGGLVQPGGSLTLSCAASYSSVSRLSMAWYRQAPGKKRELVAGISADGSTVYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRNTYWGQGTLVTVSS278 3F011EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISTDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSSWSGR Docket No.47517-770.601 279 3G01EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISADGSTLYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYAYWGQGTLVTVSS280 3G02EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISADGRTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS281 3G04EVQLVESGGGLVQPGGSLTLSCVASGTSVSFLSMAWYRQAPGKKRELVAGISADGSTIYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRRTYWGQGTLVTVSS282 3G06EVQLVESGGGLVQPGGSLTLSCAASGSSVKFLSMAWYRQAPGKKRELVAGISADGSTLYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRRTYWGQGTLVTVSS283 3G07EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISRDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTSRYTYWGQGTLVTVSS284 3G08EVQLVESGGGLVQPGGSLTLSCAASGSRVSFLSMAWYRQAPGKKRELVAGISKDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRVTYWGQGTLVTVSS285 3G09EVQLVESGGGLVQPGGSLTLSCAASGSSVSVLSMAWYRQAPGKKRELVAGISADGSTDYIGSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRTTYWGQGTLVTVSS286 3G010EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISVDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS287 3G011EVQLVESGGGLVQPGGSLTLSCAASGSRVSFLSMAWYRQAPGKKRELVAGISADGSTGYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWATRYTYWGQGTLVTVSS288 3H01EVQLVESGGGLVQPGGSLTLSCVASGSSVKFLSMAWYRQAPGKKRELVAGISGDGSTTYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRRTYWGQGTLVTVSS289 3H03EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISTDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYALRWTTRYTYWGQGTLVTVSS290 3H06EVQLVESGGGLVQPGGSLTLSCAASGSSVSQLSMAWYRQAPGKKRELVAGISADGSTDYFDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRGTYWGQGTLVTVSS291 3H07EVQLVESGGGLVQPGGSLTLSCAASGSRVSFLSMAWYRQAPGKKRELVAGISADGSTSYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS292 3H09EVQLVESGGGLVQPGGSLTLSCAASKSSVSFLSMAWYRQAPGKKRELVAGISADGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRATYWGQGTLVTVSS293 3H010EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISADGSTAYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRRTYWGQGTLVTVSS294 3H011EVQLVESGGGLVQPGGSLTLSCAASGSSVKFLSMAWYRQAPGKKRELVAGISADGSTVYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWPTRYTYWGQGTLVTVSS295 4A01EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISQDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS296 4A02EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISNDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWKTRYTYWGQGTLVTVSS297 4A04EVQLVESGGGLVQPGGSLTLSCAASGSRVSFLSMAWYRQAPGKKRELVAGISARGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWSTRYTYWGQGTLVTVSS298 4A05EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSLAWYRQAPGKKRELVAGISADGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWKTRRTYWGQGTLVTVSS299 4A06EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISRDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRRTYWGQGTLVTVSS300 4A07EVQLVESGGGLVQPGGSLTLSCAASGSKVSFLSMAWYRQAPGKKRELVAGISADGSTLYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYRYWGQGTLVTVSS301 4A08EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISADGSTNYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS302 4A010EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISADGSTVYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYKYWGQGTLVTVSS303 4A011EVQLVESGGGLVQPGGSLTLSCAASGSKVSFLSMAWYRQAPGKKRELVAGISADGSTTYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWKTRYTYWGQGTLVTVSS304 4A09EVQLVESGGGLVQPGGSLTLSCAASGSSVKFLSMAWYRQAPGKKRELVAGISADGSTDYIGSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRVTYWGQGTLVTVSS305 4B01EVQLVESGGGLVQPGGSLTLSCAASGSSVKFLSMAWYRQAPGKKRELVAGISRDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRFTYWGQGTLVTVSS306 4B02EVQLVESGGGLVQPGGSLTLSCAASGSRVSFLSMAWYRQAPGKKRELVAGISADGSTTYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRFTYWGQGTLVTVSS307 4B04EVQLVESGGGLVQPGGSLTLSCAASGSSVLFLSMAWYRQAPGKKRELVAGVSSDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS308 4B05EVQLVESGGGLVQPGGSLTLSCAASGSRVSFLSMAWYRQAPGKKRELVAGISADGHTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYTHWGQGTLVTVSSWSGR Docket No.47517-770.601 309 4B06EVQLVESGGGLVQPGGSLTLSCAASGSRVSFLSMAWYRQAPGKKRELVAGISADGSTDYFDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTRRYTYWGQGTLVTVSS310 4B07EVQLVESGGGLVQPGGSLTLSCAASGSSVGFLSMAWYRQAPGKKRELVAGISADGSTVYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYTYWGQGTLVTVSS311 4B08EVQLVESGGGLVQPGGSLTLSCAASGSSVSFMSMAWYRQAPGKKRELVAGISADGSTDYIASVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRSTYWGQGTLVTVSS312 4B09EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISADGSTDYISSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYSWTTRYTYWGQGTLVTVSS313 4B011EVQLVESGGGLVQPGGSLTLSCAASGSSVTFLSMAWYRQAPGKKRELVAGISADGSTVYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRGTYWGQGTLVTVSS314 4C01EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISADGSTVYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWKTRYTYWGQGTLVTVSS315 4C02EVQLVESGGGLVQPGGSLTLSCAASGSKVSFLSMAWYRQAPGKKRELVAGISADGSTTYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRFTYWGQGTLVTVSS316 4C03EVQLVESGGGLVQPGGSLTLSCAASGSKVSFMSMAWYRQAPGKKRELVAGISVDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS317 4C05EVQLVESGGGLVQPGGSLTLSCAASGSSVSNLSMAWYRQAPGKKRELVAGISADGSTAYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRRTYWGQGTLVTVSS318 4C06EVQLVESGGGLVQPGGSLTLSCAASNSSVSKLSMAWYRQAPGKKRELVAGISADGSTAYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWSTRYTYWGQGTLVTVSS319 4C07EVQLVESGGGLVQPGGSLTLSCAASGSKVSFLSMAWYRQAPGKKRELVAGISADGSKDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRLTYWGQGTLVTVSS320 4C08EVQLVESGGGLVQPGGSLTLSCVASGSQVSFLSMAWYRQAPGKKRELVAGISADGSTDYFDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTRRYTYWGQGTLVTVSS321 4C010EVQLVESGGGLVQPGGSLTLSCAASGSKVSFMSMAWYRQAPGKKRELVAGISADGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRLTYWGQGTLVTVSS322 4C011EVQLVESGGGLVQPGGSLTLSCAASGSRVSFLSMAWYRQAPGKKRELVAGISADGSTVYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTRRYTYWGQGTLVTVSS323 4D01EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISADGSTVYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRRTYWGQGTLVTVSS324 4D02EVQLVESGGGLVQPGGSLTLSCAASGSKVSFLSMAWYRQAPGKKRELVAGISARGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYQWTTRYTYWGQGTLVTVSS325 4D03EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISATGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTRRYTYWGQGTLVTVSS326 4D04EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSIAWYRQAPGKKRELVAGISKDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRMTYWGQGTLVTVSS327 4D05EVQLVESGGGLVQPGGSLTLSCAASGSSSSFLSMAWYRQAPGKKRELVAGISADGSTVYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRRTYWGQGTLVTVSS328 4D06EVQLVESGGGLVQPGGSLTLSCAASGSSVKFLSMAWYRQAPGKKRELVAGISPDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYRYWGQGTLVTVSS329 4D08EVQLVESGGGLVQPGGSLTLSCAASGSSVNFLSMAWYRQAPGKKRELVAGISADGSTHYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWLTRYTYWGQGTLVTVSS330 4D09EVQLVESGGGLVQPGGSLTLSCAASGSSVKFLSMAWYRQAPGKKRELVAGISADGSTDYILSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYEWTTRYTYWGQGTLVTVSS331 4D010EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISADGSTDYIHSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS332 4D011EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISVDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS333 4E01EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSVAWYRQAPGKKRELVAGISRDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS334 4E02EVQLVESGGGLVQPGGSLTLSCAASGSQVSFLSMAWYRQAPGKKRELVAGISADGSTVYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWSTRYTYWGQGTLVTVSS335 4E06EVQLVESGGGLVQPGGSLTLSCAASGTSVSFLSMAWYRQAPGKKRELVAGISADGSTDYIRSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRLTYWGQGTLVTVSS336 4E07EVQLVESGGGLVQPGGSLTLSCAASGSRVSFLSMAWYRQAPGKKRELVAGISADGSTMYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRLTYWGQGTLVTVSS337 4E08EVQLVESGGGLVQPGGSLTLSCAASGSSVKFLSMAWYRQAPGKKRELVAGISTDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYKWTTRYTYWGQGTLVTVSS338 4E09EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSSAWYRQAPGKKRELVAGISADGSTLYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRSTYWGQGTLVTVSSWSGR Docket No.47517-770.601 339 4E010EVQLVESGGGLVQPGGSLTLSCAASGSSVKFLSMAWYRQAPGKKRELVAGISADGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS340 4E011EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISATGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWSTRYTYWGQGTLVTVSS341 4F02EVQLVESGGGLVQPGGSLTLSCAASGSTVSFLSMAWYRQAPGKKRELVAGISHDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYTYWGQGTLVTVSS342 4F03EVQLVESGGGLVQPGGSLTLSCAASGSSVQFLSMAWYRQAPGKKRELVAGISYDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS343 4F04EVQLVESGGGLVQPGGSLTLSCAASRSSVSFLSMAWYRQAPGKKRELVAGISTDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWLTRYTYWGQGTLVTVSS344 4F08EVQLVESGGGLVQPGGSLTLSCAASGSKVSFLSMAWYRQAPGKKRELVAGISADGSTAYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS345 4F09EVQLVESGGGLVQPGGSLTLSCAASGSRVSFLSMAWYRQAPGKKRELVAGISADGSTDYIESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYTYWGQGTLVTVSS346 4F010EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISIDGSTDYIKSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYRYWGQGTLVTVSS347 4F011EVQLVESGGGLVQPGGSLTLSCAASGSKVSFLSMAWYRQAPGKKRELVAGISADGSKDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYTYWGQGTLVTVSS348 4G01EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISADGSTVYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWPTRYTYWGQGTLVTVSS349 4G02EVQLVESGGGLVQPGGSLTLSCAASGSSVKFLSMAWYRQAPGKKRELVAGISRDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRHTYWGQGTLVTVSS350 4G03EVQLVESGGGLVQPGGSLTLSCAASGSSVKFLSMAWYRQAPGKKRELVAGISADGSTDYIHSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTRRYTYWGQGTLVTVSS351 4G05EVQLVESGGGLVQPGGSLTLSCAASGSSVSILSMAWYRQAPGKKRELVAGISADGSTIYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWHTRYTYWGQGTLVTVSS352 4G07EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSVAWYRQAPGKKRELVAGISANGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTNRYTYWGQGTLVTVSS353 4G08EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISTDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYRYWGQGTLVTVSS354 4G09EVQLVESGGGLVQPGGSLTLSCAASGSRVSFLSMAWYRQAPGKKRELVAGISYDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRRTYWGQGTLVTVSS355 4G010EVQLVESGGGLVQPGGSLTLSCAASGHSVSFLSMAWYRQAPGKKRELVAGISADGSTDYIASVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWSTRYTYWGQGTLVTVSS356 4G011EVQLVESGGGLVQPGGSLTLSCAASGSSVRFLSMAWYRQAPGKKRELVAGISADGSTDYIGSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWSTRYTYWGQGTLVTVSS357 4H01EVQLVESGGGLVQPGGSLTLSCAASGSSVSFLSMAWYRQAPGKKRELVAGISANGSTDYYDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWRTRYTYWGQGTLVTVSS358 4H03EVQLVESGGGLVQPGGSLTLSCAASGSRVSFLSMAWYRQAPGKKRELVAGISADGSTSYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYTYWGQGTLVTVSS359 4H04EVQLVESGGGLVQPGGSLTLSCAASGSSVKFLSMAWYRQAPGKKRELVAGVSADGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYEWTTRYTYWGQGTLVTVSS360 4H05EVQLVESGGGLVQPGGSLTLSCAASGSSVSRLSMAWYRQAPGKKRELVAGISARGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRSTYWGQGTLVTVSS361 4H06EVQLVESGGGLVQPGGSLTLSCAASGRSVSFLSMAWYRQAPGKKRELVAGISADGSTIYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRYTYWGQGTLVTVSS362 4H07EVQLVESGGGLVQPGGSLTLSCAASGRSVSFLSMAWYRQAPGKKRELVAGISANGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWSTRYTYWGQGTLVTVSS363 4H08EVQLVESGGGLVQPGGSLTLSCAASGSSVKFLSMAWYRQAPGKKRELVAGISADGSTDYVDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWSTRYTYWGQGTLVTVSS364 4H09EVQLVESGGGLVQPGGSLTLSCAASGSSVSKLSMAWYRQAPGKKRELVAGISADGSTDYRDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTYRYTYWGQGTLVTVSS365 4H011EVQLVESGGGLVQPGGSLTLSCAASGSSVSRLSMAWYRQAPGKKRELVAGISVDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRLTYWGQGTLVTVSSEVQLVESGGGLVQPGGSLTLSCAASGSSVKFLSLAWYRQAPGKKRELVAGISADGSTDYI 66 4DL3 09-M34LSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYEWTTRYTYWGQGTLVTVSS 4H1EVQLVESGGGLVQPGGSLTLSCAASGSSVSRLSLAWYRQAPGKKRELVAGISVDGSTDYID367 1-M34LSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTTRLTYWGQGTLVTVSS368 41B11EVQLVESGGGLVQPGGSLTLSCVASGTSSSINAMGWYRRAPGKQRELVAGISSDGSKVFNESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRPAAGSPMRYWGQGTLVTVSSWSGR Docket No.47517-770.601 369 41C02EVQLVESGGGLVQPGGSLTLSCVASGTTSSINAIGWYRRAPGKQRELVAGISSDGSEVYTDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVDGSPLRYWGQGTLVTVSS370 41D01 EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDDSNVYYESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSKRYWGQGTLVTVSS371 41D02 EVQLVESGGGLVQPGGSLTLSCVASGQTYRVNAFGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFSAGSGTEMSYWGQGTLVTVSS372 41D03EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMAWYRRAPGKQRELVAGISSDESTLYVDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFGSLSGSSTTYWGQGTLVTVSS373 41D07EVQLVESGGGLVQPGGSLTLSCVASGSASLTNATGWYRRAPGKQRELVAGISSDDSKVYSDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFGSVSGSWTRYWGQGTLVTVSS374 41E01EVQLVESGGGLVQPGGSLTLSCVASGYPSLNNAMGWYRRAPGKQRELVAGISSDGSQVYGASVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRLVSGSSMSYWGQGTLVTVSS375 41E02EVQLVESGGGLVQPGGSLTLSCVASGSSSTINAIGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTGSGTSKSYWGQGTLVTVSS376 41F07 EVQLVESGGGLVQPGGSLTLSCVASGSTSYINAMGWYRRAPGKQRELVAGISSDGSNMYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFSNMSGTTRRYWGQGTLVTVSS377 41G01 EVQLVESGGGLVQPGGSLTLSCVASGSTSSVNALGWYRRAPGKQRELVAGISSDGSKVYTDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVPGSAMGYWGQGTLVTVSS378 42A03 EVQLVESGGGLVQPGGSLTLSCVASGSTSLSNAVGWYRRAPGKQRELVAGISSDGSKVSAESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRAESGSSMGYWGQGTLVTVSS379 42A06EVQLVESGGGLVQPGGSLTLSCVASGSTSSTNAIGWYRRAPGKQRELVAGISSDGSKVYDDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTLYGSSRSYWGQGTLVTVSS380 42A07EVQLVESGGGLVQPGGSLTLSCVASGLTSTINAMGWYRRAPGKQRELVAGISSDGSKVYDDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFSPFSGSDTGYWGQGTLVTVSS381 42A08EVQLVESGGGLVQPGGSLTLSCVASGVSPSKNAIGWYRRAPGKQRELVAGISSDGSAVYVGSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFSTFSGSSISYWGQGTLVTVSS382 42A11EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAVGWYRRAPGKQRELVAGISSDGSYVYSESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTLAGSEMRYWGQGTLVTVSS383 42B06 EVQLVESGGGLVQPGGSLTLSCVASGSTTMNNAMAWYRRAPGKQRELVAGISSDSSHVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSGVRYWGQGTLVTVSS384 42B10 EVQLVESGGGLVQPGGSLTLSCVASGSTSKINAIGWYRRAPGKQRELVAGISSDSSIVYTDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRPGAGHSNSYWGQGTLVTVSS385 42C01EVQLVESGGGLVQPGGSLTLSCVASGQTTALNAMGWYRRAPGKQRELVAGISSDGSEVNTDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRRASGTAMSYWGQGTLVTVSS386 42C03EVQLVESGGGLVQPGGSLTLSCVASGATSSINAIGWYRRAPGKQRELVAGISSDGSKLSSDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFTSASGTDLSYWGQGTLVTVSS387 42C07EVQLVESGGGLVQPGGSLTLSCVASGSTSTINAMGWYRRAPGKQRELVAGISSDNSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRSANGSSKRYWGQGTLVTVSS388 42C08EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAMGWYRRAPGKQRELVAGISSDGSRVYFDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFKTIAGAGMRYWGQGTLVTVSS389 42C10 EVQLVESGGGLVQPGGSLTLSCVASGSTSLVNAMGWYRRAPGKQRELVAGISSDGSLVYAESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRYGSGSSLSYWGQGTLVTVSS390 42C11 EVQLVESGGGLVQPGGSLTLSCVASGSTSLNNAIGWYRRAPGKQRELVAGISSDGSVVYVDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVPGASMKYWGQGTLVTVSS391 42D05EVQLVESGGGLVQPGGSLTLSCVASGSTSPVNAMAWYRRAPGKQRELVAGISSDGSKVYVDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVDGSAISYWGQGTLVTVSS392 42D06EVQLVESGGGLVQPGGSLTLSCVASGTTSSMNAIGWYRRAPGKQRELVAGISSDGSKLYDESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVKGSGGSYWGQGTLVTVSS393 42D07EVQLVESGGGLVQPGGSLTLSCVASGETSSINAMAWYRRAPGKQRELVAGISSDYSKLYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSRGYWGQGTLVTVSS394 42D08EVQLVESGGGLVQPGGSLTLSCVASGSTSTINAIGWYRRAPGKQRELVAGISSDSSKVYTESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRPGPGSQMAYWGQGTLVTVSS395 42E01EVQLVESGGGLVQPGGSLTLSCVASGSTYSMNAMGWYRRAPGKQRELVAGISSDGSQVYVDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVAGSASGYWGQGTLVTVSS396 42E02 EVQLVESGGGLVQPGGSLTLSCVASGSPSSINAYGWYRRAPGKQRELVAGISSDGSKVYSDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGSSYSYWGQGTLVTVSS397 42E05 EVQLVESGGGLVQPGGSLTLSCVASGSTSTINAIGWYRRAPGKQRELVAGISSDGSKVYVDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFINLKGSSMAYWGQGTLVTVSS398 42E06EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAIGWYRRAPGKQRELVAGISSDGSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRMVTGSYGGYWGQGTLVTVSSWSGR Docket No.47517-770.601 399 42E07EVQLVESGGGLVQPGGSLTLSCVASGSISSINAMGWYRRAPGKQRELVAGISSDGSSVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFKSSYGLPMRYWGQGTLVTVSS400 42F01 EVQLVESGGGLVQPGGSLTLSCVASGSTQVNNAMAWYRRAPGKQRELVAGISSDGSQVYYGSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFKTVSGQSLRYWGQGTLVTVSS401 42F08 EVQLVESGGGLVQPGGSLTLSCVASGSTASFNAMAWYRRAPGKQRELVAGISSDGSKVYTDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVTGRAARYWGQGTLVTVSS402 42F10EVQLVESGGGLVQPGGSLTLSCVASGSPLSINAIGWYRRAPGKQRELVAGISSDGSKVSADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFGPAIGASRTYWGQGTLVTVSS403 42G05EVQLVESGGGLVQPGGSLTLSCVASGSTTFINAIGWYRRAPGKQRELVAGISSDGSKVYEDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTVSGAPKSYWGQGTLVTVSS404 42G07EVQLVESGGGLVQPGGSLTLSCVASGSTSSINAIGWYRRAPGKQRELVAGISSDRSKVYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFHTVSGSSMSYWGQGTLVTVSS405 42H05EVQLVESGGGLVQPGGSLTLSCVASGETDTINAVGWYRRAPGKQRELVAGISSDGSKVYAESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRRLEGYSNRYWGQGTLVTVSS406 42H08 EVQLVESGGGLVQPGGSLTLSCVASGSTSPINAIGWYRRAPGKQRELVAGISSDGSVVTTESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFRTGSGSSMGYWGQGTLVTVSS407 42H11 EVQLVESGGGLVQPGGSLTLSCVASGSITSSNAMGWYRRAPGKQRELVAGISSDGSHVHQESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYYFTTVTGSSMSYWGQGTLVTVSS408 51A01EVQLVESGGGLVQPGGSLTLSCAASRYSVSNLSMAWYRQAPGKKRELVAGISADGSTVYVESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYYWTERRPYWGQGTLVTVSS409 51A02EVQLVESGGGLVQPGDSLTLSCAASMSTVSVLSMAWYRQAPGKKRELVAGISSDGSTVYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAIYYCYAYSWDDAHPYWGQGTLVTVSS410 51A03EVQLVESGGGLVQPGGSLTLSCAASDSYVSLLSMAWYRQAPGKKRELVAGISVDGSTHYVASVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWMTRLTYWGQGTLVTVSS411 51A05EVQLVESGGGLVQPGGSLTLSCAASDSAVSVLSIAWYRQAPGKKRELVAGISTDGSKHYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYDWADAQPYWGQGTLVTVSS412 51B01EVQLVESGGGLVQPGGSLTLSCAASHSSVTSLSLAWYRQAPGKKRELVAGISYDGSKYYAESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYSWTDRLPYWGQGTLVTVSS413 51B04EVQLVESGGGLVQPGGSLTLSCAASDSVVKFLSMAWYRQAPGKKRELVAGISANGSRTYMESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWATRLPYWGQGTLVTVSS414 51B11EVQLVESGGGLVQPGGSLTLSCAASDPSVWNLSMAWYRQAPGKKRELVAGISPDGSTDYVDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYKWSNRLPYWGQGTLVTVSS415 51C02EVQLVESGGGLVQPGGSLTLSCAASGTSVMLLSLAWYRQAPGKKRELVAGISPNGSAVYTESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYGWKTRQPYWGQGTLVTVSS416 51D01EVQLVESGGGLVQPGGSLTLSCAASSSPVSNLSLAWYRQAPGKKRELVAGISPDGSTAYMESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWPNRRGYWGQGTLVTVSS417 51D03EVQLVESGGGLVQPGGSLTLSCAASWRSVLLLSVAWYRQAPGKKRELVAGISNDGSTDYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYDWTTRQRYWGQGTLVTVSS418 51E02EVQLVESGGGLVQPGGSLTLSCAASSSSVQYLSMAWYRQAPGKKRELVAGISTDGSAVYFDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYNWSYAQPYWGQGTLVTVSS419 51E03EVQLVESGGGLVQPGGSLTLSCAASGTSVSLLSLAWYRQAPGKKRELVAGISTGGSTHYIESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYNWTDSLQYWGQGTLVTVSS420 51E05EVQLVESGGGLVQPGGSLTLSCAASLSSVSNLSIAWYRQAPGKKRELVAGISTDGSTVYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYSWTTSLPYWGQGTLVTVSS421 51F01EVQLVESGGGLVQPGGSLTLSCAASMYSVSFLSMAWYRQAPGKKRELVAGISNEGSTYYMDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYKWRSRSTYWGQGTLVTVSS422 51F02EVQLVESGGGLVQPGGSLTLSCAASKSSVSHLSLAWYRQAPGKKRELVAGISADGSHVYTNSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYSQTTRDPYWGQGTLVTVSS423 51F03EVQLVESGGGLVQPGGSLTLSCAASYTSVLDLSIAWYRQAPGKKRELVAGISDDGSRYYTDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTARDTYWGQGTLVTVSS424 51F04EVQLVESGGGLVQPGGSLTLSCAASMSDVSFLSMAWYRQAPGKKRELVAGISAEGSTLYMESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWTSRLSYWGQGTLVTVSS425 51G02EVQLVESGGGLVQPGGSLTLSCAASESSVSFLSSAWYRQAPGKKRELVAGISTDGSTVYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYSWTTRSRYWGQGTLVTVSS426 51G04EVQLVESGGGLVQPGGSLTLSCAASGDSVSLLSMAWYRQAPGKKRELVAGISANGSTSYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYNWTSRYRYWGQGTLVTVSS427 51G10EVQLVESGGGLVQPGGSLTLSCAASGSDVWYLSLAWYRQAPGKKRELVAGISDDGSRHYIESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYSWKTRFPYWGQGTLVTVSS428 51H04EVQLVESGGGLVQPGGSLTLSCAASKSAVAFLSIAWYRQAPGKKRELVAGISPDGSTVYIESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYSWTTRYPYWGQGTLVTVSSWSGR Docket No.47517-770.601 429 51H05EVQLVESGGGLVQPGGSLTLSCAASFSAVAYLSMAWYRQAPGKKRELVAGISDDGSTVYVDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYEWTNALPYWGQGTLVTVSS430 52B01EVQLVESGGGLVQPGGSLTLSCAASVYSVYDLSTAWYRQAPGKKRELVAGISDDGSTVYFDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYSWITRSPYWGQGTLVTVSS431 52C04EVQLVESGGGLVQPGGSLTLSCAASGDSVSFLSMAWYRQAPGKKRELVAGISDEGSTVYIGSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYSWTTRRQYWGQGTLVTVSS432 52D04EVQLVESGGGLVQPGGSLTLSCAASSSSVSLLSLAWYRQAPGKKRELVAGISDDGSIVYMDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYSWITRSPYWGQGTLVTVSS433 53A04EVQLVESGGGLVQPGGSLTLSCAASADSVSFLSIAWYRQAPGKKRELVAGISDDGSKHYFDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWEESRQYWGQGTLVTVSS434 53A05EVQLVESGGGLVQPGGSLTLSCAASASSVTLLSIAWYRQAPGKKRELVAGISTDGSTDYLHSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYTWTTRLPYWGQGTLVTVTS435 53A09EVQLVESGGGLVQPGGSLTLSCAASADSVSFLSIAWYRQAPGKKRELVAGISDDGSKHYFDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWEESRQYWGQGTLVTVSS436 53B05EVQLVESGGGLVQPGGSLTLSCAASGTSVWLLSMAWYRQAPGKKRELVAGISYDGSTVYVESVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYSWTTRQPYWGQGTLVTVSS437 53B06EVQLVESGGGLVQPGGSLTLSCAASGSSVSILSIAWYRQAPGKKRELVAGISDDGSTVYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYVWGTRLPYWGQGTLVTVSS438 53C03EVQLVESGGGLVQPGGSLTLSCAASGTAVSNLSIAWYRQAPGKKRELVAGISDDGSTVYVDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYEWTNALPYWGQGTLVTVSS439 53C04EVQLVESGGGLVQPGGSLTLSCAASGSAVSMLSLAWYRQAPGKKRELVAGISDDGSQVYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYRWEDALTYWGQGTLVTVSS440 53H03EVQLVESGGGLVQPGGSLTLSCAASGMTVFFLSMAWYRQAPGKKRELVAGISVDGSTVYSDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYSWTTRYPYWGQGTLVTVSS441 53H04EVQLVESGGGLVQPGGSLTLSCAASQYSVTFLSVAWYRQAPGKKRELVAGISDDGSNVYIDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYSWIDSLRYWGQGTLVTVSS442 54B05EVQLVESGGGLVQPGGSLTLSCAASGETVSFLSLAWYRQAPGKKRELVAGISTDGSTVYFVSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYSWTTPRAYWGQGTLVTVSSSEQ ID NO. name CDR1 443 DL1 GSIFSIASMG 444 DL74 GSIFSIASMG 445 DL31 GSIFSIASMA 446 DL3 ESIFSINVMA 447 DL80 GSSFSITSMA 448 DL18 SSIFSISSMS 449 DL94 SSIFSISSMS 450 DL17 GSTLNIKIMA 451 DL46 GSTLNIKIMA 452 DL15 GSTFNIKTMA 453 DL26 GSTFNIKLMA 454 DL83 GSTFNFKIMA 455 DL5 GFMFSSYSMS 456 DL22 GFMFSSYSMS 457 DL85 GFTFSSHSMS 458 DL69 GSSFSHNTMG 459 DL27 GGRFSYATMG 460 DL51 GSRFSYATMG 461 DL54 GSTFTSNVMG 462 DL11 GSSVSFLSMA 463 DL19 GSSVSFLSMA 464 DL68 GSSVSFLSMA 465 DL14 GSSVSFLSMAWSGR Docket No.47517-770.601 466 DL67 GSSVSFLSMA 467 DL56 GSSVSFLSMA 468 DL13 GSSVSFLSMA 469 DL77 GSSVSFLSIA 470 DL79 GSSVSFLSMA 471 DL20 GSSVSFLSMA 472 DL41 GSSVSFLSMA 473 DL59 GSSVSFLSMA 474 DL16 GSSVSFLSMA 475 DL6 GSSVSFLSMA 476 DL84 GFTLDYYAIG 477 DL2 GSTSSINAMG 478 DL43 GSTSSINAMG 479 DL92 GITSSVYSMG 480 DL10 GRTSMFNSMG 481 DL82 GRTSMVNSMG 482 DL23 GSVSMFNSMG 483 DL42 GSIFSIAVMG 484 DL45 SGIFSDMSMV 485 DL58 GSISSIIVMG 486 DL70 GSISSIIVMG 487 DL89 GSIFTTNSMG 488 DL38 GSREISTMG 489 DL52 GSREISTMG 490 DL64 GSREISTMG 491 DL33 GSREISTMG 492 DL12 GSIFRGAAMY 493 DL29 GSISSFNFMS 494 DL61 GTIFTASTMG 495 DH1 GSIFSIASMG 496 DH10 GRTSMFNSMG 497 DH11 GSSVSFLSMA 498 DH12 GSIFRGAAMY 499 DH15 GSTFNIKTMA 500 DH17 GSTLNIKIMA 501 DH18 SSIFSISSMS 502 DH2 GSTSSINAMG 503 DH22 GFMFSSYSMS 504 DH23 GSVSMFNSMG 505 DH27 GGRFSYATMG 506 DH29 GSISSFNFMS 507 DH3 ESIFSINVMA 508 DH38 GSREISTMG 509 DH42 GSIFSIAVMG 510 DH43 GSTSSINAMG 511 DH45 SGIFSDMSMV 512 DH5 GFMFSSYSMSWSGR Docket No.47517-770.601 513 DH51 GSRFSYATMG 514 DH54 GSTFTSNVMG 515 DH56 GSSVSFLSMA 516 DH58 GSISSIIVMG 517 DH6 GSSVSFLSMA 518 DH61 GTIFTASTMG 519 DH67 GSSVSFLSMA 520 DH69 GSSFSHNTMG 521 DH70 GSISSIIVMG 522 DH80 GSSFSITSMA 523 DH82 GRTSMVNSMG 524 DH83 GSTFNFKIMA 525 DH84 GFTLDYYAIG 526 DH89 GSIFTTNSMG 527 DH92 GITSSVYSMG 528 DH94 SSIFSISSMS 529 1A01 GFTSSINAMG 530 1A03 GSTSSINAMA 531 1A04 GSTSSINAMG 532 1A05 GSPSSINAMG 533 1A06 GSTSSINAMG 534 1A07 GSISSINAMG 535 1A09 GSTSSINAMA 536 1A010 GSTSSINAYG 537 1A011 GSTSSINAIG 538 1A012 GSTSSINAMA 539 1B01 GSTSIINAMG 540 1B02 GSTSSINAMG 541 1B03 GKTSSINAMA 542 1B04 GTTSSINAMG 543 1B05 GSTSSINAMA 544 1B07 GSGSSINAMG 545 1B08 GTTSSINAMG 546 1B09 GSTSSINAMA 547 1B010 GSTSRINAMG 548 1B011 GSTSRINAMG 549 1C01 GSTSSINAMG 550 1C02 GSTSSINAMA 551 1C03 GSTSSINAMA 552 1C04 GNTSSINAMA 553 1C05 GSTSSINAMA 554 1C06 GSTSIINAMG 555 1C07 GSTSSINAMA 556 1C08 GSTSRINAMG 557 1C010 GSTSRINAMG 558 1C011 GTTSSINAMG 559 1C012 GITSSINAMGWSGR Docket No.47517-770.601 560 1D01 GSTSDINAMG 561 1D02 GSTSSINAMA 562 1D03 GSTSSINAIG 563 1D04 GSTSSKNAMG 564 1D06 GSTSSINAMG 565 1D08 GLTSSINAMG 566 1D09 GSTSSINAMA 567 1D010 GSTSSNNAMA 568 1D011 GSTSSINAMA 569 1D012 GSTSHINAMG 570 1E02 GQTSSINAMG 571 1E04 GSTSRINGMG 572 1E05 GSTSVINAMA 573 1E07 GSTSSINAMA 574 1E08 GKTSSINAMG 575 1E09 GSTSSINAMA 576 1E010 GSVSSINAMG 577 1E011 GNTSSINAMG 578 1E012 GSTSSTNAMG 579 1F01 GSTSSINAMG 580 1F02 GSTSSINAMA 581 1F04 GGTSSINAMG 582 1F05 GSTRSINAMG 583 1F06 GTTSSINAMG 584 1F07 GSTSSINAMG 585 1F08 GSTSSINAMA 586 1F09 GNTSSINAMG 587 1F010 GSTSRINAMG 588 1F011 GSTSSINAIG 589 1F012 GLTSSINAMG 590 1G01 GSTSSINAMA 591 1G04 GSTSSTNAMG 592 1G05 GSTSSINAIG 593 1G06 GSTSSINAIG 594 1G07 GSTSSINAMG 595 1G09 GSTSSINAMG 596 1G011 GSTSSINAMA 597 1H01 GSTSSINAMA 598 1H02 GSKSSINAMG 599 1H06 GTTSSINAMG 600 1H07 GSTSSINAFG 601 1H08 GSTFSINAMG 602 1H010 GSTRSINAMG 603 1H011 GSTSSINAIG 604 1H012 GSTSSINAMG 605 2A01 GSTSSINAMG 606 2A03 GTTSSINAMGWSGR Docket No.47517-770.601 607 2A04 GSTSSINAMA 608 2A05 GRTSSINAMG 609 2A06 GSTSSRNAMG 610 2A08 GSTKSINAMG 611 2A09 GSTSSRNAMG 612 2A011 GSTSSINAIG 613 2B01 GSTSLINAMG 614 2B02 GSTSSINAMA 615 2B03 GSTSSINAMG 616 2B05 GTTSSINAMG 617 2B07 GSTSSINAFG 618 2B010 GSTSSRNAMG 619 2B011 GNTSSINAMG 620 2B012 GTTSSINAMG 621 2C01 GSTASINAMG 622 2C02 GSTSSINAVG 623 2C04 GSTSSRNAMG 624 2C06 GSTNSINAMG 625 2C07 GSTSSINAMA 626 2C08 GSTSRINAMG 627 2C09 GSTSNINAMG 628 2C010 GSTSKINAMG 629 2D02 GSTSSINALG 630 2D03 GKTSSINAMG 631 2D04 GSTSSINAVG 632 2D05 GSTSRINAMG 633 2D06 GSTSSINAMG 634 2D07 GSTSSINAVG 635 2D09 GTTSSINAMG 636 2D010 GSTSSINAMG 637 2D011 GTTSSINAMG 638 2D012 GKTSSINAMG 639 2E01 GSTSSINAMG 640 2E02 GSTSAINAMG 641 2E05 GSPSSINAYG 642 2E06 GSTSSINAMG 643 2E08 GSRSSINAMG 644 2E09 GSVSSINAMG 645 2E010 GSTSSINAMA 646 2E011 GSTSSINAIG 647 2F01 GSTSSINAMG 648 2F02 GSTSSINAVG 649 2F03 GSTSSINAMA 650 2F06 GSTSSINAYG 651 2F07 GSTSSINAVG 652 2F08 GSKSSINAMG 653 2F09 GSTSSINAMAWSGR Docket No.47517-770.601 654 2F11 GSVSSINAMG 655 2G03 GSTSSINAMG 656 2G04 GSTSSINAMG 657 2G07 GSTSSINAMA 658 2G08 GSTSYINAMG 659 2G09 GSTSSINAMG 660 2G011 GSTSSINAMG 661 2H010 GSTSSINAMG 662 2H011 GSTSRINAMG 663 2H02 GSTSSINAMA 664 2H03 GSTSSINAMA 665 2H04 GSTSSINAMG 666 2H06 GSTSTINAMG 667 2H07 GSTSSINAVG 668 2H08 GSTSSINAMG 669 2E05-M106Y GSPSSINAYG 670 2E05-M106Q GSPSSINAYG 671 3A01 GSSVKFLSMA 672 3A02 GSSVSFLSLA 673 3A03 GSRVSFLSMA 674 3A04 GSQVSFLSMA 675 3A05 GSSVSFLSMA 676 3A06 GSKVSFLSMA 677 3A08 GSSVGFLSMA 678 3A09 GSSVSFLSMA 679 3A010 GSRVSFLSMA 680 3A011 GSSVSFLSLA 681 3B01 GSSVSFLSMA 682 3B02 GSSVQFLSMA 683 3B04 GSNVSFLSMA 684 3B05 GSSVKFLSMA 685 3B06 GKSVSFLSMA 686 3B07 GSRVSFLSMA 687 3B09 GSHVSFLSMA 688 3B010 GSSVSFLSMA 689 3B011 GSSVSFLSMA 690 3C01 GSSVRFLSMA 691 3C02 GSSVRFLSMA 692 3C03 GSSVRFLSMA 693 3C04 GSHVSFLSMA 694 3C05 GTSVSFLSMA 695 3C06 GTSVSFLSIA 696 3C08 GSSVKFLSMA 697 3C09 GSSVSFLSMA 698 3C011 GSSVRFLSMA 699 3D01 GSSVSFLSMA 700 3D02 GSSVRFLSMAWSGR Docket No.47517-770.601 701 3D03 GSSVVFLSMA 702 3D05 GSSVRFLSMA 703 3D07 GSSVRFLSMA 704 3D08 GSSVRFLSMA 705 3D09 GSSVSRLSMA 706 3D010 GSSKSFLSMA 707 3D011 GSSVSRLSMA 708 3E01 GSSVKFLSMA 709 3E02 GSGVRFLSMA 710 3E03 GSSVRFLSMA 711 3E04 GSSVHFLSMA 712 3E09 GSSVRFLSMA 713 3E011 GSKVSFLSMA 714 3F03 GSSVSFLSMA 715 3F05 GSKVSFLSMA 716 3F06 GSRVSFLSMA 717 3F08 GSRVSFLSMA 718 3F09 GSSVRFLSMA 719 3F010 YSSVSRLSMA 720 3F011 GSSVSFLSMA 721 3G01 GSSVSFLSMA 722 3G02 GSSVSFLSMA 723 3G04 GTSVSFLSMA 724 3G06 GSSVKFLSMA 725 3G07 GSSVSFLSMA 726 3G08 GSRVSFLSMA 727 3G09 GSSVSVLSMA 728 3G010 GSSVSFLSMA 729 3G011 GSRVSFLSMA 730 3H01 GSSVKFLSMA 731 3H03 GSSVRFLSMA 732 3H06 GSSVSQLSMA 733 3H07 GSRVSFLSMA 734 3H09 KSSVSFLSMA 735 3H010 GSSVSFLSMA 736 3H011 GSSVKFLSMA 737 4A01 GSSVRFLSMA 738 4A02 GSSVRFLSMA 739 4A04 GSRVSFLSMA 740 4A05 GSSVSFLSLA 741 4A06 GSSVRFLSMA 742 4A07 GSKVSFLSMA 743 4A08 GSSVSFLSMA 744 4A010 GSSVRFLSMA 745 4A011 GSKVSFLSMA 746 4A09 GSSVKFLSMA 747 4B01 GSSVKFLSMAWSGR Docket No.47517-770.601 748 4B02 GSRVSFLSMA 749 4B04 GSSVLFLSMA 750 4B05 GSRVSFLSMA 751 4B06 GSRVSFLSMA 752 4B07 GSSVGFLSMA 753 4B08 GSSVSFMSMA 754 4B09 GSSVSFLSMA 755 4B011 GSSVTFLSMA 756 4C01 GSSVRFLSMA 757 4C02 GSKVSFLSMA 758 4C03 GSKVSFMSMA 759 4C05 GSSVSNLSMA 760 4C06 NSSVSKLSMA 761 4C07 GSKVSFLSMA 762 4C08 GSQVSFLSMA 763 4C010 GSKVSFMSMA 764 4C011 GSRVSFLSMA 765 4D01 GSSVRFLSMA 766 4D02 GSKVSFLSMA 767 4D03 GSSVRFLSMA 768 4D04 GSSVSFLSIA 769 4D05 GSSSSFLSMA 770 4D06 GSSVKFLSMA 771 4D08 GSSVNFLSMA 772 4D09 GSSVKFLSMA 773 4D010 GSSVSFLSMA 774 4D011 GSSVRFLSMA 775 4E01 GSSVSFLSVA 776 4E02 GSQVSFLSMA 777 4E06 GTSVSFLSMA 778 4E07 GSRVSFLSMA 779 4E08 GSSVKFLSMA 780 4E09 GSSVSFLSSA 781 4E010 GSSVKFLSMA 782 4E011 GSSVSFLSMA 783 4F02 GSTVSFLSMA 784 4F03 GSSVQFLSMA 785 4F04 RSSVSFLSMA 786 4F08 GSKVSFLSMA 787 4F09 GSRVSFLSMA 788 4F010 GSSVSFLSMA 789 4F011 GSKVSFLSMA 790 4G01 GSSVRFLSMA 791 4G02 GSSVKFLSMA 792 4G03 GSSVKFLSMA 793 4G05 GSSVSILSMA 794 4G07 GSSVSFLSVAWSGR Docket No.47517-770.601 795 4G08 GSSVRFLSMA 796 4G09 GSRVSFLSMA 797 4G010 GHSVSFLSMA 798 4G011 GSSVRFLSMA 799 4H01 GSSVSFLSMA 800 4H03 GSRVSFLSMA 801 4H04 GSSVKFLSMA 802 4H05 GSSVSRLSMA 803 4H06 GRSVSFLSMA 804 4H07 GRSVSFLSMA 805 4H08 GSSVKFLSMA 806 4H09 GSSVSKLSMA 807 4H011 GSSVSRLSMA 808 4D09-M34L GSSVKFLSLA 809 4H11-M34L GSSVSRLSLA 810 41B11 GTSSSINAMG 811 41C02 GTTSSINAIG 812 41D01 GSTSSINAMA 813 41D02 GQTYRVNAFG 814 41D03 GSTSSINAMA 815 41D07 GSASLTNATG 816 41E01 GYPSLNNAMG 817 41E02 GSSSTINAIG 818 41F07 GSTSYINAMG 819 41G01 GSTSSVNALG 820 42A03 GSTSLSNAVG 821 42A06 GSTSSTNAIG 822 42A07 GLTSTINAMG 823 42A08 GVSPSKNAIG 824 42A11 GSTSSINAVG 825 42B06 GSTTMNNAMA 826 42B10 GSTSKINAIG 827 42C01 GQTTALNAMG 828 42C03 GATSSINAIG 829 42C07 GSTSTINAMG 830 42C08 GSTSSINAMG 831 42C10 GSTSLVNAMG 832 42C11 GSTSLNNAIG 833 42D05 GSTSPVNAMA 834 42D06 GTTSSMNAIG 835 42D07 GETSSINAMA 836 42D08 GSTSTINAIG 837 42E01 GSTYSMNAMG 838 42E02 GSPSSINAYG 839 42E05 GSTSTINAIG 840 42E06 GSTSSINAIG 841 42E07 GSISSINAMGWSGR Docket No.47517-770.601 842 42F01 GSTQVNNAMA 843 42F08 GSTASFNAMA 844 42F10 GSPLSINAIG 845 42G05 GSTTFINAIG 846 42G07 GSTSSINAIG 847 42H05 GETDTINAVG 848 42H08 GSTSPINAIG 849 42H11 GSITSSNAMG 850 51A01 RYSVSNLSMA 851 51A02 MSTVSVLSMA 852 51A03 DSYVSLLSMA 853 51A05 DSAVSVLSIA 854 51B01 HSSVTSLSLA 855 51B04 DSVVKFLSMA 856 51B11 DPSVWNLSMA 857 51C02 GTSVMLLSLA 858 51D01 SSPVSNLSLA 859 51D03 WRSVLLLSVA 860 51E02 SSSVQYLSMA 861 51E03 GTSVSLLSLA 862 51E05 LSSVSNLSIA 863 51F01 MYSVSFLSMA 864 51F02 KSSVSHLSLA 865 51F03 YTSVLDLSIA 866 51F04 MSDVSFLSMA 867 51G02 ESSVSFLSSA 868 51G04 GDSVSLLSMA 869 51G10 GSDVWYLSLA 870 51H04 KSAVAFLSIA 871 51H05 FSAVAYLSMA 872 52B01 VYSVYDLSTA 873 52C04 GDSVSFLSMA 874 52D04 SSSVSLLSLA 875 53A04 ADSVSFLSIA 876 53A05 ASSVTLLSIA 877 53A09 ADSVSFLSIA 878 53B05 GTSVWLLSMA 879 53B06 GSSVSILSIA 880 53C03 GTAVSNLSIA 881 53C04 GSAVSMLSLA 882 53H03 GMTVFFLSMA 883 53H04 QYSVTFLSVA 884 54B05 GETVSFLSLA SEQ.ID NO.name CDR2885 DL1 VITSFSSTNYADSVKGWSGR Docket No.47517-770.601 886 DL74 VITSFSSTNYADSVKG 887 DL31 AITSFSSTNYADSVKG 888 DL3 RITSGGSTNYADSVKG 889 DL80 AITSFGSTNYADSVKD 890 DL18 AITTFDYTNYADSVKG 891 DL94 AITSFGSTNYADSVKG 892 DL17 TLTSGGNTNYADSVKG 893 DL46 TLTSGGNTNYADSVKG 894 DL15 TLTSGGNTNYADSVKG 895 DL26 TLTSGGNTNYADSVKG 896 DL83 SLTSEGLTNYRDSVKG 897 DL5 AITTWGSTNYADSVKG 898 DL22 AITSYGSTNYADSVKG 899 DL85 AITTYGSTNYIDSVKG 900 DL69 RITTFGTTNYADSVKG 901 DL27 RITSSGFSTNYADSVKG 902 DL51 RITSSGFSTNYADSVKG 903 DL54 NMHSGGSTNYADSVKG 904 DL11 GISVDGSTNYADSVKG 905 DL19 GISVDGSTNYADSVKG 906 DL68 GISVDGSTNYADSVKG 907 DL14 GISVDGSTNYADSVKG 908 DL67 GISVDGSTNYADSVKG 909 DL56 GISTDGSTNYVDSVKG 910 DL13 GISTDGTTNYVDSVKD 911 DL77 GISTDGTTNYVDSVKD 912 DL79 GISTDGTTNYVDSVKD 913 DL20 GISTDGSTNYADSVKG 914 DL41 GISTDGSTNYADSVKG 915 DL59 GISTDGSTNYADSVKG 916 DL16 GISSDGSTNYVDSVKG 917 DL6 GISADGSTDYIDSVKG 918 DL84 GISSDGSTHYVDSVKG 919 DL2 GISSDGSKNYADSVKG 920 DL43 GISSDGSKVYADSVKG 921 DL92 GSSSDGSTHYVDSVRG 922 DL10 IIRSGGSSNYADTVKG 923 DL82 LITSGGSSNYADTVKG 924 DL23 IITSGGSSNYADTVKG 925 DL42 TIFDGSYTNYADSVKG 926 DL45 SITTFGSTNYADPVKG 927 DL58 TITRDGTRNYADSLKG 928 DL70 TISRGGTRTYADSVKG 929 DL89 LIGSAGSTKYADSVKG 930 DL38 RITSGGITKYADSVKG 931 DL52 RITSGGITKYADSVKG 932 DL64 RITSGGITKYADSVKGWSGR Docket No.47517-770.601 933 DL33 RITSGGITKYADSVKG 934 DL12 AITTSGNTSYADSVKG 935 DL29 VITRGGATNYADSVKG 936 DL61 SIAGDGRTNYAESTEG 937 DH1 VITSFSSTNYADSVKG 938 DH10 IIRSGGSSNYADTVKG 939 DH11 GISVDGSTNYADSVKG 940 DH12 AITTSGNTSYADSVKG 941 DH15 TLTSGGNTNYADSVKG 942 DH17 TLTSGGNTNYADSVKG 943 DH18 AITTFDYTNYADSVKG 944 DH2 GISSDGSKNYADSVKG 945 DH22 AITSYGSTNYADSVKG 946 DH23 IITSGGSSNYADTVKG 947 DH27 RITSSGFSTNYADSVKG 948 DH29 VITRGGATNYADSVKG 949 DH3 RITSGGSTNYADSVKG 950 DH38 RITSGGITKYADSVKG 951 DH42 TIFDGSYTNYADSVKG 952 DH43 GISSDGSKVYADSVKG 953 DH45 SITTFGSTNYADPVKG 954 DH5 AITTWGSTNYADSVKG 955 DH51 RITSSGFSTNYADSVKG 956 DH54 NMHSGGSTNYADSVKG 957 DH56 GISTDGSTNYVDSVKG 958 DH58 TITRDGTRNYADSLKG 959 DH6 GISADGSTDYIDSVKG 960 DH61 SIAGDGRTNYAESTEG 961 DH67 GISVDGSTNYADSVKG 962 DH69 RITTFGTTNYADSVKG 963 DH70 TISRGGTRTYADSVKG 964 DH80 AITSFGSTNYADSVKD 965 DH82 LITSGGSSNYADTVKG 966 DH83 SLTSEGLTNYRDSVKG 967 DH84 GISSDGSTHYVDSVKG 968 DH89 LIGSAGSTKYADSVKG 969 DH92 GSSSDGSTHYVDSVRG 970 DH94 AITSFGSTNYADSVKG 971 1A01 GISSDGSFVYADSVKG 972 1A03 GISSDGSKVYADSVKG 973 1A04 GISSDGSKVYEDSVKG 974 1A05 GISSDGSKVYADSVKG 975 1A06 GISSDGSSVYADSVKG 976 1A07 GISSDGSKVYADSVKG 977 1A09 GISSDGSKLYADSVKG 978 1A010 GISSDGSKVYADSVKG 979 1A011 GISSDGSKVYIDSVKGWSGR Docket No.47517-770.601 980 1A012 GISSDGSKVYSDSVKG 981 1B01 GISSDGSKVIADSVKG 982 1B02 GISSDGSKIYADSVKG 983 1B03 GISSDGSKVYTDSVKG 984 1B04 GISSDGSLVYADSVKG 985 1B05 GISSDGSKVYADSVKG 986 1B07 GISSDGSKVYSDSVKG 987 1B08 GISSDGSKVYVDSVKG 988 1B09 GISSDGSKVYVDSVKG 989 1B010 GISSDGSKVYADSVKG 990 1B011 GISSDGSKVYADSVKG 991 1C01 GISSDGSKVYRDSVKG 992 1C02 GISSDGSKVYSDSVKG 993 1C03 GISSDNSKVYADSVKG 994 1C04 GISSDGSKVYADSVKG 995 1C05 GISSDGSKVYADSVKG 996 1C06 GISSDGSKVYEDSVKG 997 1C07 GISSDGSKVYADSVKG 998 1C08 GISSDGSKVYAVSVKG 999 1C010 GVSSDGSKVYADSVKG 1000 1C011 GISSDGSKVYEDSVKG 1001 1C012 GISSDGSKVYAGSVKG 1002 1D01 GISSDKSKVYADSVKG 1003 1D02 GISSNGSKVYADSVKG 1004 1D03 GISSDGSKVLADSVKG 1005 1D04 GISSDGSKVYADSVKG 1006 1D06 GISSDNSKVYADSVKG 1007 1D08 GISSDGSKVYADSVKG 1008 1D09 GISSDGSKVYTDSVKG 1009 1D010 GISSDGSKVYTDSVKG 1010 1D011 GISSDNSKVYADSVKG 1011 1D012 GISSDGSRVYADSVKG 1012 1E02 GISSDGSQVYADSVKG 1013 1E04 GISSDGSKAYADSVKG 1014 1E05 GISSDGSKVYAKSAKG 1015 1E07 GISSDGSKVYNDSVKG 1016 1E08 GISSDGSKVIADSVKG 1017 1E09 GISSDGSKVYTDSVKG 1018 1E010 GISSDGSKVYIDSVKG 1019 1E011 GISSDGSKVYYDSVKG 1020 1E012 GISSDGSKVYVDSVKG 1021 1F01 GISSDGSKVYGDSVKG 1022 1F02 GISSDQSKVYADSAKG 1023 1F04 GISSDGSKVYSDSVKG 1024 1F05 GISSDGSKVYADSVKG 1025 1F06 GISSDGSKVIADSVKG 1026 1F07 GISSDGSKVDADSVKGWSGR Docket No.47517-770.601 1027 1F08 GISSDGSKVYKDSVKG 1028 1F09 GISSNGSKVYADSVKG 1029 1F010 GISSDGSKVYKDSVKG 1030 1F011 GISSDGSKVYADSVKG 1031 1F012 GISSDGSKVYQDSVKG 1032 1G01 GISSDGSKVYAESVKG 1033 1G04 GISSDGSKVLADSVKG 1034 1G05 GISSDGSKYYADSVKG 1035 1G06 GISSDGSKVYAVSVKG 1036 1G07 GISSDGSKVVADSVKG 1037 1G09 GISSDGSKVYADSVKG 1038 1G011 GISSDGSKVYADSVKG 1039 1H01 GISSDNSKVYADSVKG 1040 1H02 GISSDGSKVYAQSVKG 1041 1H06 GISSDGSKVYVDSVKG 1042 1H07 GISSDGSKVYSDSVKG 1043 1H08 GISSDGSKVLADSVKG 1044 1H010 GISSDGSKVYNDSVKG 1045 1H011 GISSDGSKVYNDSVKG 1046 1H012 GISSDGSKVYVDSVKG 1047 2A01 GISSDGSKVVADSVKG 1048 2A03 GISSDGSKVYGDSVKG 1049 2A04 GISSDGSKVYTDSVKG 1050 2A05 GISSDGSKVYNDSVKG 1051 2A06 GISSDGSKVTADSVKG 1052 2A08 GISSDGSKVYRDSVKG 1053 2A09 GISSNGSKVYSDSVKG 1054 2A011 GISSDGSKVYSDSVKG 1055 2B01 GISSDGSKVYADSVKG 1056 2B02 GISSDGSKVYADSVKG 1057 2B03 GISSDGSLVYADSVKG 1058 2B05 GISSDGTKVYADSVKG 1059 2B07 GISSDGSKVYADSVKG 1060 2B010 GISSDGSKLYLDSVKG 1061 2B011 GISSDGSRVYADSVKG 1062 2B012 GISSDGSKVYNDSVKG 1063 2C01 GISSDGSKVYADSVKG 1064 2C02 GISSDGSKVYVDSVKG 1065 2C04 GISSDGSKLYADSVKG 1066 2C06 GISSDGSKVYKDSVKG 1067 2C07 GISSDGSKVYADSVKG 1068 2C08 GISSDGSKVYQDSVKG 1069 2C09 GISSDGTKIYADSAKV 1070 2C010 GISSDRSKVYADSVKG 1071 2D02 GISSDGSLVYADSVKG 1072 2D03 GISSDGSKVYADSVKG 1073 2D04 GISSDGSKVYRDSVKGWSGR Docket No.47517-770.601 1074 2D05 GISSDGSKVYADSVKG 1075 2D06 GISSDGSKVYSDSVKG 1076 2D07 GISSDGTKVYRDSVKG 1077 2D09 GISSDGSKVYNDSVKG 1078 2D010 GISSDGSKVYADSVKG 1079 2D011 GISSDGSKVYADSVKG 1080 2D012 GISSDGSKVYTDSVKG 1081 2E01 GISPDGTKAYADSAKV 1082 2E02 GISSDGSKVYVDSVKG 1083 2E05 GISSDGSKVYSDSVKG 1084 2E06 GISSDGSKVYASSVKG 1085 2E08 GISADGSKVYADSVKG 1086 2E09 GISSDGSKVYASSAKG 1087 2E010 GISSDGSKVYADSVKG 1088 2E011 GISSDGSSVYADSVKG 1089 2F01 GISSDGSKVYSDSVKG 1090 2F02 GISSDGSKVYAGSVKG 1091 2F03 GISSDNSKVYADSVKG 1092 2F06 GISSDGSAVYADSVKG 1093 2F07 GISSDGSSVYADSVKG 1094 2F08 GISSNGTKVYADSAKV 1095 2F09 GISSDGSKLYADSVKG 1096 2F11 GISSDGSKVYKDSVKG 1097 2G03 GISSDGSLVYADSVKG 1098 2G04 GISSDGSLVYADSVKG 1099 2G07 GISSDGSKVYADSVKG 1100 2G08 GISSDGSKVYADSVKG 1101 2G09 GVSSDGSKVYADSVKG 1102 2G011 GISRDGSKVYADSVKG 1103 2H010 GISSDGSKLYADSVKG 1104 2H011 GISSDGSKVYADSVKG 1105 2H02 GISSDGSKVYADSVKG 1106 2H03 GISSDGSKVYADSVKG 1107 2H04 GISSDTSKVYADSVKG 1108 2H06 GISSDGSKVYADSVKG 1109 2H07 GISSDGSTVYADSVKG 1110 2H08 GISKDGSKVYADSAKG 11112E05-M106YGISSDGSKVYSDSVKG1112 2E05-M106QGISSDGSKVYSDSVKG1113 3A01 GISADGSTDYIDSVKG 1114 3A02 GISADGSTAYIDSVKG 1115 3A03 GISRDGSTDYIDSVKG 1116 3A04 GISRDGSTDYIDSVKG 1117 3A05 GISEAGSTDYIDSVKG 1118 3A06 GISADGSTDYVDSVKG 1119 3A08 GISADGSTDYIRSVKGWSGR Docket No.47517-770.601 1120 3A09 GISADGSVDYIDSVKG 1121 3A010 GISADGSTLYIDSVKG 1122 3A011 GISTDGSTDYIDSVKG 1123 3B01 GISGDGSTDYIDSVKG 1124 3B02 GISADGSTDYINSVKG 1125 3B04 GISARGSTDYIDSVKG 1126 3B05 GISADGSTTYIDSVKG 1127 3B06 GISKDGSTDYIDSVKG 1128 3B07 GISADGSTTYIDSVKG 1129 3B09 GISANGSTDYIDSVKG 1130 3B010 GISRDGSTDYIDSVKG 1131 3B011 GISADGSADYIDSVKG 1132 3C01 GISAHGSTDYIDSVKG 1133 3C02 GISADGSTIYIDSVKG 1134 3C03 GISRDGSTVYIDSVKG 1135 3C04 GISADGPTDYIDSVKG 1136 3C05 GISADGSTTYIDSVKG 1137 3C06 GISADGSTDYIASVKG 1138 3C08 GISLDGSTDYIDSVKG 1139 3C09 GISADGSTIYIDSVKG 1140 3C011 GISAHGSTDYIDSVKG 1141 3D01 GISRDGSTDYIDSVKG 1142 3D02 GISRDGSTDYIDSVKG 1143 3D03 GISADGSMDYIDSVKG 1144 3D05 GISADGSTDYIDSVKG 1145 3D07 GISADGSTDYIDSVKG 1146 3D08 GISANGSTDYIDSVKG 1147 3D09 GISANGSTTYIDSVKG 1148 3D010 GISADGSTSYIDSVKG 1149 3D011 GISADGSRDYIDSVKG 1150 3E01 GISADGSTMYIDSVKG 1151 3E02 GISPDGSTDYIDSVKG 1152 3E03 GISGDGSTDYIDSVKG 1153 3E04 GISRDGSTDYIDSVKG 1154 3E09 GISRDGSTDYIDSVKG 1155 3E011 GISRDGSTDYIDSVKG 1156 3F03 GISADGSTDYIDSVKG 1157 3F05 GISTDGSTDYIDSVKG 1158 3F06 GISADGSTSYIDSVKG 1159 3F08 GISADGSTLYIDSVKG 1160 3F09 GISRDGSTDYIDSVKG 1161 3F010 GISADGSTVYIDSVKG 1162 3F011 GISTDGSTDYIDSVKG 1163 3G01 GISADGSTLYIDSVKG 1164 3G02 GISADGRTDYIDSVKG 1165 3G04 GISADGSTIYIDSVKG 1166 3G06 GISADGSTLYIDSVKGWSGR Docket No.47517-770.601 1167 3G07 GISRDGSTDYIDSVKG 1168 3G08 GISKDGSTDYIDSVKG 1169 3G09 GISADGSTDYIGSVKG 1170 3G010 GISVDGSTDYIDSVKG 1171 3G011 GISADGSTGYIDSVKG 1172 3H01 GISGDGSTTYIDSVKG 1173 3H03 GISTDGSTDYIDSVKG 1174 3H06 GISADGSTDYFDSVKG 1175 3H07 GISADGSTSYIDSVKG 1176 3H09 GISADGSTDYIDSVKG 1177 3H010 GISADGSTAYIDSVKG 1178 3H011 GISADGSTVYIDSVKG 1179 4A01 GISQDGSTDYIDSVKG 1180 4A02 GISNDGSTDYIDSVKG 1181 4A04 GISARGSTDYIDSVKG 1182 4A05 GISADGSTDYIDSVKG 1183 4A06 GISRDGSTDYIDSVKG 1184 4A07 GISADGSTLYIDSVKG 1185 4A08 GISADGSTNYIDSVKG 1186 4A010 GISADGSTVYIDSVKG 1187 4A011 GISADGSTTYIDSVKG 1188 4A09 GISADGSTDYIGSVKG 1189 4B01 GISRDGSTDYIDSVKG 1190 4B02 GISADGSTTYIDSVKG 1191 4B04 GVSSDGSTDYIDSVKG 1192 4B05 GISADGHTDYIDSVKG 1193 4B06 GISADGSTDYFDSVKG 1194 4B07 GISADGSTVYIDSVKG 1195 4B08 GISADGSTDYIASVKG 1196 4B09 GISADGSTDYISSVKG 1197 4B011 GISADGSTVYIDSVKG 1198 4C01 GISADGSTVYIDSVKG 1199 4C02 GISADGSTTYIDSVKG 1200 4C03 GISVDGSTDYIDSVKG 1201 4C05 GISADGSTAYIDSVKG 1202 4C06 GISADGSTAYIDSVKG 1203 4C07 GISADGSKDYIDSVKG 1204 4C08 GISADGSTDYFDSVKG 1205 4C010 GISADGSTDYIDSVKG 1206 4C011 GISADGSTVYIDSVKG 1207 4D01 GISADGSTVYIDSVKG 1208 4D02 GISARGSTDYIDSVKG 1209 4D03 GISATGSTDYIDSVKG 1210 4D04 GISKDGSTDYIDSVKG 1211 4D05 GISADGSTVYIDSVKG 1212 4D06 GISPDGSTDYIDSVKG 1213 4D08 GISADGSTHYIDSVKGWSGR Docket No.47517-770.601 1214 4D09 GISADGSTDYILSVKG 1215 4D010 GISADGSTDYIHSVKG 1216 4D011 GISVDGSTDYIDSVKG 1217 4E01 GISRDGSTDYIDSVKG 1218 4E02 GISADGSTVYIDSVKG 1219 4E06 GISADGSTDYIRSVKG 1220 4E07 GISADGSTMYIDSVKG 1221 4E08 GISTDGSTDYIDSVKG 1222 4E09 GISADGSTLYIDSVKG 1223 4E010 GISADGSTDYIDSVKG 1224 4E011 GISATGSTDYIDSVKG 1225 4F02 GISHDGSTDYIDSVKG 1226 4F03 GISYDGSTDYIDSVKG 1227 4F04 GISTDGSTDYIDSVKG 1228 4F08 GISADGSTAYIDSVKG 1229 4F09 GISADGSTDYIESVKG 1230 4F010 GISIDGSTDYIKSVKG 1231 4F011 GISADGSKDYIDSVKG 1232 4G01 GISADGSTVYIDSVKG 1233 4G02 GISRDGSTDYIDSVKG 1234 4G03 GISADGSTDYIHSVKG 1235 4G05 GISADGSTIYIDSVKG 1236 4G07 GISANGSTDYIDSVKG 1237 4G08 GISTDGSTDYIDSVKG 1238 4G09 GISYDGSTDYIDSVKG 1239 4G010 GISADGSTDYIASVKG 1240 4G011 GISADGSTDYIGSVKG 1241 4H01 GISANGSTDYYDSVKG 1242 4H03 GISADGSTSYIDSVKG 1243 4H04 GVSADGSTDYIDSVKG 1244 4H05 GISARGSTDYIDSVKG 1245 4H06 GISADGSTIYIDSVKG 1246 4H07 GISANGSTDYIDSVKG 1247 4H08 GISADGSTDYVDSVKG 1248 4H09 GISADGSTDYRDSVKG 1249 4H011 GISVDGSTDYIDSVKG 12504D09-M34LGISADGSTDYILSVKG 12514H11-M34LGISVDGSTDYIDSVKG 1252 41B11 GISSDGSKVFNESVKG 1253 41C02 GISSDGSEVYTDSVKG 1254 41D01 GISSDDSNVYYESVKG 1255 41D02 GISSDGSKVYADSVKG 1256 41D03 GISSDESTLYVDSVKG 1257 41D07 GISSDDSKVYSDSVKG 1258 41E01 GISSDGSQVYGASVKG 1259 41E02 GISSDGSKVYADSVKGWSGR Docket No.47517-770.601 1260 41F07 GISSDGSNMYADSVKG 1261 41G01 GISSDGSKVYTDSVKG 1262 42A03 GISSDGSKVSAESVKG 1263 42A06 GISSDGSKVYDDSVKG 1264 42A07 GISSDGSKVYDDSVKG 1265 42A08 GISSDGSAVYVGSVKG 1266 42A11 GISSDGSYVYSESVKG 1267 42B06 GISSDSSHVYADSVKG 1268 42B10 GISSDSSIVYTDSVKG 1269 42C01 GISSDGSEVNTDSVKG 1270 42C03 GISSDGSKLSSDSVKG 1271 42C07 GISSDNSKVYADSVKG 1272 42C08 GISSDGSRVYFDSVKG 1273 42C10 GISSDGSLVYAESVKG 1274 42C11 GISSDGSVVYVDSVKG 1275 42D05 GISSDGSKVYVDSVKG 1276 42D06 GISSDGSKLYDESVKG 1277 42D07 GISSDYSKLYADSVKG 1278 42D08 GISSDSSKVYTESVKG 1279 42E01 GISSDGSQVYVDSVKG 1280 42E02 GISSDGSKVYSDSVKG 1281 42E05 GISSDGSKVYVDSVKG 1282 42E06 GISSDGSKVYADSVKG 1283 42E07 GISSDGSSVYADSVKG 1284 42F01 GISSDGSQVYYGSVKG 1285 42F08 GISSDGSKVYTDSVKG 1286 42F10 GISSDGSKVSADSVKG 1287 42G05 GISSDGSKVYEDSVKG 1288 42G07 GISSDRSKVYADSVKG 1289 42H05 GISSDGSKVYAESVKG 1290 42H08 GISSDGSVVTTESVKG 1291 42H11 GISSDGSHVHQESVKG 1292 51A01 GISADGSTVYVESVKG 1293 51A02 GISSDGSTVYIDSVKG 1294 51A03 GISVDGSTHYVASVKG 1295 51A05 GISTDGSKHYIDSVKG 1296 51B01 GISYDGSKYYAESVKG 1297 51B04 GISANGSRTYMESVKG 1298 51B11 GISPDGSTDYVDSVKG 1299 51C02 GISPNGSAVYTESVKG 1300 51D01 GISPDGSTAYMESVKG 1301 51D03 GISNDGSTDYIDSVKG 1302 51E02 GISTDGSAVYFDSVKG 1303 51E03 GISTGGSTHYIESVKG 1304 51E05 GISTDGSTVYIDSVKG 1305 51F01 GISNEGSTYYMDSVKG 1306 51F02 GISADGSHVYTNSVKGWSGR Docket No.47517-770.601 1307 51F03 GISDDGSRYYTDSVKG 1308 51F04 GISAEGSTLYMESVKG 1309 51G02 GISTDGSTVYIDSVKG 1310 51G04 GISANGSTSYIDSVKG 1311 51G10 GISDDGSRHYIESVKG 1312 51H04 GISPDGSTVYIESVKG 1313 51H05 GISDDGSTVYVDSVKG 1314 52B01 GISDDGSTVYFDSVKG 1315 52C04 GISDEGSTVYIGSVKG 1316 52D04 GISDDGSIVYMDSVKG 1317 53A04 GISDDGSKHYFDSVKG 1318 53A05 GISTDGSTDYLHSVKG 1319 53A09 GISDDGSKHYFDSVKG 1320 53B05 GISYDGSTVYVESVKG 1321 53B06 GISDDGSTVYIDSVKG 1322 53C03 GISDDGSTVYVDSVKG 1323 53C04 GISDDGSQVYIDSVKG 1324 53H03 GISVDGSTVYSDSVKG 1325 53H04 GISDDGSNVYIDSVKG 1326 54B05 GISTDGSTVYFVSVKG SEQ.ID name CDR3 NO. 1327 DL1 RYFERTD 1328 DL74 RYFERTD 1329 DL31 RYFERTD 1330 DL3 YQGLYAY 1331 DL80 RVFDHVY 1332 DL18 RAFGRDY 1333 DL94 RTMGRDY 1334 DL17 WDGVGGAY 1335 DL46 WDGVGGAY 1336 DL15 WNGVGGAY 1337 DL26 WDGVGGAY 1338 DL83 WDGVGGAY 1339 DL5 RSWNNY 1340 DL22 RSWNNY 1341 DL85 RSWNNY 1342 DL69 ESFGRIWYN 1343 DL27 QHFGTDS 1344 DL51 QQFGTDS 1345 DL54 YGIQRAEGY 1346 DL11 YRWVGRDTY 1347 DL19 YRWVGRDTY 1348 DL68 YRWVGRDTY 1349 DL14 YRWEGRDTY 1350 DL67 YRWEGRNTYWSGR Docket No.47517-770.601 1351 DL56 YRWVGRYTY 1352 DL13 YRWVGRDTY 1353 DL77 YRWVGRDTY 1354 DL79 YRWVGRDTY 1355 DL20 YRWVDRYTY 1356 DL41 YRWIDRYTY 1357 DL59 YRWVDRYTY 1358 DL16 YRWVGRDTY 1359 DL6 YRWTTRYTY 1360 DL84 YRWVGGYTY 1361 DL2 FRTVAASSMQY 1362 DL43 FRTVSGSSMRY 1363 DL92 NRGFAGAPSY 1364 DL10 YFQSSY 1365 DL82 YFQSSY 1366 DL23 YFQSSY 1367 DL42 HWTQGSVPKES 1368 DL45 RSYSSDY 1369 DL58 RYGDINY 1370 DL70 RYGDINY 1371 DL89 YDSRSY 1372 DL38 YDNINAY 1373 DL52 YDNINAY 1374 DL64 YDNINAY 1375 DL33 YDNINAY 1376 DL12 WIAGKAY 1377 DL29 RSQLGST 1378 DL61 YYLDTYAY 1379 DH1 RYFERTD 1380 DH10 YFQSSY 1381 DH11 YRWVGRDTY 1382 DH12 WIAGKAY 1383 DH15 WNGVGGAY 1384 DH17 WDGVGGAY 1385 DH18 RAFGRDY 1386 DH2 FRTVAASSMQY 1387 DH22 RSWNNY 1388 DH23 YFQSSY 1389 DH27 QHFGTDS 1390 DH29 RSQLGST 1391 DH3 YQGLYAY 1392 DH38 YDNINAY 1393 DH42 HWTQGSVPKES 1394 DH43 FRTVSGSSMRY 1395 DH45 RSYSSDY 1396 DH5 RSWNNY 1397 DH51 QQFGTDSWSGR Docket No.47517-770.601 1398 DH54 YGIQRAEGY 1399 DH56 YRWVGRYTY 1400 DH58 RYGDINY 1401 DH6 YRWTTRYTY 1402 DH61 YYLDTYAY 1403 DH67 YRWEGRNTY 1404 DH69 ESFGRIWYN 1405 DH70 RYGDINY 1406 DH80 RVFDHVY 1407 DH82 YFQSSY 1408 DH83 WDGVGGAY 1409 DH84 YRWVGGYTY 1410 DH89 YDSRSY 1411 DH92 NRGFAGAPSY 1412 DH94 RTMGRDY 1413 1A01 FRHVSGSSMRY 1414 1A03 FRTVSGSSSRY 1415 1A04 FRTVSGSSMRY 1416 1A05 FRTVRGSSMSY 1417 1A06 FRTVSGSSKRY 1418 1A07 FRMVSGSSMRY 1419 1A09 FRTVQGSSMRY 1420 1A010 FRTVYGSSMRY 1421 1A011 FRTVSGSSYRY 1422 1A012 FRTVLGSSMRY 1423 1B01 FRRVSGSSMRY 1424 1B02 FRTVSGSSMRY 1425 1B03 FRTVSGSSARY 1426 1B04 FRIVRGSSMRY 1427 1B05 YRTVSGSSMRY 1428 1B07 FRHVSGSSMRY 1429 1B08 FRFVSGSSMRY 1430 1B09 FRTVSGSSMRY 1431 1B010 FRTKSGSSMRY 1432 1B011 FRTVYGSSMRY 1433 1C01 FRTVSGSSMGY 1434 1C02 FRTVSGSSMRS 1435 1C03 FRTVGGSSMRY 1436 1C04 FRTVSGSSMRY 1437 1C05 FRTVSGSHMRY 1438 1C06 FRAVSGSSMRY 1439 1C07 FRTVSGSSMRY 1440 1C08 FRTVSGSPMRY 1441 1C010 FRTVSGSSMSY 1442 1C011 FRTVSGSSMRY 1443 1C012 FRTVRGSSMRY 1444 1D01 FRTVRGSSMRYWSGR Docket No.47517-770.601 1445 1D02 FRQVSGSSMRY 1446 1D03 FRIVSGSSMGY 1447 1D04 FRTVSGASMRY 1448 1D06 FRTVHGSSMRY 1449 1D08 FRMVSGSSMRY 1450 1D09 FRTISGSSMRY 1451 1D010 FRTRSGSSMRY 1452 1D011 FRTVSGHSMRY 1453 1D012 FRTVSGGSMRY 1454 1E02 FRTKSGSSMRY 1455 1E04 FRTASGTSMRY 1456 1E05 FNTVSGSSMRY 1457 1E07 FRTVRGSSQRY 1458 1E08 FRTVLGSSMRY 1459 1E09 FRTRSGSSMRY 1460 1E010 FRTVSGLSMRY 1461 1E011 FRTVRGSSQRY 1462 1E012 FRTVSGSSMVY 1463 1F01 FRTVSRSSMRY 1464 1F02 FRTVSGSSMSY 1465 1F04 FRTVSGSSARY 1466 1F05 FHTVSGSSMRY 1467 1F06 FRTVLGSSMRY 1468 1F07 FRTVSGSSMRY 1469 1F08 FRNVSGSSMRY 1470 1F09 FRTVTGSSMRY 1471 1F010 FRTVSGSSMRY 1472 1F011 FRTVKGSSMRY 1473 1F012 FRTNSGSSMRY 1474 1G01 FRTVSGASMRY 1475 1G04 FRTVNLSSMRY 1476 1G05 FRTVTGSSMRY 1477 1G06 FRKVSGSSARY 1478 1G07 FRTYSGSSMRY 1479 1G09 FRTVSKSSMRY 1480 1G011 FKTVSGSSMRY 1481 1H01 FRTRSGSSMRY 1482 1H02 FRTSSGSSMRY 1483 1H06 FRFLSGSSMRY 1484 1H07 FRTVSGSSMRY 1485 1H08 FRLVSGSSMRY 1486 1H010 FRTVSGSSMRF 1487 1H011 FRTQSGSSMRY 1488 1H012 FRTVSGSSMPY 1489 2A01 FRTLSGSSMRY 1490 2A03 FRTVSGSAMRY 1491 2A04 FRTTSGSSMRYWSGR Docket No.47517-770.601 1492 2A05 FRTVSGTSMRY 1493 2A06 FRTRSGSSMRY 1494 2A08 FRTSSGSSMRY 1495 2A09 FRTVSGSSMSY 1496 2A011 FRPVSGSSMRY 1497 2B01 FRHVSGSSMRY 1498 2B02 FRTKSGSSMRY 1499 2B03 FTTVSGSSMRY 1500 2B05 FHTVSGSSMRY 1501 2B07 FRTVRGSSMRY 1502 2B010 FRTVLGSSMRY 1503 2B011 FRTVSGSSMRS 1504 2B012 FRTVRGSSMRY 1505 2C01 FRYVSGSSMRY 1506 2C02 FRTVYGSSMRY 1507 2C04 FRTVLGSSMRY 1508 2C06 YRTVSGSSMRY 1509 2C07 FRSVSGSSMRY 1510 2C08 FRRVSGSSMRY 1511 2C09 FRTVSGTSMRY 1512 2C010 FRTVAGSSMRY 1513 2D02 FRIVSGSSMRY 1514 2D03 FRTVSGVSMRY 1515 2D04 FRTVQGSSMRY 1516 2D05 FRTASGSSMRY 1517 2D06 FRTVSGSSSRY 1518 2D07 FRTVQGSSMRY 1519 2D09 FRTVRGSSMRY 1520 2D010 FRTKSGSSMRY 1521 2D011 FRTVWGSSMRY 1522 2D012 FRTRSGSSMRY 1523 2E01 FHTVCGTSMGY 1524 2E02 FRTVSGSSQRY 1525 2E05 FRTVSGSSMSY 1526 2E06 FRTVRGSSMRY 1527 2E08 FRTQSGSSMRY 1528 2E09 FRTLSGSSMRY 1529 2E010 FHTVSGSSMRY 1530 2E011 FRRVSGSSMRY 1531 2F01 FRLVSGSSMRY 1532 2F02 FRTVSGSYMRY 1533 2F03 FRTVGGSSMRY 1534 2F06 FRTHSGSSMRY 1535 2F07 FRTVSTSSMRY 1536 2F08 FRTVLGTSMRY 1537 2F09 FRTVSGSSMRY 1538 2F11 FRTVSGSSMGYWSGR Docket No.47517-770.601 1539 2G03 FRTVSGSSMRA 1540 2G04 FRILSGSSMRY 1541 2G07 FRTVQGSSMRY 1542 2G08 FRTVSGQSMGY 1543 2G09 FRTVSGSSARY 1544 2G011 FRYVSGSSMRY 1545 2H010 FRTVSGSSMRY 1546 2H011 FRRVSGSSMRY 1547 2H02 FHTVSGSSMRY 1548 2H03 FRQVSGSSMRY 1549 2H04 FRTVSGSYMRY 1550 2H06 FRTASGSSMRY 1551 2H07 FRTVSGHSMRY 1552 2H08 FRTVSGSSSRY 1553 2E05- FRTVSGSSYSY M106Y 1554 2E05- FRTVSGSSQSY M106Q 1555 3A01 YRWTRRYTY 1556 3A02 YRWRTRYTY 1557 3A03 YRWTTRRTY 1558 3A04 YRWTTRYIY 1559 3A05 YRWRTRYTY 1560 3A06 YRWTRRYTY 1561 3A08 YRWRTRYTY 1562 3A09 YRWTTRYIY 1563 3A010 YRWTTRRTY 1564 3A011 YRWRTRYTY 1565 3B01 YRWTTRYTY 1566 3B02 YRWRTRYTY 1567 3B04 YHWTTRYTY 1568 3B05 YRWTTRRTY 1569 3B06 YRWTTRYTY 1570 3B07 YRWTTRYTY 1571 3B09 YRWTTRYAY 1572 3B010 YRWVTRYTY 1573 3B011 YRWVTRYTY 1574 3C01 YRWSTRYTY 1575 3C02 YRWRTRYTY 1576 3C03 YRWTTRGTY 1577 3C04 YRWDTRYTY 1578 3C05 YRWTTRRTY 1579 3C06 YRWRTRYTY 1580 3C08 YRWTGRYTY 1581 3C09 YRWRTRYTY 1582 3C011 YRWRTRYTY 1583 3D01 YRWITRYTY 1584 3D02 YRWITRYTYWSGR Docket No.47517-770.601 1585 3D03 YRWRTRYTY 1586 3D05 YRWTRRYTY 1587 3D07 YSWTTRYTY 1588 3D08 YRWTNRYTY 1589 3D09 YRWTTRYRY 1590 3D010 YRWTTRYTY 1591 3D011 YRWTTRYKY 1592 3E01 YRWHTRYTY 1593 3E02 YRWTRRYTY 1594 3E03 YRWMTRYTY 1595 3E04 YRWTTRYRY 1596 3E09 YRWSTRYTY 1597 3E011 YRWTTRYTF 1598 3F03 YRWRTRYTY 1599 3F05 YRWTTRRTY 1600 3F06 YRWATRYTY 1601 3F08 YRWHTRYTY 1602 3F09 YRWGTRYTY 1603 3F010 YRWTTRNTY 1604 3F011 YRWRTRYTY 1605 3G01 YRWTTRYAY 1606 3G02 YRWRTRYTY 1607 3G04 YRWTTRRTY 1608 3G06 YRWTTRRTY 1609 3G07 YRWTSRYTY 1610 3G08 YRWTTRVTY 1611 3G09 YRWTTRTTY 1612 3G010 YRWRTRYTY 1613 3G011 YRWATRYTY 1614 3H01 YRWTTRRTY 1615 3H03 LRWTTRYTY 1616 3H06 YRWTTRGTY 1617 3H07 YRWRTRYTY 1618 3H09 YRWTTRATY 1619 3H010 YRWTTRRTY 1620 3H011 YRWPTRYTY 1621 4A01 YRWRTRYTY 1622 4A02 YRWKTRYTY 1623 4A04 YRWSTRYTY 1624 4A05 YRWKTRRTY 1625 4A06 YRWTTRRTY 1626 4A07 YRWTTRYRY 1627 4A08 YRWRTRYTY 1628 4A010 YRWTTRYKY 1629 4A011 YRWKTRYTY 1630 4A09 YRWTTRVTY 1631 4B01 YRWTTRFTYWSGR Docket No.47517-770.601 1632 4B02 YRWTTRFTY 1633 4B04 YRWRTRYTY 1634 4B05 YRWTTRYTH 1635 4B06 YRWTRRYTY 1636 4B07 YRWTTRYTY 1637 4B08 YRWTTRSTY 1638 4B09 YSWTTRYTY 1639 4B011 YRWTTRGTY 1640 4C01 YRWKTRYTY 1641 4C02 YRWTTRFTY 1642 4C03 YRWRTRYTY 1643 4C05 YRWTTRRTY 1644 4C06 YRWSTRYTY 1645 4C07 YRWTTRLTY 1646 4C08 YRWTRRYTY 1647 4C010 YRWTTRLTY 1648 4C011 YRWTRRYTY 1649 4D01 YRWTTRRTY 1650 4D02 YQWTTRYTY 1651 4D03 YRWTRRYTY 1652 4D04 YRWTTRMTY 1653 4D05 YRWTTRRTY 1654 4D06 YRWTTRYRY 1655 4D08 YRWLTRYTY 1656 4D09 YEWTTRYTY 1657 4D010 YRWRTRYTY 1658 4D011 YRWRTRYTY 1659 4E01 YRWRTRYTY 1660 4E02 YRWSTRYTY 1661 4E06 YRWTTRLTY 1662 4E07 YRWTTRLTY 1663 4E08 YKWTTRYTY 1664 4E09 YRWTTRSTY 1665 4E010 YRWRTRYTY 1666 4E011 YRWSTRYTY 1667 4F02 YRWTTRYTY 1668 4F03 YRWRTRYTY 1669 4F04 YRWLTRYTY 1670 4F08 YRWRTRYTY 1671 4F09 YRWTTRYTY 1672 4F010 YRWTTRYRY 1673 4F011 YRWTTRYTY 1674 4G01 YRWPTRYTY 1675 4G02 YRWTTRHTY 1676 4G03 YRWTRRYTY 1677 4G05 YRWHTRYTY 1678 4G07 YRWTNRYTYWSGR Docket No.47517-770.6...
Claims
WSGR Docket No.47517-770.601 CLAIMS WHAT IS CLAIMED IS:
1. A method for inducing long term immunity in a subject, comprising administering an effective amount of a Delta Like Ligand 3 (DLL3) targeting trispecific protein to the subject, wherein the DLL3 targeting trispecific protein comprises (a) a first domain (A) which specifically binds to human CD3; (b) a second domain (B) which is a half-life extension domain; and (c) a third domain (C) which specifically binds to DLL3. 2 A method for inducing epitope spreading in a subject, comprising administering an effective amount of a Delta Like Ligand 3 (DLL3) targeting trispecific protein to the subject, wherein the DLL3 targeting trispecific protein comprises (a) a first domain (A) which specifically binds to human CD3; (b) a second domain (B) which is a half-life extension domain; and (c) a third domain (C) which specifically binds to DLL3. 3 A method for increasing memory T cells in a subject, comprising administering an effective amount of a Delta Like Ligand 3 (DLL3) targeting trispecific protein to the subject, wherein the DLL3 targeting trispecific protein comprises (a) a first domain (A) which specifically binds to human CD3; (b) a second domain (B) which is a half-life extension domain; and (c) a third domain (C) which specifically binds to DLL3; wherein the memory T cells are increased in the subject as compared to a subject without the administration. 4 A method for treating a subject in need thereof, comprising administering an effective amount of a Delta Like Ligand 3 (DLL3) targeting trispecific protein to the subject, wherein the DLL3 targeting trispecific protein comprises (a) a first domain (A) which specifically binds to human CD3; (b) a second domain (B) which is a half-life extension domain; and (c) a third domain (C) which specifically binds to DLL3; wherein the subject in need thereof is prone to cancer relapse. 5 The method of any one of claims 1-4, wherein the DLL3 targeting trispecific protein is administered at a dosage of about 1 µg to about 100 mg. 6 The method of any one of claims 1-4, wherein the DLL3 targeting trispecific protein is administered at a dosage of about 1 µg to about 14 mg.WSGR Docket No.47517-770.601 7. The method of any one of claims 1-4, wherein the DLL3 targeting trispecific protein is administered at a dosage of about 1 µg to about 5 mg.
8. The method of any one of claims 1-4, wherein the DLL3 targeting trispecific protein is administered at a dosage of about 1 µg to about 2 mg.
9. The method of any one of claims 1-4, wherein the DLL3 targeting trispecific protein is administered at a dosage of about 1 µg to about 1 mg.
10. The method of any one of claims 1-4, wherein the DLL3 targeting trispecific protein is administered at a dosage of about 15 µg to about 3600 µg.
11. The method of any one of claims 1-4, wherein the DLL3 targeting trispecific protein is administered at a dosage of about 15 µg.
12. The method of any one of claims 1-4, wherein the DLL3 targeting trispecific protein is administered at a dosage of about 45 µg.
13. The method of any one of claims 1-4, wherein the DLL3 targeting trispecific protein is administered at a dosage of about 135 µg.
14. The method of any one of claims 1-4, wherein the DLL3 targeting trispecific protein is administered at a dosage of about 405 µg.
15. The method of any one of claims 1-4, wherein the DLL3 targeting trispecific protein is administered at a dosage of about 1215 µg.
16. The method of any one of claims 1-4, wherein the DLL3 targeting trispecific protein is administered at a dosage of about 3600 µg.
17. The method of any one of claims 1-4, wherein the DLL3 targeting trispecific protein is administered at a dosage of about 5 mg.
18. The method of any one of claims 1-4, wherein the DLL3 targeting trispecific protein is administered at a dosage of about 7 mg.
19. The method of any one of claims 1-4, wherein the DLL3 targeting trispecific protein is administered at a dosage of about 10 mg.
20. The method of any one of claims 1-4, wherein the DLL3 targeting trispecific protein is administered at a dosage of about 12 mg.
21. The method of any one of claims 1-4, wherein the DLL3 targeting trispecific protein is administered at a dosage of about 14 mg.
22. The method of any one of claims 1-4, wherein the DLL3 targeting trispecific protein is administered at a dosage of about 20 mg.
23. The method of any one of claims 1-4, wherein the DLL3 targeting trispecific protein is administered at a dosage of about 50 mg.WSGR Docket No.47517-770.601 24. The method of any one of claims 1-23, wherein the DLL3 targeting trispecific protein is administered once a week.
25. The method of any one of claims 1-23, wherein the DLL3 targeting trispecific protein is administered twice per week.
26. The method of any one of claims 1-23, wherein the DLL3 targeting trispecific protein is administered every other week.
27. The method of any one of claims 1-23, wherein the DLL3 targeting trispecific protein is administered every three weeks.
28. The method of any one of claims 1-27, wherein the DLL3 targeting trispecific protein is administered intravenously, intraperitoneally, subcutaneously, intramuscularly, topically or intradermally.
29. The method of any one of claims 1-28, wherein the domains are linked in the order H2N- (A)-(B)-(C)-COOH, or by linkers L1 and L2.
30. The method of any one of claims 1-29, wherein the DLL3 targeting trispecific protein is administered according to a schedule comprising the following steps: (i) administration of a first dose of the DLL3 targeting trispecific protein, and (ii) administration of a second dose of the DLL3 targeting trispecific protein, wherein the second dose is higher than the first dose.
31. The method of claim 30, wherein the first dose is about 1 mg to about 50 mg.
32. The method of claim 30, wherein the first dose is about 1 mg to about 20 mg.
33. The method of claim 30, wherein the first dose is about 1 mg to about 10 mg.
34. The method of claim 30, wherein the first dose is about 1 mg to about 5 mg.
35. The method of claim 30, wherein the first dose is about 1 mg to about 3 mg.
36. The method of claim 30, wherein the first dose is about 2000 µg.
37. The method of claim 30, wherein the first dose is about 3600 µg.
38. The method of any one of claims 30-37, wherein the first dose is administered for about 1 week to about 36 weeks.
39. The method of any one of claims 30-37, wherein the first dose is administered for about 1 week to about 27 weeks.
40. The method of any one of claims 30-37, wherein the first dose is administered for about 1 week to about 18 weeks.
41. The method of any one of claims 30-37, wherein the first dose is administered for about 1 week to about 9 weeks.
42. The method of any one of claims 30-41, wherein the first dose is administered once a day.WSGR Docket No.47517-770.601 43. The method of any one of claims 30-41, wherein the first dose is administered twice a day.
44. The method of any one of claims 30-41, wherein the first dose is administered three times a day.
45. The method of any one of claims 30-41, wherein the first dose is administered five times a day.
46. The method of any one of claims 30-41, wherein the first dose is administered once a week.
47. The method of any one of claims 30-41, wherein the first dose is administered twice per week.
48. The method of any one of claims 30-41, wherein the first dose is administered every other week.
49. The method of any one of claims 30-41, wherein the first dose is administered every three weeks.
50. The method of any one of claims 30-41, wherein the first dose is administered intravenously, intraperitoneally, subcutaneously, intramuscularly, topically or intradermally.
51. The method of claim 30, wherein the second dose is about 1 mg to about 100 mg.
52. The method of claim 30, wherein the second dose is about 1 mg to about 50 mg.
53. The method of claim 30, wherein the second dose is about 50 mg to about 100 mg.
54. The method of claim 30, wherein the second dose is about 7.2 mg.
55. The method of claim 30, wherein the second dose is about 12 mg.
56. The method of claim 30, wherein the second dose is about 24 mg.
57. The method of any one of claims 30-56, wherein the second dose is administered for about 1 week to about 36 weeks.
58. The method of any one of claims 30-56, wherein the second dose is administered for about 1 week to about 27 weeks.
59. The method of any one of claims 30-56, wherein the second dose is administered for about 1 week to about 18 weeks.
60. The method of any one of claims 30-56, wherein the second dose is administered for about 1 week to about 9 weeks.
61. The method of any one of claims 30-60, wherein the second dose is administered once a day.
62. The method of any one of claims 30-60, wherein the second dose is administered twice a day.
63. The method of any one of claims 30-60, wherein the second dose is administered three times a day.WSGR Docket No.47517-770.601 64. The method of any one of claims 30-60, wherein the second dose is administered five times a day.
65. The method of any one of claims 30-60, wherein the second dose is administered once a week.
66. The method of any one of claims 30-60, wherein the second dose is administered twice per week.
67. The method of any one of claims 30-60, wherein the second dose is administered every other week.
68. The method of any one of claims 30-60, wherein the second dose is administered every three weeks.
69. The method of any one of claims 30-68, wherein the second dose is maintained to the end of the schedule after the administration of the first dose.
70. The method of any one of claims 30-69, wherein the second dose is administered intravenously, intraperitoneally, subcutaneously, intramuscularly, topically or intradermally.
71. The method of any one of claims 1-70, wherein the DLL3 targeting trispecific protein has an elimination half-time of at least 12 hours, at least 20 hours, at least 25 hours, at least 30 hours, at least 35 hours, at least 40 hours, at least 45 hours, at least 50 hours, or at least 100 hours.
72. The method of any one of claims 1-71, wherein the third domain comprises a VHH domain.
73. The method of claim 72, wherein the VHH domain is human, humanized, affinity matured, or a combination thereof.
74. The method of any one of claims 1-73, wherein the third domain comprises one or more sequences selected from the group consisting of SEQ ID NO: 1-442.
75. The method of any one of claims 1-74, wherein the first domain comprises a variable light chain and variable heavy chain each of which is capable of specifically binding to human CD3.
76. The method of claim 75, wherein the first domain is humanized or human.
77. The method of any one of claims 1-76, wherein the second domain binds human serum albumin.
78. The method of claim 77, wherein the second domain comprises a scFv, a variable heavy domain (VH), a variable light domain (VL), a peptide, a ligand, or a small molecule.
79. The method of any one of claims 29-78, wherein linkers L1 and L2 are each independently selected from (GS)n, (GGS)n, (GGGS)n, (GGSG)n, (GGSGG)n, (GGGGS)n, or GGGGSGGGS, wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.WSGR Docket No.47517-770.601 80. The method of any one of claims 29-78, wherein linkers L1 and L2 are each independently (GGGGS)4, (GGGGS)3, or GGGGSGGGS.
81. The method of any one of claims 29-80, wherein the domains are linked in the order H2N- (C)-L1-(B)-L2-(A)-COOH.
82. The method of any one of claims 1-81, wherein the DLL3 targeting trispecific protein is less than about 80 kDa.
83. The method of any one of claims 1-81, wherein the DLL3 targeting trispecific protein is about 50 to about 75 kDa.
84. The method of any one of claims 1-81, wherein the DLL3 targeting trispecific protein is less than about 60 kDa.
85. The method of any one of claims 1-81, wherein the DLL3 targeting trispecific protein comprises a sequence selected from the group consisting of SEQ ID NO: 1890-1891.
86. The method of any one of claims 1-81, wherein the DLL3 targeting trispecific protein comprises a sequence as set forth in SEQ ID NO: 1890.
87. The method of any one of claims 1-86, wherein the subject has a cancer or is prone to have a cancer.
88. The method of any one of claims 1-86, wherein the subject is prone to cancer relapse.
89. The method of claim 87 or 88, wherein the cancer comprises a cancer associated with DLL3.
90. The method of any one of claims 87-89, wherein the cancer is a neuroendocrine cancer, a prostate cancer, a lung cancer, a stomach cancer, a squamous cell carcinoma, a pancreatic cancer, a cholangiocarcinoma, a triple negative breast cancer or an ovarian cancer.
91. The method of any one of claims 87-89, wherein the cancer is a small cell lung cancer.
92. The method of any one of claims 87-89, wherein the cancer is a neuroendocrine prostate cancer.
93. The method of any one of claims 1-92, wherein CD8+ / CD69+T cells in the subject are increased after the administration as compared to CD8+ / CD69+T cells in a subject without the administration.
94. The method of any one of claims 1-93, wherein CD8+ / CD25+T cells in the subject are increased after the administration as compared to CD8+ / CD25+T cells in a subject without the administration.
95. The method of claim 93, wherein the CD8+ / CD69+T cells are increased by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at leastWSGR Docket No.47517-770.601 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 25%, at least 30%, or at least 35% as compared to the subject without the administration.
96. The method of claim 93, wherein the CD8+ / CD69+T cells are increased by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 25%, about 30%, or about 35% as compared to the subject without the administration.
97. The method of claim 94, wherein the CD8+ / CD25+T cells are increased by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 25%, at least 30%, or at least 35% as compared to the subject without the administration.
98. The method of claim 94, wherein the CD8+ / CD25+T cells are increased by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 25%, about 30%, or about 35% as compared to the subject without the administration.
99. The method of any one of claims 93-98, wherein the CD8+ / CD69+T cells or the CD8+ / CD25+ T cells are increased about 12 hours, about 24 hours, about 48 hours, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days post the administration.
100. The method of any one of claims 93-99, wherein the CD8+ / CD69+T cells or the CD8+ / CD25+ T cells are increased within about 12 hours, about 24 hours, about 48 hours, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days upon the administration.
101. The method of any one of claims 1-2 and 4-92, wherein memory T cells are increased in the subject as compared to a subject without the administration.
102. The method of claim 101, wherein the memory T cells comprises central memory T cells, effector memory T cells, tissue-resident memory T cells, or stem cell-like memory T cells.
103. The method of claim 101 or 102, wherein the memory T cells are increased by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 25%, at least 30%, or at least 35% as compared to the subject without the administration.WSGR Docket No.47517-770.601 104. The method of claim 101 or 102, wherein the memory T cells are increased by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 25%, about 30%, or about 35% as compared to the subject without the administration.
105. The method of any one of claims 102-104, wherein the central memory T cells comprise T cells expressing at least one marker selected from the group consisting of CCR7+, CD45RA- , CD45RO+, CD62L+, and CD27+.
106. The method of claim 105, wherein the central memory T cells comprise T cells expressing CCR7+, CD45RA-, CD45RO+, CD62L+, and CD27+.
107. The method of any one of claims 102-106, wherein the effector memory T cells comprise T cells expressing at least one marker selected from the group consisting of CCR7-, CD45RA-, CD45RO+, CD62L-, and CD27-.
108. The method of claim 107, wherein the effector memory T cells comprise T cells expressing CCR7-, CD45RA-, CD45RO+, CD62L-, and CD27-.
109. The method of any one of claims 102-108, wherein the tissue-resident memory T cells comprise T cells expressing at least one marker selected from the group consisting of CD69+and CD103+.
110. The method of claim 109, wherein the tissue-resident memory T cells comprise T cells expressing CD69+and CD103+.
111. The method of any one of claims 102-110, wherein the stem cell-like memory T cells comprise T cells expressing at least one marker selected from the group consisting of CCR7+, CD95+, CD45RO-, CD27+, CD45RA+, CD62L+, and CD122+.
112. The method of claim 111, wherein the stem cell-like memory T cells comprise T cells expressing CCR7+, CD95+, CD45RO-, CD27+, CD45RA+, CD62L+, and CD122+.
113. The method of any one of claims 1-112, wherein the subject has an increased level of a cytokine after the administration as compared to a subject without the administration.
114. cytokine family.
115. The method of claim 113 or 114, wherein the cytokine comprises interleukin-2 (IL-2), IL-7, or IL-15.
116. The method of claim 112, wherein the cytokine comprises a proinflammatory cytokine or a chemokine. 117.WSGR Docket No.47517-770.601 118. The method of any one of claims 1-117, wherein tumor antigens from cancer cells of the subject are released from the cancer cells.
119. The method of claim 118, wherein endogenous T cell response is activated.
120. The method of any one of claims 1-119, wherein a long-term immunity is induced.
121. The method of any one of claims 1-120, wherein the subject had cancer and the cancer had regressed.
122. The method of claim 121, wherein the cancer regression is a result of a treatment.
123. The method of claim 122, wherein the treatment comprises administering an effective amount of the DLL3 targeting trispecific protein.
124. The method of claim 122, wherein the treatment comprises administering a therapeutic agent.
125. The method of any one of claims 121-124, wherein the tumor had regressed to an undetectable size.
126. The method of claim 125, wherein the subject had been clinically diagnosed as cancer free.
127. The method of any one of claims 121-126, wherein the subject has cancer relapse after the administration of the DLL3 targeting trispecific protein; and wherein the relapsed cancer develops slower than a relapsed cancer in a subject without the administration.
128. The method of any one of claims 121-126, wherein the subject is prone to cancer relapse; and wherein the subject is clinically cancer free.
129. The method of claim 128, wherein the subject is clinically cancer free for at least 5 days, at least 10 days, at least 15 days, at least 20 days, at least 30 days, at least 40 days, at least 50 days, at least 60 days, at least 70 days, at least 80 days, at least 90 days, or at least 100 days.
130. A method for treating a subject in need thereof, comprising determining the subject is prone to cancer relapse; and administering an effective amount of a Delta Like Ligand 3 (DLL3) targeting trispecific protein to the subject, wherein the DLL3 targeting trispecific protein comprises (a) a first domain (A) which specifically binds to human CD3; (b) a second domain (B) which is a half-life extension domain; and (c) a third domain (C) which specifically binds to DLL3.
131. A method for treating a subject in need thereof, comprising administering an effective amount of a Delta Like Ligand 3 (DLL3) targeting trispecific protein to the subject, wherein the DLL3 targeting trispecific protein comprises (a) a first domain (A) which specifically binds to human CD3; (b) a second domain (B) which is a half-life extension domain; andWSGR Docket No.47517-770.601 (c) a third domain (C) which specifically binds to DLL3; wherein the subject is determined to be prone to cancer relapse.
132. A method for enhancing immunity and immune response in a subject in need thereof, comprising administering an effective amount of a Delta Like Ligand 3 (DLL3) targeting trispecific protein to the subject, wherein the DLL3 targeting trispecific protein comprises (a) a first domain (A) which specifically binds to human CD3; (b) a second domain (B) which is a half-life extension domain; and (c) a third domain (C) which specifically binds to DLL3.
Citation Information
Patent Citations
Combination therapy with immune cell engaging proteins and immunomodulators
WO2022192225A1
DLL3 targeting trispecific proteins and methods of use
WO2022256500A2
